A Phase 3 interventional study of Cabotegravir (CAB) tablet and Rilpivirine (RPV) tablet in Infection, Human Immunodeficiency Virus and HIV Infections, sponsored by ViiV Healthcare. Active, not recruiting at 113 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.
Among the 36 studies testing cabotegravir in HIV Infections, this one is the 9th largest by enrollment, is one of 3 that started in 2016, is one of 12 in phase 3, reaches primary completion later than 0 of the 12 other live ones, and was the 11th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
Africa Health Research Institute · Sites in South Africa
Ages 15–30 · Healthy volunteers
Evandro Chagas National Institute of Infectious Disease · Sites in Brazil
Ages 18–30 · Men only · Healthy volunteers
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 11 · Phase 3 13 · Phase 4 3
First in 2008; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 618 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 200 across the 36 interventional studies. Of the 23 that completed or were terminated, 18 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 36 have an industry lead sponsor. The 7 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 18th largest by enrollment of the 210 interventional ones that give a count, is one of 8 that started in 2016, is one of 65 in phase 3, reaches primary completion later than 1 of the 26 other live ones, and was the 173rd registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing cabotegravir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06786520ViiV HealthcareA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | 2027-03-08 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing cabotegravir in HIV Infections, from their registry updates:
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
The Antiretroviral Therapy as Long Acting Suppression (ATLAS) study is being conducted to establish if human immunodeficiency virus type-1 (HIV-1) infected adult subjects with current viral suppression on a regimen with 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus a third agent, remain suppressed upon switching to a two-drug intramuscular (IM) long-acting (LA) regimen of cabotegravir (CAB) and rilpivirine (RPV). This is a Phase 3, multi-phase, randomized, open label, active-controlled, multicenter, parallel-group, non-inferiority study in HIV-1, antiretroviral therapy (ART)-adult subjects who are stably suppressed on a current antiretroviral (ARV) regimen. This study is designed to demonstrate the non-inferior antiviral activity of switching to a two drug CAB LA 400 mg + RPV LA 600 mg regimen every 4 weeks (Q4W: monthly) compared with maintenance of current ARV regimen containing 2 NRTIs plus an INI, NNRTI, or a PI. Eligible subjects will be randomized (1:1) into the Maintenance Phase at Day 1 to either continue current ART or switch to initiate oral therapy with CAB 30 mg + RPV 25 mg once daily for 4 Weeks followed by Q4 weekly (monthly) CAB LA + RPV LA injections. Following the Maintenance phase at Week 52, subjects who were randomized to continue their current ART regimen will be given an option to switch to CAB LA + RPV LA injections. Those subjects would transition to LA dosing, beginning with 4 weeks oral CAB + RPV therapy at Week 52, and receive the first IM CAB LA + RPV LA injections at Week 56.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
This study's enrollment of 618 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Browse HIV Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female subjects is eligible to participate if she is not pregnant (as confirmed by a negative serum human chorionic gonadotrophin (hCG) test at screen and a negative urine hCG test at Randomization), not lactating, and at least one of the following conditions applies:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible subjects receive Oral CAB 30 mg + RPV 25 mg once daily for four weeks, IM CAB LA 600 mg and RPV LA 900 mg for the first injection, and Week 4 onwards subjects will receive CAB LA (400 mg) + RPV LA (600 mg) injections every 4 weeks until withdrawal.
Drug: Cabotegravir (CAB) tablet · Drug: Rilpivirine (RPV) tablet · Drug: Cabotegravir - Injectable Suspension (CAB LA) · Drug: Rilpivirine - Injectable Suspension (RPV LA)
Eligible subjects will continue their current anti-retroviral regimen (2 NRTIs plus an INI, NNRTI, or a PI) for 52 weeks. After 52 weeks subjects have the option to continue study participation by switching to CAB LA + RPV LA in the Extension Phase where they will follow the procedure of CAB LA + RPV LA arm.
Drug: 2 NRTIs plus an INI, NNRTI, or PI
It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat
It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with "TMC" and the other side with "25". Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose
It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection
It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
Acceptable stable (initial or second) ARV regimens include 2 NRTIs plus: * INI with the exception of ABC/DTG/3TC (either the initial or second cART regimen) * NNRTI (either the initial or second cART regimen) * Boosted PI (or atazanavir \[ATV\] unboosted) (either the initial or second PI-based cART regimen)
Number of Participants With Virologic Failure (HIV-1 Ribonucleic Acid [RNA] >=50 Copies Per Millilter [mL]) Using Snapshot Algorithm at Week 48
Number of participants with virologic failure endpoint (HIV-1 RNA\>=50 c/mL) as per Food and Drug Administration (FDA) snapshot algorithm at Week 48 was assessed to demonstrate the non-inferior antiviral activity of switching to intramuscular (IM) CAB LA+RPV LA every 4 weeks compared to continuation of current ART regimen over 48 weeks in HIV-1 infected ART-experienced participants. The HIV-1 RNA \>=50 copies/mL per snapshot algorithm was determined by the last available on-treatment HIV-1 RNA measurement within the analysis visit window of interest.
Time frame: Week 48
Number of Participants With HIV-1 RNA <50 Copies/mL Using Snapshot Algorithm at Week 48
Plasma samples were collected for quantitative analysis of HIV-1 RNA. Number of participants with plasma HIV-1 RNA \<50 copies/mL at Week 48 using FDA snapshot algorithm was assessed to demonstrate antiviral and immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART. The HIV-1 RNA \<50 copies/mL per snapshot algorithm was determined by the last available on-treatment HIV-1 RNA measurement within the analysis visit window of interest.
Time frame: Week 48
Number of Participants With HIV-1 RNA <200 Copies/mL Using Snapshot Algorithm at Week 48
Number of participants with plasma HIV-1 RNA \<200 copies/mL at Week 48 using the snapshot algorithm was assessed based on the antiviral and immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART.
Time frame: Week 48
Number of Participants With Confirmed Virologic Failure (CVF)
The CVF is defined as rebound as indicated by two consecutive plasma HIV-1-RNA levels \>=200 copies/mL after prior suppression to \<200 copies/mL. The outcome displays only visits during which at least one new CVF occurs. Plasma samples were collected for quantitative analysis of HIV-1 RNA.
Time frame: Weeks 8, 12, 20, 24, 32 and 40
Absolute Values for Plasma HIV-1 RNA at Week 48
Logarithm to base 10 (log10) values for plasma HIV-1 RNA has been presented.
Time frame: Week 48
Change From Baseline Values for Plasma HIV-1 RNA
Plasma for quantitative HIV-1 RNA were collected at indicated time points. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as: HIV-1 RNA(log 10) at Week 48 - HIV-1 RNA(log 10) at Baseline.
Time frame: Baseline and Week 48
Absolute Values for CD4+ Lymphocyte Count at Week 48
Blood samples were collected and CD4+ cell count assessment by flow cyclometry was carried out to evaluate the immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to current ART.
Time frame: Week 48
Change From Baseline Values for CD4+ Lymphocyte Count at Week 48
Blood samples were collected and CD4+ cell count assessment by flow cyclometry was carried out to evaluate the immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to current ART.Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value at Week 48 minus Baseline value.
Time frame: Baseline (Day 1) and Week 48
Number of Participants With Disease Progression
Disease progression was defined as HIV-associated conditions, acquired immunodeficiency syndrome (AIDS), and death through 48 Weeks. Data of participants who experienced disease progression to Centers for Disease Control and Prevention (CDC) Stage III or death has been presented.
Time frame: Up to Week 48
Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement. Safety Population comprised of all randomized participants who received at least one dose of IP during the maintenance phase of the study (on or after Day 1 visit). Participants will be assessed according to actual treatment received.
Time frame: Up to Week 48
Number of Participants With Severity of Adverse Events
Severity of adverse events (AEs) were defined as per The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table) Version 2.0, November 2014. Severity grades for AEs were as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 were all deaths related to an AE.
Time frame: Up to Week 48
Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets
Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, neutrophils, monocytes, and platelets at indicated time points.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume
Blood samples were collected for the analysis of hematology parameter including erythrocyte mean corpuscular volume at indicated time points.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Hematology Parameters: Erythrocytes
Blood samples were collected for the analysis of hematology parameters including erythrocytes at indicated time points.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Hematology Parameters: Hemoglobin
Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated time points.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Hematology Parameters: Hematocrit
Blood samples were collected for the analysis of hematology parameters including hematocrit at indicated time points.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets
Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, neutrophils, monocytes, and platelets at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume
Blood samples were collected for the analysis of hematology parameter including erythrocyte mean corpuscular volume at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline for Hematology Parameters: Erythrocytes
Blood samples were collected for the analysis of hematology parameters including erythrocytes at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline for Hematology Parameters: Hematocrit
Blood samples were collected for the analysis of hematology parameters including hematocrit at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline for Hematology Parameters: Hemoglobin
Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK)
Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK at indicated time points.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin
Blood samples were collected for the analysis of clinical chemistry parameter-albumin at indicated time points.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine
Blood samples were collected for the analysis of clinical chemistry parameters including bilirubin, creatinine and direct bilirubin at indicated time points.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48
Blood samples were collected for the analysis of clinical chemistry parameters which includes total CO2, chloride, glucose, phosphate, potassium, sodium and urea at indicated time points.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase
Blood samples were collected for the analysis of clinical chemistry parameter-lipase at indicated time points.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance
Blood samples were collected for the analysis of clinical chemistry parameter-creatinine clearance at indicated timepoints. Glomerular filtration rate (GFR) will be estimated by the central laboratory using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48
The dipstick test gives results in a semi-quantitative manner and results for urinalysis parameters (ketones, glucose, bilirubin, occult blood, nitrite and blood protein) can be read as positive, trace, 1+, 2+, 3+ and 4+ indicating proportional concentrations in the urine sample. The urine parameters were graded according to Division of AIDS (DAIDS) scale where Grade 1 indicates mild (trace to 1+), Grade 2 indicates moderate (2+) and Grade 3 indicates severe (3+ or higher). Only participants with abnormal findings for urinalysis at any visit has been presented.
Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48.
Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48
Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0).
Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48
Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK
Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK. Baseline values is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin
Blood samples were collected for the analysis of clinical chemistry parameter-albumin. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine
Blood samples were collected for the analysis of clinical chemistry parameters including bilirubin, creatinine and direct bilirubin. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48
Blood samples were collected for the analysis of clinical chemistry parameters which includes total CO2, chloride, glucose, phosphate, potassium, sodium and urea. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase
Blood samples were collected for the analysis of clinical chemistry parameter-lipase. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance.
Blood samples were collected for the analysis of clinical chemistry parameter-creatinine clearance. GFR will be estimated by the central laboratory using the CKD-EPI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline Values for Fasting Lipid Panel Over Time Including Week 48
Blood samples were collected for the analysis of fasting lipid parameters- total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Week 48
Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48
Urine biomarker samples were collected for the analysis of urine albumin/creatinine ratio and urine protein/creatinine ratio.Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48
Change From Baseline Values in Urine Creatinine Over Time Including Week 48
Urine biomarker samples were collected for the analysis of urine creatinine. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48
Change From Baseline Values in Urine Phosphate Over Time Including Week 48
Urine biomarker samples were collected for the analysis of urine phosphate. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48
Change From Baseline Values in Urine Retinol Binding Protein Over Time Including Week 48
Urine biomarker samples were collected for the analysis of urine retinol binding protein. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Week 48
Change From Baseline Values in Urine Specific Gravity Over Time Including Week 48
Urine biomarker samples were collected for the analysis of urine specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The dipstick test gives results in a semi-quantitative manner. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. The urine specific gravity was measured as the ratio of urine density compared with water density.
Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48
Change From Baseline Values in Urine pH Over Time Including Week 48
Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0). The dipstick test gives results in a semi-quantitative manner. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48
Number of Participants Who Discontinued or Withdrawn Due to AEs Over Time Including Week 48
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.
Time frame: Up to Week 48
Percentage Change From Baseline in Fasting Lipids Overtime Including Week 48
Blood samples were collected at Baseline and at Week 48 to assess fasting lipids which included total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Percentage change from Baseline is calculated as: value at Week 48 minus Baseline value divided by Baseline value multiplied by 100.
Time frame: Baseline (Day 1) and at Week 48
Number of Participants With Phenotypic Resistance Through Week 48
Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria.The CVF population comprised of all participants in ITT-E population who met CVF criteria.Phenotypic Resistance data for following drugs:CAB,dolutegravir(DTG),elvitegravir(EVG), raltegravir(RAL),delavirdine(DLV),efavirenz(EFV),etravirine(ETR),nevirapine(NVP),RPV,lamivudine(3TC),abacavir(ABC),emtricitabine(FTC),tenofovir(TDF),zidovudine(ZDV),stavudine(d4T),didanosine(ddI), atazanavir(ATV),darunavir(DRV),fosamprenavir(FPV),indinavir(IDV),lopinavir(LPV),nelfinavir(NFV),rito-navir(RTV),saquinavir(SQV) and tipranavir(TPV) in participants meeting CVF criteria is presented.Phenotypic resistance, partially sensitive, and Sensitive were defined based on fold change(FC) value from Monogram as:resistance(FC\>clinical higher cutoff/biologic cutoff),partially sensitive(FC \<=clinical higher cutoff and \> clinical lower cutoff),sensitive(FC \<= clinical lower cutoff/biologic cutoff).
Time frame: At the time of CVF
Number of Participants With Genotypic Resistance Through Week 48
Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria. Genotypic Resistance data for the following drugs: DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented.
Time frame: At the time of CVF
Number of Participants With AEs by Using Baseline Third Agent Treatment Class Overtime Including Week 48
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.
Time frame: Up to Week 48
Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK
Blood samples were collected for the analysis of clinical chemistry parameters to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin
Blood samples were collected for the analysis of clinical chemistry parameter: albumin to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine
Blood samples were collected for the analysis of clinical chemistry parameter: bilirubin, direct bilirubin and creatinine to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance
Blood samples were collected for the analysis of clinical chemistry parameter: creatinine clearance to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). GFR will be estimated by the central laboratory using the CKD-EPI.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase
Blood samples were collected for the analysis of clinical chemistry parameter: lipase to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48
Blood samples were collected for the analysis of clinical chemistry parameters: CO2, chloride, glucose, phosphate, potassium, sodium and urea to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48
Blood samples were collected for the analysis of fasting lipid panel: triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).
Time frame: Baseline (Day 1) and at Week 48
Number of Participants Discontinued or Withdrawn Due to AEs When Baseline Third Agent Treatment Class Was Used Over Time Including Week 48
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.
Time frame: Up to Week 48
Plasma Trough Concentration (Ctrough) for CAB LA Evaluable
Blood samples will be collected at indicated time points for pharmacokinetic (PK) analysis of CAB LA. PK population includes all participants who received CAB and / or RPV and underwent PK sampling during the study, and provided CAB and /or RPV plasma concentration data.
Time frame: Pre-dose at Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Ctrough for RPV LA Evaluable
Blood samples will be collected at indicated time points for PK analysis of RPV LA.
Time frame: Pre-dose at Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Area Under the Curve (AUC) for CAB LA
AUC values are Bayesian PK parameter estimates obtained from a population PK meta-analysis of the data collected from studies 201585 and 201584 # NCT02938520. Blood samples from the current study 201585 were collected at indicated time points to analyze concentration in plasma for CAB LA.
Time frame: Pre-dose at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48; 1 Week post-dose at Weeks 5 and 41
AUC for RPV LA
AUC values are Bayesian PK parameter estimates obtained from a population PK meta-analysis of the data collected from studies 201585 and 201584 # NCT02938520. Blood samples from the current study 201585 were collected at indicated time points to analyze concentration in plasma for RPV LA.
Time frame: Pre-dose at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48; 1 Week post-dose at Weeks 5 and 41
Maximum Concentration (Cmax) in Plasma for CAB LA Evaluable at Week 41
Blood samples will be collected at indicated time points for PK analysis of CAB LA.
Time frame: Week 41- 1 Week post dose
Cmax in Plasma for RPV LA Evaluable at Week 41
Blood samples will be collected at indicated time points for PK analysis of RPV LA.
Time frame: Week 41- 1 Week post dose
Percentage of Participants With a Virologic Failure Using Snapshot Algorithm by Baseline Third Agent
Percentage of participants with virologic failure endpoint as per FDA snapshot algorithm at Week 48 was assessed based on the non-inferior antiviral activity of switching IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART regimen over 48 weeks in HIV-1 infected ART-experienced participants. The HIV-RNA \>=50 copies/mL per snapshot algorithm was determined using a Cochran-Mantel Haenszel test stratified by baseline third agent class: INI, NNRTI, or PI.
Time frame: Week 48
Percentage of Participants With Plasma HIV-1 RNA <50copies/mL Using Snapshot Algorithm by Baseline Third Agent
Percentage of participants with HIV-1 RNA \< 50copies/mL endpoint as per FDA snapshot algorithm at Week 48 was assessed based on the non-inferior antiviral activity of switching IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART regimen over 48 weeks in HIV-1 infected ART-experienced participants. The HIV-RNA \<50 copies/mL per snapshot algorithm was determined using a Cochran-Mantel Haenszel test stratified by baseline third agent class: INI, NNRTI, or PI.
Time frame: Week 48
Number of Participants With Severity of Adverse Events by Baseline Third Agents
Severity of AEs were defined as per The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table). Severity grades for AEs were as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 were all deaths related to an AE.
Time frame: Up to Week 48
Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK
Blood samples were collected for the analysis of clinical chemistry parameters: ALT, ALP, AST and CK to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin
Blood samples were collected for the analysis of clinical chemistry parameter: albumin to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine
Blood samples were collected for the analysis of clinical chemistry parameter: bilirubin, direct bilirubin and creatinine to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance
Blood samples were collected for the analysis of clinical chemistry parameter: creatinine clearance to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). GFR will be estimated by the central laboratory using the CKD-EPI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase
Blood samples were collected for the analysis of clinical chemistry parameter: lipase to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48
Blood samples were collected for the analysis of clinical chemistry parameters: CO2, chloride, glucose, phosphate, potassium, sodium and urea to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48
Blood samples were collected for the analysis of fasting lipid panel: triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Week 48
Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48
Plasma samples were collected from participants who met confirmed virologic withdrawal criteria to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Genotypic Resistance data for the following drugs: DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented.
Time frame: At the time of CVF
Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48
Plasma samples were collected from participants who met confirmed virologic withdrawal criteria to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Phenotypic Resistance data for the following drugs: CAB, DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented. Phenotypic resistance, partially sensitive, and Sensitive were defined based on FC value from Monogram as: resistance (FC\>clinical higher cutoff/biologic cutoff), partially sensitive (FC \<=clinical higher cutoff and \> clinical lower cutoff), sensitive (FC \<= clinical lower cutoff/biologic cutoff).
Time frame: At the time of CVF
Change From Week 5 in Dimension Scores Using Percerption of Injection Questionnaire (PIN)-Last Observation Carried Forward (LOCF) in Q4W Arm
The PIN questionnaire explores the bother of pain at the injection site and injection site reactions (ISR), anxiety before and after injection, willingness to receive an HIV injectable treatment the following visit and satisfaction with the mode of treatment administration of individuals receiving injection and perceptions of individuals associated with receiving injections.This measure contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial.Scores range from 1 to 5, and questions are phrased in such a way as to ensure that 1 always equated with the most favourable perception of vaccination, and 5 the most unfavourable.Dimension scores include bother from ISR, leg movement, sleep and acceptability.The score of a domain is calculated as the mean of all items with the domain.Higher scores represent worse perception of injection. LOCFwas used as primary method of analysis
Time frame: Week 5 and at Weeks 41 and 48
Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm
The PIN questionnaire explores the bother of pain at the injection site and injection site reactions(ISR), anxiety before and after injection, willingness to receive an HIV injectable treatment the following visit and satisfaction with the mode of treatment administration of individuals receiving injection and perceptions of individuals associated with receiving injections.This measure contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial.Scores range from 1 to 5, and questions are phrased in such a way as to ensure that 1 always equated with the most favourable perception of vaccination, and 5 the most unfavourable.Dimension scores include bother from ISR, leg movement, sleep and acceptability.The score of a domain is calculated as the mean of all items with the domain.Higher scores represent worse perception of injection. LOCF was used as primary method of analysis
Time frame: Weeks 5, 41 and 48
Change From Baseline in Life Satisfaction (LISAT) Using HIV/AIDs-targeted Quality of Life (HATQoL) Questionnaire
The HATQoL questionnaire was used to assess the health related QoL (HRQoL). It comprises of three dimensions: LISAT, medication worries (MEDWO) and disclosure worries (DISWO). The total imputed value score for LISAT is calculated on a 0-100 scale using the formula: LISAT 100=\[100 divided by (20 minus 4)\]\*(LISAT minus 4). A response of 5 in LISAT score shows satisfaction all of the time and 1 as none of the time. The higher the score, the greater satisfaction to life and the less worry. The transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% confidence interval (CI).Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 24 and 48
Change From Baseline in HIV Medication, MEDWO Using HATQoL
The HATQoL questionnaire was used to assess the health related QoL (HRQoL). It comprises of three dimensions: LISAT, medication worries (MEDWO) and disclosure worries (DISWO). The total imputed value score for MEDWO is calculated on a 0-100 scale using the formula: MEDWO 100=\[100 divided by (20 minus 5)\]\*(MEDWO minus 5). A response of 1 in MEDWO score shows less medication worries all of the time and 5 as none of the time. The higher the score, the greater satisfaction to life and the less worry. The transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline and at Weeks 24 and 48
Change From Baseline in DISWO Using HATQoL
The HATQoL questionnaire was used to assess the health related QoL (HRQoL). It comprises of three dimensions: LISAT, medication worries (MEDWO) and disclosure worries (DISWO). The total imputed value score for DISWO is calculated on a 0-100 scale using the formula: DISWO 100=\[100 divided by (20 minus 5)\]\*(DISWO minus 5). A response of 1 in DISWO score shows less medication worries all of the time and 5 as none of the time. The higher the score, the greater satisfaction to life and the less worry. The transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline and at Weeks 24 and 48
Change From Baseline in Health Status Using 12-item Short Form Survey (SF-12)
The SF-12 questionnaire consists of 7 questions which measures the degree of general health status and mental health distress. Each question is scored 0-5, except for question 2 scored 0-3. The HRQoL using SF-12 for the total score, physical component summary (PCS) and the mental component summary (MCS) were assessed for the two treatment groups. Missing Total or the component scores was imputed using LOCF. The PCS/MCS are calculated using computer software purchased from QualityMetric (http://www.qualitymetric.com). The higher the score, the better will be the health status. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline and at Weeks 24 and 48
Change From Baseline in Total Treatment Satisfaction Using HIV Treatment Satisfaction Questionnaire (HIVTSQs) at Weeks 4b, 24 and 44
The HIVTSQ for total treatment satisfaction score is computed with 1-11 items. These 1-11 items are summed to produce a score with a possible range of -33 to 33. The item 12 in the scale will be calculated as an individual score.The higher the score, the greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment.A score of 0 represents no change. A maximum of 5 items can be missing, the missing scores will be imputed with the mean of the completed item scores. If 6 or more items are missing, then the overall treatment satisfaction scale score should not be computed and will remain missing.LOCF was used as primary method of analysis. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. Data has been presented with respect to actual treatment received to the participants
Time frame: Baseline and at Weeks 4b, 24 and 44
Change in Treatment Satisfaction Over Time Using HIVTSQ Change (HIVTSQc) at Week 48 in Q4W Arm
The HIVTSQ for total treatment satisfaction score is computed with 1-11 items. These 1-11 items are summed to produce a score with a possible range of -33 to 33. The item 12 in the scale will be calculated as an individual score.The higher the score, the greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment.A score of 0 represents no change. A maximum of 5 items can be missing, the missing scores will be imputed with the mean of the completed item scores. If 6 or more items are missing, then the overall treatment satisfaction scale score should not be computed and will remain missing.LOCF was used as primary method of analysis. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. Data has been presented with respect to actual treatment received to the participants
Time frame: Week 48
Change From Baseline in Treatment Acceptance at Weeks 8, 24 and 48 Using "General Acceptance" Dimension of the Chronic Treatment Acceptance (ACCEPT) Questionnaire
The ACCEPT questionnaire is a generic medication acceptance measure assessing how participants weigh advantages and disadvantages of long-term medication.The questionnaire consists of 25 items that capture six dimensions.3 questions that focus on general acceptance of study medication will be analyzed.Items on the scale are rated as 1-5 scores:1:totally disagree,2:somewhat disagree,3:somewhat agree, 4:totally agree and 5:I don't know.Total score of the dimension is calculated as the mean of the recoded items of the dimension and then linearly transformed to be on a scale from 0 to 100:score:Total Score=(mean of the recoded items in the dimension minus1)divided by2\*100.LOCF was used as primary method of analysis.Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI.Baseline value is defined as the latest pre-treatment assessment with a non-missing value.Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value
Time frame: Baseline and at Weeks 8, 24 and 48
Change From 4b in Tolerability of Injection at Week 5, 40 and 41 Using Numeric Rating Scale (NRS) Within CAB LA+RPV LA Arm
The NRS questionnaire is used to assess the tolerability of injections in CAB LA+RPV LA arm only. The questionnaire consists of one single question and will assess maximum level of pain experienced with the most recent injections ranking from no pain (0) to extreme pain (10). Missing scores was imputed using LOCF.
Time frame: Weeks 4b, 5, 40 and 41
Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44
HIVTSQc is a 12 item questionnaire. The individual treatment change item scores on HIVTSQc scale are rated as +3 ('much more satisfied', 'much more convenient', 'much more flexible',etc.) to -3 ('much less satisfied', 'much less convenient', 'much less flexible', etc.). The higher the score, the greater the improvement in satisfaction with each aspect of treatment and the lower the score, the greater the deterioration in satisfaction with each aspect of treatment. LOCF was used as primary method of analysis. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline and Weeks 4b, 24 and 44
Number of Participants With Different Demographic Parameters for Inter-subject Variability
Blood samples were planned to be collected at indicated time points for PK analysis of CAB LA and RPV LA. Demographic parameters including, but not limited to, age, sex, race, body weight, body mass index, and relevant laboratory parameters were planned to be evaluated as potential predictors of inter subject variability for pharmacokinetic parameters.
Time frame: Upto Week 48
This was a phase III, randomized, open-label, active-controlled, multi-center, parallel-group, non-inferiority study to evaluate the antiviral activity and safety of two long-acting (LA) injectable drugs, cabotegravir (CAB) plus rilpivirine (RPV) when compared to current standard of care conducted in virologically suppressed human immunodeficiency.
| Milestone | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Started | 308 | 308 |
| Completed | 281 | 290 |
| Not completed | 27 | 18 |
| Withdrew: Adverse event | 13 | 5 |
| Withdrew: Withdrawal by subject | 1 | 5 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Protocol-specified withdrawal criterion | 1 | 0 |
| Withdrew: Protocol violation | 5 | 3 |
| Withdrew: Lack of efficacy | 3 | 4 |
| Withdrew: Ongoing | 1 | 0 |
Number of participants with virologic failure endpoint (HIV-1 RNA\>=50 c/mL) as per Food and Drug Administration (FDA) snapshot algorithm at Week 48 was assessed to demonstrate the non-inferior antiviral activity of switching to intramuscular (IM) CAB LA+RPV LA every 4 weeks compared to continuation of current ART regimen over 48 weeks in HIV-1 infected ART-experienced participants. The HIV-1 RNA \>=50 copies/mL per snapshot algorithm was determined by the last available on-treatment HIV-1 RNA measurement within the analysis visit window of interest.
| Participants | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Number of Participants With Virologic Failure (HIV-1 Ribonucleic Acid [RNA] >=50 Copies Per Millilter [mL]) Using Snapshot Algorithm at Week 48 | 5 | 3 |
Plasma samples were collected for quantitative analysis of HIV-1 RNA. Number of participants with plasma HIV-1 RNA \<50 copies/mL at Week 48 using FDA snapshot algorithm was assessed to demonstrate antiviral and immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART. The HIV-1 RNA \<50 copies/mL per snapshot algorithm was determined by the last available on-treatment HIV-1 RNA measurement within the analysis visit window of interest.
| Participants | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Number of Participants With HIV-1 RNA <50 Copies/mL Using Snapshot Algorithm at Week 48 | 285 | 294 |
Number of participants with plasma HIV-1 RNA \<200 copies/mL at Week 48 using the snapshot algorithm was assessed based on the antiviral and immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART.
| Participants | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Number of Participants With HIV-1 RNA <200 Copies/mL Using Snapshot Algorithm at Week 48 | 286 | 295 |
The CVF is defined as rebound as indicated by two consecutive plasma HIV-1-RNA levels \>=200 copies/mL after prior suppression to \<200 copies/mL. The outcome displays only visits during which at least one new CVF occurs. Plasma samples were collected for quantitative analysis of HIV-1 RNA.
| Participants | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Week 8 | 1 | 0 |
| Week 12 | 2 | 0 |
| Week 20 | 2 | 2 |
| Week 24 | 3 | 2 |
| Week 32 | 3 | 3 |
| Week 40 | 3 | 4 |
Logarithm to base 10 (log10) values for plasma HIV-1 RNA has been presented.
| log10 copies/mL | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Absolute Values for Plasma HIV-1 RNA at Week 48 | 1.505 ± 0.0470 | 1.518 ± 0.1123 |
Plasma for quantitative HIV-1 RNA were collected at indicated time points. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as: HIV-1 RNA(log 10) at Week 48 - HIV-1 RNA(log 10) at Baseline.
| log10 copies/mL | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Change From Baseline Values for Plasma HIV-1 RNA | -0.013 ± 0.1940 | 0.012 ± 0.1201 |
Blood samples were collected and CD4+ cell count assessment by flow cyclometry was carried out to evaluate the immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to current ART.
| Cells per cubic millimeter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Absolute Values for CD4+ Lymphocyte Count at Week 48 | 685.3 ± 262.97 | 716.7 ± 292.85 |
Blood samples were collected and CD4+ cell count assessment by flow cyclometry was carried out to evaluate the immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to current ART.Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value at Week 48 minus Baseline value.
| Cells per cubic millimeter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Change From Baseline Values for CD4+ Lymphocyte Count at Week 48 | 9.9 ± 187.24 | 19.4 ± 168.80 |
Disease progression was defined as HIV-associated conditions, acquired immunodeficiency syndrome (AIDS), and death through 48 Weeks. Data of participants who experienced disease progression to Centers for Disease Control and Prevention (CDC) Stage III or death has been presented.
| Participants | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Number of Participants With Disease Progression | 8 | 8 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement. Safety Population comprised of all randomized participants who received at least one dose of IP during the maintenance phase of the study (on or after Day 1 visit). Participants will be assessed according to actual treatment received.
| Participants | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Any non-SAE | 263 | 117 |
| Any SAE | 13 | 14 |
Severity of adverse events (AEs) were defined as per The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table) Version 2.0, November 2014. Severity grades for AEs were as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 were all deaths related to an AE.
| Participants | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Grade 1 | 101 | 115 |
| Grade 2 | 158 | 81 |
| Grade 3 | 27 | 19 |
| Grade 4 | 8 | 4 |
| Grade 5 | 0 | 1 |
Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, neutrophils, monocytes, and platelets at indicated time points.
| 10^9 cells per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Basophils, Baseline, n=308, 307 | 0.021 ± 0.0147 | 0.021 ± 0.0148 |
| Basophils, Week 4, n=299, 291 | 0.024 ± 0.0153 | 0.023 ± 0.0161 |
| Basophils, Week 8, n=216, 294 | 0.023 ± 0.0188 | 0.022 ± 0.0155 |
| Basophils, Week 12, n=293, 290 | 0.022 ± 0.0154 | 0.022 ± 0.0157 |
| Basophils, Week 16, n=274, 292 | 0.022 ± 0.0147 | 0.022 ± 0.0140 |
| Basophils, Week 20, n=273, 292 | 0.023 ± 0.0182 | 0.024 ± 0.0195 |
| Basophils, Week 24, n=277, 292 | 0.023 ± 0.0139 | 0.024 ± 0.0133 |
| Basophils, Week 28, n=266, 295 | 0.024 ± 0.0150 | 0.023 ± 0.0138 |
| Basophils, Week 32, n=262, 283 | 0.025 ± 0.0171 | 0.024 ± 0.0159 |
| Basophils, Week 36, n=260, 282 | 0.029 ± 0.0211 | 0.028 ± 0.0190 |
| Basophils, Week 40, n=258, 280 | 0.035 ± 0.0266 | 0.031 ± 0.0206 |
| Basophils, Week 44, n=258, 268 | 0.037 ± 0.0275 | 0.033 ± 0.0222 |
| Basophils, Week 48, n=246, 274 | 0.040 ± 0.0253 | 0.039 ± 0.0249 |
| Eosinophils, Baseline, n=308, 307 | 0.142 ± 0.1409 | 0.140 ± 0.1538 |
| Eosinophils, Week 4, n=299, 291 | 0.168 ± 0.1587 | 0.145 ± 0.1422 |
| Eosinophils, Week 8, n=216, 294 | 0.154 ± 0.1379 | 0.131 ± 0.1333 |
| Eosinophils, Week 12, n=293, 290 | 0.142 ± 0.1172 | 0.132 ± 0.1471 |
| Eosinophils, Week 16, n=274, 292 | 0.153 ± 0.1395 | 0.131 ± 0.1584 |
| Eosinophils, Week 20, n=273, 292 | 0.152 ± 0.1480 | 0.116 ± 0.1094 |
| Eosinophils, Week 24, n=277, 292 | 0.143 ± 0.1323 | 0.121 ± 0.1337 |
| Eosinophils, Week 28, n=266, 295 | 0.144 ± 0.1266 | 0.129 ± 0.1320 |
| Eosinophils, Week 32, n=262, 283 | 0.170 ± 0.1643 | 0.131 ± 0.1319 |
| Eosinophils, Week 36, n=260, 282 | 0.150 ± 0.1403 | 0.132 ± 0.1162 |
| Eosinophils, Week 40, n=258, 280 | 0.161 ± 0.1206 | 0.132 ± 0.1124 |
| Eosinophils, Week 44, n=258, 268 | 0.175 ± 0.1471 | 0.136 ± 0.1126 |
| Eosinophils, Week 48, n=246, 274 | 0.174 ± 0.1412 | 0.140 ± 0.1265 |
| Leukocytes, Baseline, n=308, 307 | 5.87 ± 1.928 | 5.65 ± 1.897 |
| Leukocytes, Week 4, n=300, 298 | 6.43 ± 2.154 | 5.81 ± 1.733 |
| Leukocytes, Week 8, n=217, 301 | 6.14 ± 1.875 | 5.64 ± 1.663 |
| Leukocytes, Week 12, n=294, 293 | 6.24 ± 1.876 | 5.77 ± 1.751 |
| Leukocytes, Week 16, n=279, 295 | 6.27 ± 1.920 | 5.82 ± 1.756 |
| Leukocytes, Week 20, n=276, 298 | 6.27 ± 1.947 | 5.70 ± 1.721 |
| Leukocytes, Week 24, n=279, 294 | 6.18 ± 1.931 | 5.78 ± 1.756 |
| Leukocytes, Week 28, n=268, 297 | 6.08 ± 1.949 | 5.73 ± 1.637 |
| Leukocytes, Week 32, n=267, 288 | 6.30 ± 1.914 | 5.73 ± 1.666 |
| Leukocytes, Week 36, n=264, 285 | 6.14 ± 1.831 | 5.80 ± 1.968 |
| Leukocytes, Week 40, n=264, 286 | 6.24 ± 2.046 | 5.74 ± 1.713 |
| Leukocytes, Week 44, n=269, 279 | 6.15 ± 1.884 | 5.66 ± 1.745 |
| Leukocytes, Week 48, n=252, 282 | 6.01 ± 1.943 | 5.62 ± 1.679 |
| Lymphocytes, Baseline, n=308, 307 | 1.943 ± 0.6073 | 1.940 ± 0.6880 |
| Lymphocytes, Week 4, n=299, 291 | 2.127 ± 0.6942 | 2.059 ± 0.6929 |
| Lymphocytes, Week 8, n=216, 294 | 1.995 ± 0.6347 | 1.975 ± 0.6549 |
| Lymphocytes, Week 12, n=293, 290 | 1.984 ± 0.6428 | 2.026 ± 0.6996 |
| Lymphocytes, Week 16, n=274, 292 | 2.057 ± 0.6840 | 2.029 ± 0.6584 |
| Lymphocytes, Week 20, n=273, 292 | 2.035 ± 0.6140 | 2.030 ± 0.6906 |
| Lymphocytes, Week 24, n=277, 292 | 2.016 ± 0.6523 | 1.980 ± 0.6047 |
| Lymphocytes, Week 28, n=266, 295 | 2.049 ± 0.6960 | 2.016 ± 0.6476 |
| Lymphocytes, Week 32, n=262, 283 | 2.020 ± 0.6157 | 2.007 ± 0.6511 |
| Lymphocytes, Week 36, n=260, 282 | 1.960 ± 0.6009 | 1.984 ± 0.6444 |
| Lymphocytes, Week 40, n=258, 280 | 1.994 ± 0.6149 | 1.957 ± 0.6305 |
| Lymphocytes, Week 44, n=258, 268 | 2.016 ± 0.6457 | 1.970 ± 0.6219 |
| Lymphocytes, Week 48, n=246, 274 | 1.900 ± 0.5725 | 1.915 ± 0.6204 |
| Neutrophils, Baseline, n=308, 307 | 3.437 ± 1.6106 | 3.209 ± 1.5748 |
| Neutrophils, Week 4, n=299, 291 | 3.708 ± 1.8763 | 3.244 ± 1.3931 |
| Neutrophils, Week 8, n=216, 294 | 3.597 ± 1.6128 | 3.190 ± 1.3370 |
| Neutrophils, Week 12, n=293, 290 | 3.724 ± 1.5751 | 3.268 ± 1.4153 |
| Neutrophils, Week 16, n=274, 292 | 3.670 ± 1.6777 | 3.308 ± 1.3870 |
| Neutrophils, Week 20, n=273, 292 | 3.707 ± 1.6532 | 3.188 ± 1.3345 |
| Neutrophils, Week 24, n=277, 292 | 3.613 ± 1.5978 | 3.289 ± 1.4381 |
| Neutrophils, Week 28, n=266, 295 | 3.528 ± 1.5464 | 3.221 ± 1.2962 |
| Neutrophils, Week 32, n=262, 283 | 3.704 ± 1.6196 | 3.228 ± 1.2909 |
| Neutrophils, Week 36, n=260, 282 | 3.629 ± 1.5688 | 3.314 ± 1.6341 |
| Neutrophils, Week 40, n=258, 280 | 3.688 ± 1.7685 | 3.280 ± 1.4190 |
| Neutrophils, Week 44, n=258, 268 | 3.571 ± 1.5425 | 3.169 ± 1.4140 |
| Neutrophils, Week 48, n=246, 274 | 3.450 ± 1.5649 | 3.172 ± 1.3627 |
| Monocytes, Baseline, n=308, 307 | 0.353 ± 0.1745 | 0.339 ± 0.1596 |
| Monocytes, Week 4, n=299, 291 | 0.404 ± 0.1951 | 0.367 ± 0.1694 |
| Monocytes, Week 8, n=216, 294 | 0.369 ± 0.1628 | 0.358 ± 0.1875 |
| Monocytes, Week 12, n=293, 290 | 0.375 ± 0.1563 | 0.342 ± 0.1693 |
| Monocytes, Week 16, n=274, 292 | 0.364 ± 0.1537 | 0.345 ± 0.1645 |
| Monocytes, Week 20, n=273, 292 | 0.356 ± 0.1526 | 0.342 ± 0.1632 |
| Monocytes, Week 24, n=277, 292 | 0.370 ± 0.1632 | 0.341 ± 0.1632 |
| Monocytes, Week 28, n=266, 295 | 0.354 ± 0.1631 | 0.333 ± 0.1592 |
| Monocytes, Week 32, n=262, 283 | 0.378 ± 0.1629 | 0.351 ± 0.1801 |
| Monocytes, Week 36, n=260, 282 | 0.376 ± 0.1593 | 0.366 ± 0.1824 |
| Monocytes, Week 40, n=258, 280 | 0.402 ± 0.1612 | 0.359 ± 0.1823 |
| Monocytes, Week 44, n=258, 268 | 0.409 ± 0.1643 | 0.388 ± 0.1795 |
| Monocytes, Week 48, n=246, 274 | 0.407 ± 0.1600 | 0.384 ± 0.1742 |
| Platelets, Baseline, n=308, 308 | 231.1 ± 56.75 | 232.9 ± 59.28 |
| Platelets, Week 4, n=300, 298 | 233.5 ± 55.09 | 238.1 ± 61.98 |
| Platelets, Week 8, n=216, 298 | 227.4 ± 47.04 | 234.0 ± 61.84 |
| Platelets, Week 12, n=294, 290 | 230.2 ± 57.32 | 237.8 ± 64.42 |
| Platelets, Week 16, n=279, 294 | 226.1 ± 56.82 | 236.4 ± 61.63 |
| Platelets, Week 20, n=274, 297 | 226.5 ± 58.11 | 237.7 ± 61.51 |
| Platelets, Week 24, n=279, 292 | 224.9 ± 53.19 | 239.8 ± 64.11 |
| Platelets, Week 28, n=268, 295 | 224.7 ± 54.15 | 239.0 ± 62.32 |
| Platelets, Week 32, n=267, 289 | 226.5 ± 50.84 | 239.3 ± 59.53 |
| Platelets, Week 36, n=267, 284 | 229.0 ± 53.90 | 242.9 ± 66.12 |
| Platelets, Week 40, n=263, 288 | 230.1 ± 53.48 | 240.8 ± 61.92 |
| Platelets, Week 44, n=270, 286 | 235.5 ± 55.80 | 241.4 ± 61.73 |
| Platelets, Week 48, n=253, 281 | 230.5 ± 54.33 | 240.2 ± 62.95 |
Blood samples were collected for the analysis of hematology parameter including erythrocyte mean corpuscular volume at indicated time points.
| Femtoliters | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Baseline, n=308, 308 | 95.7 ± 7.97 | 96.6 ± 9.35 |
| Week 4, n=300, 300 | 94.6 ± 6.88 | 96.9 ± 9.31 |
| Week 8, n=218, 301 | 92.7 ± 5.76 | 96.8 ± 9.25 |
| Week 12, n=294, 293 | 91.7 ± 5.69 | 96.9 ± 9.34 |
| Week 16, n=280, 296 | 90.6 ± 5.48 | 96.8 ± 9.64 |
| Week 20, n=276, 298 | 90.3 ± 5.37 | 97.0 ± 9.63 |
| Week 24, n=279, 294 | 90.2 ± 5.44 | 96.9 ± 9.75 |
| Week 28, n=268, 297 | 90.2 ± 5.68 | 97.2 ± 9.77 |
| Week 32, n=268, 291 | 90.1 ± 5.55 | 96.7 ± 9.36 |
| Week 36, n=267, 288 | 89.8 ± 5.64 | 96.5 ± 9.08 |
| Week 40, n=264, 289 | 89.9 ± 5.57 | 96.5 ± 9.05 |
| Week 44, n=273, 286 | 89.9 ± 5.52 | 96.2 ± 9.08 |
| Week 48, n=255, 284 | 89.9 ± 5.58 | 96.2 ± 9.38 |
Blood samples were collected for the analysis of hematology parameters including erythrocytes at indicated time points.
| 10^12 cells per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Baseline, n=308, 308 | 4.55 ± 0.563 | 4.49 ± 0.570 |
| Week 4, n=300, 300 | 4.59 ± 0.503 | 4.45 ± 0.567 |
| Week 8, n=218, 301 | 4.68 ± 0.479 | 4.49 ± 0.566 |
| Week 12, n=294, 293 | 4.79 ± 0.464 | 4.51 ± 0.580 |
| Week 16, n=280, 296 | 4.84 ± 0.475 | 4.48 ± 0.549 |
| Week 20, n=276, 298 | 4.86 ± 0.459 | 4.48 ± 0.586 |
| Week 24, n=279, 294 | 4.86 ± 0.471 | 4.48 ± 0.572 |
| Week 28, n=268, 297 | 4.85 ± 0.456 | 4.47 ± 0.565 |
| Week 32, n=268, 291 | 4.84 ± 0.452 | 4.48 ± 0.550 |
| Week 36, n=267, 288 | 4.81 ± 0.462 | 4.49 ± 0.561 |
| Week 40, n=264, 289 | 4.84 ± 0.456 | 4.49 ± 0.572 |
| Week 44, n=273, 286 | 4.86 ± 0.448 | 4.49 ± 0.572 |
| Week 48, n=255, 284 | 4.81 ± 0.448 | 4.50 ± 0.600 |
Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated time points.
| Grams per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Baseline, n=308, 308 | 142.2 ± 17.24 | 141.4 ± 16.29 |
| Week 4, n=300, 300 | 141.7 ± 16.30 | 140.5 ± 16.44 |
| Week 8, n=218, 301 | 141.5 ± 16.08 | 141.2 ± 16.51 |
| Week 12, n=294, 293 | 142.4 ± 15.90 | 141.6 ± 16.62 |
| Week 16, n=280, 296 | 142.5 ± 16.19 | 140.5 ± 15.81 |
| Week 20, n=276, 298 | 142.6 ± 15.52 | 141.2 ± 16.62 |
| Week 24, n=279, 294 | 143.3 ± 15.66 | 141.6 ± 16.18 |
| Week 28, n=268, 297 | 142.8 ± 16.05 | 140.9 ± 15.89 |
| Week 32, n=268, 291 | 143.0 ± 15.42 | 141.8 ± 15.81 |
| Week 36, n=267, 288 | 142.7 ± 16.31 | 142.3 ± 15.72 |
| Week 40, n=264, 289 | 143.5 ± 15.80 | 142.4 ± 15.90 |
| Week 44, n=273, 286 | 143.6 ± 15.66 | 142.1 ± 16.38 |
| Week 48, n=255, 284 | 142.7 ± 15.93 | 142.8 ± 16.34 |
Blood samples were collected for the analysis of hematology parameters including hematocrit at indicated time points.
| Proportion of red blood cells in blood | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Baseline, n=308, 308 | 0.4333 ± 0.04804 | 0.4305 ± 0.04454 |
| Week 4, n=300, 300 | 0.4325 ± 0.04570 | 0.4283 ± 0.04548 |
| Week 8, n=218, 301 | 0.4327 ± 0.04570 | 0.4310 ± 0.04580 |
| Week 12, n=294, 293 | 0.4379 ± 0.04483 | 0.4338 ± 0.04640 |
| Week 16, n=280, 296 | 0.4369 ± 0.04626 | 0.4304 ± 0.04418 |
| Week 20, n=276, 298 | 0.4378 ± 0.04476 | 0.4312 ± 0.04755 |
| Week 24, n=279, 294 | 0.4376 ± 0.04589 | 0.4312 ± 0.04595 |
| Week 28, n=268, 297 | 0.4364 ± 0.04607 | 0.4308 ± 0.04555 |
| Week 32, n=268, 291 | 0.4350 ± 0.04311 | 0.4299 ± 0.04431 |
| Week 36, n=267, 288 | 0.4311 ± 0.04462 | 0.4295 ± 0.04348 |
| Week 40, n=264, 289 | 0.4342 ± 0.04381 | 0.4300 ± 0.04449 |
| Week 44, n=273, 286 | 0.4357 ± 0.04288 | 0.4282 ± 0.04472 |
| Week 48, n=255, 284 | 0.4318 ± 0.04438 | 0.4286 ± 0.04465 |
Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, neutrophils, monocytes, and platelets at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
| 10^9 cells per liters | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Basophils, Week 4, n=299, 290 | 0.003 ± 0.0202 | 0.003 ± 0.0185 |
| Basophils, Week 8, n=216, 293 | 0.003 ± 0.0204 | 0.000 ± 0.0181 |
| Basophils, Week 12, n=293, 289 | 0.002 ± 0.0205 | 0.001 ± 0.0197 |
| Basophils, Week 16, n=274, 291 | 0.001 ± 0.0186 | 0.001 ± 0.0181 |
| Basophils, Week 20, n=273, 291 | 0.002 ± 0.0225 | 0.002 ± 0.0212 |
| Basophils, Week 24, n=277, 291 | 0.002 ± 0.0169 | 0.003 ± 0.0167 |
| Basophils, Week 28, n=266, 294 | 0.003 ± 0.0200 | 0.002 ± 0.0181 |
| Basophils, Week 32, n=262, 282 | 0.005 ± 0.0199 | 0.003 ± 0.0189 |
| Basophils, Week 36, n=260, 281 | 0.009 ± 0.0231 | 0.007 ± 0.0217 |
| Basophils, Week 40, n=258, 279 | 0.014 ± 0.0292 | 0.011 ± 0.0233 |
| Basophils, Week 44, n=258, 267 | 0.017 ± 0.0283 | 0.012 ± 0.0239 |
| Basophils, Week 48, n=246, 273 | 0.019 ± 0.0273 | 0.018 ± 0.0263 |
| Eosinophils, Week 4, n=299, 290 | 0.026 ± 0.1394 | 0.009 ± 0.1409 |
| Eosinophils, Week 8, n=216, 293 | 0.015 ± 0.1278 | -0.008 ± 0.1319 |
| Eosinophils, Week 12, n=293, 289 | -0.003 ± 0.1155 | -0.010 ± 0.1533 |
| Eosinophils, Week 16, n=274, 291 | 0.009 ± 0.1246 | -0.011 ± 0.1759 |
| Eosinophils, Week 20, n=273, 291 | 0.009 ± 0.1410 | -0.027 ± 0.1352 |
| Eosinophils, Week 24, n=277, 291 | 0.002 ± 0.1228 | -0.021 ± 0.1490 |
| Eosinophils, Week 28, n=266, 294 | -0.002 ± 0.1298 | -0.011 ± 0.1387 |
| Eosinophils, Week 32, n=262, 282 | 0.022 ± 0.1629 | -0.012 ± 0.1511 |
| Eosinophils, Week 36, n=260, 281 | 0.002 ± 0.1413 | -0.012 ± 0.1382 |
| Eosinophils, Week 40, n=258, 279 | 0.019 ± 0.1319 | -0.006 ± 0.1283 |
| Eosinophils, Week 44, n=258, 267 | 0.032 ± 0.1388 | -0.004 ± 0.1061 |
| Eosinophils, Week 48, n=246, 273 | 0.032 ± 0.1321 | 0.002 ± 0.1253 |
| Leukocytes, Week 4, n=300, 297 | 0.54 ± 1.599 | 0.13 ± 1.544 |
| Leukocytes, Week 8, n=217, 300 | 0.19 ± 1.579 | -0.02 ± 1.548 |
| Leukocytes, Week 12, n=294, 292 | 0.35 ± 1.743 | 0.10 ± 1.571 |
| Leukocytes, Week 16, n=279, 294 | 0.34 ± 1.653 | 0.17 ± 1.558 |
| Leukocytes, Week 20, n=276, 297 | 0.46 ± 1.565 | 0.04 ± 1.529 |
| Leukocytes, Week 24, n=279, 293 | 0.32 ± 1.720 | 0.10 ± 1.661 |
| Leukocytes, Week 28, n=268, 296 | 0.25 ± 1.651 | 0.07 ± 1.471 |
| Leukocytes, Week 32, n=267, 287 | 0.43 ± 1.602 | 0.07 ± 1.631 |
| Leukocytes, Week 36, n=264, 284 | 0.33 ± 1.699 | 0.13 ± 1.821 |
| Leukocytes, Week 40, n=264, 285 | 0.35 ± 1.808 | 0.12 ± 1.675 |
| Leukocytes, Week 44, n=269, 278 | 0.22 ± 1.581 | -0.03 ± 1.561 |
| Leukocytes, Week 48, n=252, 281 | 0.09 ± 1.646 | -0.06 ± 1.538 |
| Lymphocytes, Week 4, n=299, 290 | 0.174 ± 0.5185 | 0.128 ± 0.5618 |
| Lymphocytes, Week 8, n=216, 293 | 0.068 ± 0.5319 | 0.023 ± 0.5250 |
| Lymphocytes, Week 12, n=293, 289 | 0.033 ± 0.5073 | 0.079 ± 0.5844 |
| Lymphocytes, Week 16, n=274, 291 | 0.114 ± 0.5596 | 0.095 ± 0.5389 |
| Lymphocytes, Week 20, n=273, 291 | 0.071 ± 0.5274 | 0.086 ± 0.5411 |
| Lymphocytes, Week 24, n=277, 291 | 0.079 ± 0.5408 | 0.049 ± 0.4863 |
| Lymphocytes, Week 28, n=266, 294 | 0.101 ± 0.6133 | 0.069 ± 0.6005 |
| Lymphocytes, Week 32, n=262, 282 | 0.063 ± 0.5392 | 0.064 ± 0.5757 |
| Lymphocytes, Week 36, n=260, 281 | 0.008 ± 0.5333 | 0.036 ± 0.5525 |
| Lymphocytes, Week 40, n=258, 279 | 0.020 ± 0.5171 | 0.035 ± 0.5280 |
| Lymphocytes, Week 44, n=258, 267 | 0.045 ± 0.5430 | 0.045 ± 0.5472 |
| Lymphocytes, Week 48, n=246, 273 | -0.063 ± 0.5528 | -0.035 ± 0.5115 |
| Neutrophils, Week 4, n=299, 290 | 0.258 ± 1.5445 | 0.004 ± 1.3601 |
| Neutrophils, Week 8, n=216, 293 | 0.080 ± 1.4401 | -0.031 ± 1.3599 |
| Neutrophils, Week 12, n=293, 289 | 0.283 ± 1.6227 | 0.028 ± 1.3884 |
| Neutrophils, Week 16, n=274, 291 | 0.181 ± 1.5415 | 0.080 ± 1.4451 |
| Neutrophils, Week 20, n=273, 291 | 0.341 ± 1.4475 | -0.019 ± 1.4228 |
| Neutrophils, Week 24, n=277, 291 | 0.175 ± 1.5883 | 0.056 ± 1.5091 |
| Neutrophils, Week 28, n=266, 294 | 0.129 ± 1.4052 | -0.001 ± 1.3377 |
| Neutrophils, Week 32, n=262, 282 | 0.291 ± 1.6015 | 0.008 ± 1.4430 |
| Neutrophils, Week 36, n=260, 281 | 0.289 ± 1.5702 | 0.077 ± 1.6758 |
| Neutrophils, Week 40, n=258, 279 | 0.245 ± 1.6621 | 0.075 ± 1.5336 |
| Neutrophils, Week 44, n=258, 267 | 0.063 ± 1.4874 | -0.105 ± 1.4587 |
| Neutrophils, Week 48, n=246, 273 | 0.009 ± 1.5413 | -0.066 ± 1.3969 |
| Monocytes, Week 4, n=299, 290 | 0.049 ± 0.1663 | 0.030 ± 0.1270 |
| Monocytes Week 8, n=216, 293 | 0.014 ± 0.1433 | 0.018 ± 0.1591 |
| Monocytes, Week 12, n=293, 289 | 0.018 ± 0.1553 | 0.001 ± 0.1367 |
| Monocytes, Week 16, n=274, 291 | 0.005 ± 0.1588 | 0.003 ± 0.1403 |
| Monocytes, Week 20, n=273, 291 | 0.003 ± 0.1527 | 0.004 ± 0.1328 |
| Monocytes, Week 24, n=277, 291 | 0.012 ± 0.1484 | 0.002 ± 0.1331 |
| Monocytes, Week 28, n=266, 294 | 0.001 ± 0.1548 | -0.004 ± 0.1343 |
| Monocytes, Week 32, n=262, 282 | 0.019 ± 0.1535 | 0.011 ± 0.1585 |
| Monocytes, Week 36, n=260, 281 | 0.016 ± 0.1501 | 0.024 ± 0.1551 |
| Monocytes, Week 40, n=258, 279 | 0.039 ± 0.1507 | 0.020 ± 0.1550 |
| Monocytes, Week 44, n=258, 267 | 0.045 ± 0.1673 | 0.045 ± 0.1539 |
| Monocytes, Week 48, n=246, 273 | 0.047 ± 0.1502 | 0.039 ± 0.1499 |
| Platelets, Week 4, n=300, 298 | 1.8 ± 38.02 | 4.3 ± 36.15 |
| Platelets, Week 8, n=216, 298 | -5.5 ± 31.98 | 0.7 ± 35.15 |
| Platelets, Week 12, n=294, 290 | -0.8 ± 40.83 | 5.5 ± 36.76 |
| Platelets, Week 16, n=279, 294 | -5.2 ± 40.67 | 4.3 ± 34.61 |
| Platelets, Week 20, n=274, 297 | -3.7 ± 36.87 | 5.5 ± 38.86 |
| Platelets, Week 24, n=279, 292 | -4.7 ± 35.22 | 6.7 ± 41.78 |
| Platelets, Week 28, n=268, 295 | -5.3 ± 35.22 | 5.4 ± 38.41 |
| Platelets, Week 32, n=267, 289 | -2.6 ± 36.51 | 6.5 ± 35.99 |
| Platelets, Week 36, n=267, 284 | -1.2 ± 37.26 | 9.8 ± 44.52 |
| Platelets, Week 40, n=263, 288 | 0.0 ± 40.74 | 9.7 ± 39.91 |
| Platelets, Week 44, n=270, 286 | 4.5 ± 38.31 | 9.2 ± 42.82 |
| Platelets, Week 48, n=253, 281 | 0.0 ± 38.63 | 10.4 ± 41.75 |
Blood samples were collected for the analysis of hematology parameter including erythrocyte mean corpuscular volume at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Femtoliters | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Week 4, n=300, 300 | -1.1 ± 2.71 | 0.2 ± 1.82 |
| Week 8, n=218, 301 | -3.0 ± 4.30 | 0.1 ± 1.76 |
| Week 12, n=294, 293 | -3.9 ± 5.23 | 0.2 ± 2.08 |
| Week 16, n=280, 296 | -4.9 ± 5.86 | 0.2 ± 2.42 |
| Week 20, n=276, 298 | -5.3 ± 5.98 | 0.3 ± 2.88 |
| Week 24, n=279, 294 | -5.4 ± 5.97 | 0.3 ± 3.24 |
| Week 28, n=268, 297 | -5.5 ± 6.11 | 0.4 ± 3.46 |
| Week 32, n=268, 291 | -5.5 ± 6.10 | 0.1 ± 3.47 |
| Week 36, n=267, 288 | -5.8 ± 6.24 | -0.0 ± 3.69 |
| Week 40, n=264, 289 | -5.6 ± 6.21 | -0.1 ± 3.62 |
| Week 44, n=273, 286 | -5.8 ± 6.33 | -0.3 ± 3.68 |
| Week 48, n=255, 284 | -5.7 ± 6.76 | -0.4 ± 3.57 |
Blood samples were collected for the analysis of hematology parameters including erythrocytes at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
| 10^12 cells per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Week 4, n=300, 300 | 0.04 ± 0.255 | -0.03 ± 0.226 |
| Week 8, n=218, 301 | 0.14 ± 0.331 | -0.01 ± 0.249 |
| Week 12, n=294, 293 | 0.23 ± 0.374 | 0.01 ± 0.252 |
| Week 16, n=280, 296 | 0.28 ± 0.380 | -0.01 ± 0.256 |
| Week 20, n=276, 298 | 0.30 ± 0.408 | -0.01 ± 0.273 |
| Week 24, n=279, 294 | 0.32 ± 0.397 | -0.01 ± 0.246 |
| Week 28, n=268, 297 | 0.28 ± 0.386 | -0.01 ± 0.246 |
| Week 32, n=268, 291 | 0.29 ± 0.393 | -0.01 ± 0.261 |
| Week 36, n=267, 288 | 0.26 ± 0.401 | -0.01 ± 0.259 |
| Week 40, n=264, 289 | 0.27 ± 0.396 | -0.01 ± 0.260 |
| Week 44, n=273, 286 | 0.31 ± 0.391 | -0.01 ± 0.264 |
| Week 48, n=255, 284 | 0.25 ± 0.394 | -0.01 ± 0.262 |
Blood samples were collected for the analysis of hematology parameters including hematocrit at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Proportion of red blood cells in blood | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Week 4, n=300, 300 | -0.0003 ± 0.02236 | -0.0023 ± 0.02194 |
| Week 8, n=218, 301 | 0.0007 ± 0.02613 | -0.0005 ± 0.02330 |
| Week 12, n=294, 293 | 0.0042 ± 0.02607 | 0.0020 ± 0.02408 |
| Week 16, n=280, 296 | 0.0038 ± 0.02509 | -0.0007 ± 0.02513 |
| Week 20, n=276, 298 | 0.0043 ± 0.02742 | 0.0002 ± 0.02613 |
| Week 24, n=279, 294 | 0.0052 ± 0.02790 | 0.0002 ± 0.02576 |
| Week 28, n=268, 297 | 0.0023 ± 0.02699 | 0.0002 ± 0.02603 |
| Week 32, n=268, 291 | 0.0022 ± 0.02872 | -0.0011 ± 0.02916 |
| Week 36, n=267, 288 | -0.0012 ± 0.02793 | -0.0011 ± 0.02797 |
| Week 40, n=264, 289 | -0.0001 ± 0.02741 | -0.0011 ± 0.02781 |
| Week 44, n=273, 286 | 0.0031 ± 0.02896 | -0.0025 ± 0.02814 |
| Week 48, n=255, 284 | -0.0021 ± 0.02717 | -0.0031 ± 0.02700 |
Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Grams per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Week 4, n=300, 300 | -0.4 ± 6.91 | -1.0 ± 6.73 |
| Week 8, n=218, 301 | -0.4 ± 8.18 | -0.6 ± 7.33 |
| Week 12, n=294, 293 | 0.0 ± 8.14 | -0.3 ± 7.52 |
| Week 16, n=280, 296 | 0.4 ± 8.22 | -1.2 ± 7.75 |
| Week 20, n=276, 298 | 0.3 ± 8.60 | -0.5 ± 8.55 |
| Week 24, n=279, 294 | 1.2 ± 8.78 | -0.0 ± 8.46 |
| Week 28, n=268, 297 | 0.3 ± 8.49 | -0.6 ± 8.68 |
| Week 32, n=268, 291 | 0.9 ± 8.94 | 0.2 ± 9.45 |
| Week 36, n=267, 288 | 0.7 ± 9.03 | 0.8 ± 9.32 |
| Week 40, n=264, 289 | 0.8 ± 8.96 | 0.7 ± 9.29 |
| Week 44, n=273, 286 | 1.7 ± 9.49 | 0.6 ± 9.53 |
| Week 48, n=255, 284 | 0.2 ± 9.26 | 0.9 ± 9.07 |
Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK at indicated time points.
| International units per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| ALT, Baseline (Day 1), n=308, 308 | 23.8 ± 13.47 | 22.4 ± 12.90 |
| ALT, Week 4, n=301, 303 | 24.4 ± 15.60 | 22.3 ± 11.10 |
| ALT, Week 8, n=229, 303 | 24.0 ± 16.85 | 24.0 ± 29.86 |
| ALT, Week 12, n=295, 299 | 29.0 ± 114.25 | 22.7 ± 13.48 |
| ALT, Week 16, n=284, 298 | 23.7 ± 22.32 | 21.8 ± 11.31 |
| ALT, Week 20, n=277, 302 | 23.1 ± 22.49 | 21.2 ± 10.50 |
| ALT, Week 24, n=284, 299 | 26.3 ± 62.05 | 21.6 ± 12.64 |
| ALT, Week 28, n=267, 296 | 21.1 ± 12.13 | 22.1 ± 14.62 |
| ALT, Week 32, n=275, 294 | 21.8 ± 12.56 | 21.8 ± 12.09 |
| ALT, Week 36, n=273, 292 | 23.2 ± 24.94 | 22.3 ± 12.17 |
| ALT, Week 40, n=270, 293 | 24.5 ± 37.39 | 22.1 ± 12.78 |
| ALT, Week 44, n=275, 293 | 21.6 ± 13.10 | 22.1 ± 13.67 |
| ALT, Week 48, n=265, 292 | 21.8 ± 13.54 | 21.7 ± 11.08 |
| ALP, Baseline (Day 1), n=308, 308 | 76.6 ± 28.20 | 77.5 ± 26.77 |
| ALP, Week 4, n=301, 303 | 70.4 ± 22.75 | 75.7 ± 25.58 |
| ALP, Week 8, n=229, 303 | 68.9 ± 21.98 | 78.8 ± 32.40 |
| ALP, Week 12, n=295, 299 | 68.9 ± 24.79 | 78.6 ± 28.87 |
| ALP, Week 16, n=284, 298 | 67.9 ± 19.76 | 77.3 ± 27.21 |
| ALP, Week 20, n=277, 302 | 67.6 ± 18.72 | 76.7 ± 25.48 |
| ALP, Week 24, n=284, 299 | 68.1 ± 19.15 | 77.5 ± 26.36 |
| ALP, Week 28, n=267, 296 | 67.6 ± 18.89 | 77.2 ± 26.72 |
| ALP, Week 32, n=275, 294 | 66.6 ± 19.14 | 75.8 ± 25.56 |
| ALP, Week 36, n=273, 292 | 66.8 ± 20.68 | 76.4 ± 25.93 |
| ALP, Week 40, n=270, 293 | 66.2 ± 17.58 | 76.2 ± 26.08 |
| ALP, Week 44, n=275, 293 | 66.1 ± 18.34 | 76.8 ± 25.82 |
| ALP, Week 48, n=265, 292 | 66.5 ± 18.84 | 77.1 ± 26.39 |
| AST, Baseline (Day 1), n=308, 308 | 23.9 ± 11.31 | 22.5 ± 10.21 |
| AST, Week 4, n=301, 303 | 23.2 ± 11.77 | 22.7 ± 10.93 |
| AST, Week 8, n=229, 303 | 24.3 ± 19.49 | 22.5 ± 12.31 |
| AST, Week 12, n=295, 299 | 26.1 ± 64.69 | 23.2 ± 10.61 |
| AST, Week 16, n=284, 298 | 24.1 ± 18.20 | 22.5 ± 8.59 |
| AST, Week 20, n=277, 302 | 23.5 ± 15.23 | 22.0 ± 6.83 |
| AST, Week 24, n=284, 298 | 24.2 ± 22.89 | 22.5 ± 9.30 |
| AST, Week 28, n=267, 296 | 22.2 ± 8.72 | 22.9 ± 9.61 |
| AST, Week 32, n=275, 294 | 22.8 ± 13.71 | 23.2 ± 12.32 |
| AST, Week 36, n=273, 292 | 23.0 ± 11.27 | 22.6 ± 7.18 |
| AST, Week 40, n=270, 293 | 23.8 ± 14.96 | 22.5 ± 7.79 |
| AST, Week 44, n=275, 293 | 22.9 ± 14.82 | 22.6 ± 10.26 |
| AST Week 48, n=265, 292 | 22.9 ± 10.35 | 23.2 ± 9.30 |
| CK, Baseline (Day 1), n=308, 308 | 196.6 ± 367.30 | 160.8 ± 367.57 |
| CK, Week 4, n=301, 303 | 192.9 ± 437.09 | 190.6 ± 472.57 |
| CK, Week 8, n=229, 303 | 275.9 ± 1064.72 | 145.4 ± 141.19 |
| CK, Week 12, n=295, 299 | 200.7 ± 484.08 | 177.0 ± 321.29 |
| CK, Week 16, n=284, 298 | 253.5 ± 849.45 | 167.5 ± 286.90 |
| CK, Week 20, n=277, 302 | 228.4 ± 570.80 | 144.5 ± 133.32 |
| CK, Week 24, n=284, 299 | 193.1 ± 444.27 | 161.2 ± 241.73 |
| CK, Week 28, n=267, 296 | 168.8 ± 163.54 | 182.7 ± 420.44 |
| CK, Week 32, n=275, 294 | 216.5 ± 593.10 | 195.9 ± 489.99 |
| CK, Week 36, n=273, 292 | 186.4 ± 325.64 | 150.7 ± 134.40 |
| CK, Week 40, n=270, 293 | 235.1 ± 624.03 | 160.7 ± 179.64 |
| CK, Week 44, n=275, 293 | 245.5 ± 1189.35 | 149.9 ± 148.23 |
| CK, Week 48, n=265, 292 | 198.8 ± 398.14 | 179.0 ± 331.51 |
Blood samples were collected for the analysis of clinical chemistry parameter-albumin at indicated time points.
| Grams per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Baseline (Day 1), n=308, 308 | 44.2 ± 3.12 | 44.3 ± 3.19 |
| Week 4, n=301, 303 | 43.7 ± 2.88 | 43.8 ± 2.87 |
| Week 8, n=229, 303 | 43.8 ± 3.06 | 43.7 ± 3.17 |
| Week 12, n=295, 299 | 43.6 ± 2.99 | 43.9 ± 3.12 |
| Week 16, n=284, 298 | 43.5 ± 2.77 | 43.5 ± 3.12 |
| Week 20, n=277, 302 | 43.4 ± 2.72 | 43.5 ± 3.07 |
| Week 24, n=284, 299 | 43.4 ± 2.74 | 43.5 ± 3.02 |
| Week 28, n=267, 296 | 43.6 ± 2.85 | 43.3 ± 3.07 |
| Week 32, n=275, 294 | 43.5 ± 2.83 | 43.4 ± 3.25 |
| Week 36, n=273, 292 | 43.3 ± 2.82 | 43.4 ± 3.07 |
| Week 40, n=270, 293 | 43.7 ± 2.72 | 43.4 ± 3.04 |
| Week 44, n=275, 293 | 43.7 ± 2.78 | 43.5 ± 3.02 |
| Week 48, n=265, 292 | 43.8 ± 2.74 | 44.0 ± 2.92 |
Blood samples were collected for the analysis of clinical chemistry parameters including bilirubin, creatinine and direct bilirubin at indicated time points.
| Micromoles per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Bilirubin, Baseline (Day 1), n=308, 308 | 9.9 ± 9.71 | 9.2 ± 6.39 |
| Bilirubin, Week 4, n=301, 303 | 9.1 ± 3.98 | 8.9 ± 6.14 |
| Bilirubin, Week 8, n=229, 303 | 9.3 ± 4.05 | 9.4 ± 9.06 |
| Bilirubin, Week 12, n=295, 299 | 9.3 ± 4.45 | 9.3 ± 6.62 |
| Bilirubin, Week 16, n=284, 298 | 10.0 ± 10.71 | 9.1 ± 6.28 |
| Bilirubin, Week 20, n=277, 302 | 9.7 ± 4.28 | 9.3 ± 7.56 |
| Bilirubin, Week 24, n=284, 298 | 9.3 ± 3.90 | 9.4 ± 8.38 |
| Bilirubin, Week 28, n=267, 296 | 9.8 ± 3.99 | 9.1 ± 7.05 |
| Bilirubin, Week 32, n=275, 294 | 9.8 ± 4.36 | 9.3 ± 7.05 |
| Bilirubin, Week 36, n=273, 292 | 9.3 ± 3.79 | 9.2 ± 7.34 |
| Bilirubin, Week 40, n=270, 293 | 9.6 ± 4.07 | 9.5 ± 9.04 |
| Bilirubin, Week 44, n=275, 293 | 9.6 ± 4.19 | 9.7 ± 8.49 |
| Bilirubin, Week 48, n=265, 292 | 9.7 ± 4.24 | 9.5 ± 6.36 |
| Direct bilirubin, Baseline (Day 1), n=308, 308 | 2.4 ± 1.35 | 2.2 ± 1.25 |
| Direct bilirubin, Week 4, n=301, 303 | 2.3 ± 1.04 | 2.3 ± 1.27 |
| Direct bilirubin, Week 8, n=229, 303 | 2.3 ± 1.08 | 2.4 ± 3.96 |
| Direct bilirubin, Week 12, n=295, 299 | 2.2 ± 1.03 | 2.3 ± 1.30 |
| Direct bilirubin, Week 16, n=284, 298 | 2.5 ± 4.98 | 2.1 ± 1.08 |
| Direct bilirubin, Week 20, n=277, 302 | 2.2 ± 0.95 | 2.0 ± 1.31 |
| Direct bilirubin, Week 24, n=284, 298 | 2.2 ± 0.99 | 2.1 ± 1.26 |
| Direct bilirubin, Week 28, n=267, 296 | 2.1 ± 0.94 | 2.0 ± 1.28 |
| Direct bilirubin, Week 32, n=275, 294 | 2.1 ± 1.00 | 2.0 ± 1.22 |
| Direct bilirubin, Week 36, n=273, 292 | 2.1 ± 1.11 | 2.1 ± 1.27 |
| Direct bilirubin, Week 40, n=270, 293 | 2.1 ± 1.08 | 2.1 ± 1.37 |
| Direct bilirubin, Week 44, n=275, 293 | 2.2 ± 0.95 | 2.2 ± 1.30 |
| Direct bilirubin, Week 48, n=265, 292 | 2.2 ± 0.92 | 2.2 ± 1.23 |
| Creatinine, Baseline (Day 1), n=308, 308 | 79.05 ± 16.380 | 77.83 ± 16.497 |
| Creatinine, Week 4, n=301, 301 | 80.17 ± 15.464 | 79.47 ± 16.284 |
| Creatinine, Week 8, n=229, 303 | 78.79 ± 16.122 | 79.22 ± 16.824 |
| Creatinine, Week 12, n=295, 299 | 78.65 ± 16.534 | 79.50 ± 17.191 |
| Creatinine, Week 16, n=284, 298 | 78.72 ± 15.606 | 79.51 ± 17.171 |
| Creatinine, Week 20, n=277, 302 | 79.75 ± 15.695 | 79.62 ± 16.909 |
| Creatinine, Week 24, n=284, 298 | 80.15 ± 18.478 | 79.05 ± 16.673 |
| Creatinine, Week 28, n=267, 296 | 80.42 ± 16.335 | 79.35 ± 16.574 |
| Creatinine, Week 32, n=275, 294 | 79.65 ± 15.044 | 79.69 ± 16.634 |
| Creatinine, Week 36, n=273, 292 | 79.73 ± 15.994 | 79.34 ± 16.527 |
| Creatinine, Week 40, n=270, 293 | 80.28 ± 15.856 | 79.42 ± 16.856 |
| Creatinine, Week 44, n=275, 293 | 79.98 ± 15.775 | 79.16 ± 16.583 |
| Creatinine, Week 48, n=265, 292 | 80.77 ± 16.456 | 78.65 ± 16.204 |
Blood samples were collected for the analysis of clinical chemistry parameters which includes total CO2, chloride, glucose, phosphate, potassium, sodium and urea at indicated time points.
| Millimoles per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| CO2, Baseline (Day 1), n=308, 308 | 22.7 ± 2.33 | 22.6 ± 2.24 |
| CO2, Week 4, n=301, 303 | 23.7 ± 2.49 | 23.3 ± 2.27 |
| CO2, Week 8, n=229, 303 | 23.1 ± 2.17 | 23.2 ± 2.47 |
| CO2, Week 12, n=295, 299 | 23.2 ± 2.14 | 23.0 ± 2.36 |
| CO2, Week 16, n=284, 298 | 22.9 ± 2.16 | 23.0 ± 2.31 |
| CO2, Week 20, n=277, 302 | 22.9 ± 2.16 | 22.9 ± 2.29 |
| CO2, Week 24, n=284, 298 | 22.9 ± 2.31 | 22.8 ± 2.41 |
| CO2, Week 28, n=267, 296 | 22.7 ± 2.42 | 22.7 ± 2.27 |
| CO2, Week 32, n=275, 294 | 22.6 ± 2.15 | 22.8 ± 2.34 |
| CO2, Week 36, n=273, 292 | 22.8 ± 2.19 | 23.0 ± 2.26 |
| CO2, Week 40, n=270, 293 | 23.1 ± 2.27 | 23.0 ± 2.45 |
| CO2, Week 44, n=275, 293 | 23.0 ± 2.19 | 23.2 ± 2.31 |
| CO2, Week 48, n=265, 292 | 22.7 ± 2.29 | 22.9 ± 2.29 |
| Chloride, Baseline (Day 1), n=308, 308 | 103.8 ± 2.03 | 103.8 ± 2.39 |
| Chloride, Week 4, n=301, 303 | 104.3 ± 2.13 | 104.3 ± 2.22 |
| Chloride, Week 8, n=229, 303 | 104.3 ± 2.26 | 104.2 ± 2.40 |
| Chloride, Week 12, n=295, 299 | 104.2 ± 2.27 | 104.3 ± 2.24 |
| Chloride, Week 16, n=284, 298 | 104.5 ± 2.21 | 104.5 ± 2.28 |
| Chloride, Week 20, n=277, 302 | 104.7 ± 2.41 | 104.5 ± 2.38 |
| Chloride, Week 24, n=284, 299 | 104.5 ± 2.36 | 104.7 ± 2.30 |
| Chloride, Week 28, n=267, 296 | 104.8 ± 2.19 | 104.8 ± 2.36 |
| Chloride, Week 32, n=275, 294 | 104.7 ± 2.50 | 104.7 ± 2.31 |
| Chloride, Week 36, n=273, 292 | 104.8 ± 2.18 | 104.6 ± 2.36 |
| Chloride, Week 40, n=270, 293 | 104.7 ± 2.22 | 104.6 ± 2.61 |
| Chloride, Week 44, n=275, 293 | 104.6 ± 2.10 | 104.6 ± 2.27 |
| Chloride, Week 48, n=265, 292 | 104.4 ± 2.38 | 104.1 ± 2.37 |
| Glucose, Baseline (Day 1), n=301, 299 | 5.00 ± 0.714 | 5.17 ± 0.988 |
| Glucose, Week 4, n=216, 226 | 5.17 ± 0.747 | 5.42 ± 1.250 |
| Glucose, Week 8, n=153, 218 | 5.16 ± 0.990 | 5.35 ± 1.037 |
| Glucose, Week 12, n=206, 221 | 5.19 ± 0.965 | 5.35 ± 1.091 |
| Glucose, Week 16, n=209, 216 | 5.22 ± 1.163 | 5.36 ± 1.317 |
| Glucose, Week 20, n=194, 221 | 5.20 ± 0.736 | 5.37 ± 1.209 |
| Glucose, Week 24, n=215, 229 | 5.24 ± 0.810 | 5.35 ± 0.840 |
| Glucose, Week 28, n=190, 226 | 5.16 ± 0.697 | 5.36 ± 0.876 |
| Glucose, Week 32, n=194, 219 | 5.33 ± 1.042 | 5.45 ± 1.102 |
| Glucose, Week 36, n=191, 220 | 5.19 ± 0.777 | 5.40 ± 1.507 |
| Glucose, Week 40, n=195, 218 | 5.30 ± 0.797 | 5.44 ± 1.227 |
| Glucose, Week 44, n=193, 213 | 5.22 ± 0.887 | 5.44 ± 1.317 |
| Glucose, Week 48, n=242, 277 | 5.08 ± 0.614 | 5.22 ± 0.963 |
| Phosphate, Baseline (Day 1), n=308, 308 | 1.042 ± 0.1771 | 1.051 ± 0.1722 |
| Phosphate, Week 4, n=301, 303 | 1.110 ± 0.1793 | 1.066 ± 0.1773 |
| Phosphate, Week 8, n=229, 303 | 1.097 ± 0.1944 | 1.042 ± 0.1843 |
| Phosphate, Week 12, n=295, 299 | 1.080 ± 0.1872 | 1.062 ± 0.1922 |
| Phosphate, Week 16, n=284, 298 | 1.081 ± 0.1796 | 1.052 ± 0.1724 |
| Phosphate, Week 20, n=277, 302 | 1.073 ± 0.1746 | 1.061 ± 0.1873 |
| Phosphate, Week 24, n=284, 299 | 1.082 ± 0.1788 | 1.057 ± 0.1849 |
| Phosphate, Week 28, n=267, 296 | 1.072 ± 0.1714 | 1.053 ± 0.1741 |
| Phosphate, Week 32, n=275, 294 | 1.061 ± 0.1730 | 1.054 ± 0.1761 |
| Phosphate, Week 36, n=273, 292 | 1.052 ± 0.1700 | 1.049 ± 0.1798 |
| Phosphate, Week 40, n=270, 293 | 1.065 ± 0.1789 | 1.046 ± 0.1763 |
| Phosphate, Week 44, n=275, 293 | 1.066 ± 0.1798 | 1.052 ± 0.1902 |
| Phosphate, Week 48, n=265, 292 | 1.077 ± 0.1816 | 1.052 ± 0.1834 |
| Potassium, Baseline (Day 1), n=308, 308 | 4.16 ± 0.281 | 4.17 ± 0.314 |
| Potassium, Week 4, n=301, 303 | 4.21 ± 0.307 | 4.28 ± 0.352 |
| Potassium, Week 8, n=229, 303 | 4.16 ± 0.296 | 4.22 ± 0.393 |
| Potassium, Week 12, n=295, 299 | 4.19 ± 0.330 | 4.24 ± 0.332 |
| Potassium, Week 16, n=284, 298 | 4.18 ± 0.316 | 4.23 ± 0.321 |
| Potassium, Week 20, n=277, 302 | 4.19 ± 0.311 | 4.21 ± 0.320 |
| Potassium, Week 24, n=284, 298 | 4.18 ± 0.287 | 4.23 ± 0.337 |
| Potassium, Week 28, n=267, 296 | 4.19 ± 0.346 | 4.24 ± 0.391 |
| Potassium, Week 32, n=275, 294 | 4.18 ± 0.368 | 4.21 ± 0.341 |
| Potassium, Week 36, n=273, 292 | 4.19 ± 0.326 | 4.23 ± 0.345 |
| Potassium, Week 40, n=270, 293 | 4.20 ± 0.301 | 4.23 ± 0.322 |
| Potassium, Week 44, n=275, 293 | 4.21 ± 0.323 | 4.23 ± 0.359 |
| Potassium, Week 48, n=265, 292 | 4.15 ± 0.271 | 4.16 ± 0.331 |
| Sodium, Baseline (Day 1), n=308, 308 | 139.0 ± 1.91 | 139.0 ± 1.76 |
| Sodium, Week 4, n=301, 303 | 139.3 ± 1.70 | 139.1 ± 1.87 |
| Sodium, Week 8, n=229, 303 | 139.1 ± 1.98 | 139.0 ± 1.80 |
| Sodium, Week 12, n=295, 299 | 139.2 ± 1.84 | 139.2 ± 1.85 |
| Sodium, Week 16, n=284, 298 | 139.1 ± 1.98 | 139.1 ± 1.96 |
| Sodium, Week 20, n=277, 302 | 139.2 ± 1.87 | 139.3 ± 1.81 |
| Sodium, Week 24, n=284, 299 | 139.3 ± 1.88 | 139.3 ± 1.96 |
| Sodium, Week 28, n=267, 296 | 139.5 ± 1.77 | 139.2 ± 2.01 |
| Sodium, Week 32, n=275, 294 | 139.3 ± 1.75 | 139.5 ± 1.84 |
| Sodium, Week 36, n=273, 292 | 139.4 ± 1.79 | 139.5 ± 2.15 |
| Sodium, Week 40, n=270, 293 | 139.4 ± 1.93 | 139.5 ± 1.97 |
| Sodium, Week 44, n=275, 293 | 139.4 ± 1.80 | 139.5 ± 1.93 |
| Sodium, Week 48, n=265, 292 | 139.4 ± 1.94 | 139.4 ± 1.83 |
| Urea, Baseline (Day 1), n=308, 308 | 5.23 ± 1.546 | 5.22 ± 1.632 |
| Urea, Week 4, n=301, 303 | 5.24 ± 1.495 | 5.28 ± 1.549 |
| Urea, Week 8, n=229, 303 | 5.32 ± 1.640 | 5.22 ± 1.529 |
| Urea, Week 12, n=295, 299 | 5.38 ± 1.612 | 5.30 ± 1.649 |
| Urea, Week 16, n=284, 298 | 5.30 ± 1.662 | 5.41 ± 1.659 |
| Urea, Week 20, n=277, 302 | 5.37 ± 1.631 | 5.33 ± 1.662 |
| Urea, Week 24, n=284, 299 | 5.49 ± 1.749 | 5.36 ± 1.639 |
| Urea, Week 28, n=267, 296 | 5.39 ± 1.756 | 5.24 ± 1.527 |
| Urea, Week 32, n=275, 294 | 5.44 ± 1.624 | 5.29 ± 1.599 |
| Urea, Week 36, n=273, 292 | 5.26 ± 1.664 | 5.20 ± 1.485 |
| Urea, Week 40, n=270, 293 | 5.47 ± 1.593 | 5.30 ± 1.537 |
| Urea, Week 44, n=275, 293 | 5.37 ± 1.531 | 5.26 ± 1.524 |
| Urea, Week 48, n=265, 292 | 5.48 ± 1.648 | 5.21 ± 1.437 |
Blood samples were collected for the analysis of clinical chemistry parameter-lipase at indicated time points.
| Units per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Baseline, n=308, 308 | 30.5 ± 22.88 | 30.8 ± 19.12 |
| Week 4, n=301, 303 | 35.3 ± 52.73 | 32.3 ± 23.30 |
| Week 8, n=227, 303 | 30.6 ± 22.70 | 31.9 ± 20.71 |
| Week 12, n=294, 297 | 33.2 ± 27.92 | 30.0 ± 18.06 |
| Week 16, n=285, 299 | 33.8 ± 30.49 | 33.9 ± 34.69 |
| Week 20, n=278, 302 | 31.0 ± 21.73 | 31.6 ± 28.88 |
| Week 24, n=283, 299 | 33.1 ± 24.09 | 33.8 ± 29.69 |
| Week 28, n=267, 297 | 32.9 ± 27.42 | 33.1 ± 19.69 |
| Week 32, n=274, 294 | 35.7 ± 60.63 | 33.8 ± 21.64 |
| Week 36, n=273, 292 | 36.2 ± 51.58 | 31.6 ± 18.46 |
| Week 40, n=269, 293 | 35.7 ± 36.06 | 31.4 ± 15.80 |
| Week 44, n=274, 293 | 33.3 ± 26.29 | 33.3 ± 20.44 |
| Week 48, n=264, 290 | 34.3 ± 30.97 | 32.4 ± 20.40 |
Blood samples were collected for the analysis of clinical chemistry parameter-creatinine clearance at indicated timepoints. Glomerular filtration rate (GFR) will be estimated by the central laboratory using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).
| Milliliter per minute per 1.73meter^2 | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Baseline, n=308, 308 | 100.5 ± 18.30 | 101.1 ± 17.72 |
| Week 4, n=301, 301 | 98.7 ± 17.26 | 98.9 ± 17.93 |
| Week 8, n=227, 303 | 100.1 ± 17.19 | 99.5 ± 17.59 |
| Week 12, n=295, 297 | 100.9 ± 17.72 | 99.2 ± 18.34 |
| Week 16, n=284, 297 | 100.5 ± 17.26 | 99.0 ± 18.32 |
| Week 20, n=277, 302 | 99.4 ± 17.37 | 98.7 ± 17.73 |
| Week 24, n=283, 298 | 98.9 ± 17.04 | 98.9 ± 17.44 |
| Week 28, n=267, 296 | 98.5 ± 17.66 | 99.0 ± 17.33 |
| Week 32, n=274, 294 | 99.1 ± 16.89 | 98.4 ± 17.54 |
| Week 36, n=273, 292 | 99.0 ± 17.19 | 98.6 ± 16.85 |
| Week 40, n=268, 293 | 98.5 ± 17.32 | 98.5 ± 17.37 |
| Week 44, n=274, 293 | 98.2 ± 16.96 | 99.0 ± 17.39 |
| Week 48, n=264, 291 | 97.6 ± 16.97 | 99.3 ± 17.09 |
The dipstick test gives results in a semi-quantitative manner and results for urinalysis parameters (ketones, glucose, bilirubin, occult blood, nitrite and blood protein) can be read as positive, trace, 1+, 2+, 3+ and 4+ indicating proportional concentrations in the urine sample. The urine parameters were graded according to Division of AIDS (DAIDS) scale where Grade 1 indicates mild (trace to 1+), Grade 2 indicates moderate (2+) and Grade 3 indicates severe (3+ or higher). Only participants with abnormal findings for urinalysis at any visit has been presented.
| Participants | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Urine bilirubin,Baseline (Day 1),Trace, n=303, 301 | 0 | 0 |
| Urine bilirubin, Baseline (Day 1), 1+, n=303, 301 | 6 | 7 |
| Urine bilirubin, Baseline (Day 1), 2+, n=303, 301 | 0 | 0 |
| Urine bilirubin, Baseline (Day 1), 3+, n=303, 301 | 0 | 0 |
| Urine glucose, Baseline (Day 1), Trace, n=303, 301 | 1 | 1 |
| Urine glucose, Baseline (Day 1), 1+, n=303, 301 | 0 | 1 |
| Urine glucose, Baseline (Day 1), 2+, n=303, 301 | 0 | 0 |
| Urine glucose, Baseline (Day 1), 3+, n=303, 301 | 0 | 1 |
| Urine ketones, Baseline (Day 1), Trace, n=303, 301 | 16 | 17 |
| Urine ketones, Baseline (Day 1), 1+, n=303, 301 | 4 | 0 |
| Urine ketones, Baseline (Day 1), 2+, n=303, 301 | 2 | 1 |
| Urine ketones, Baseline (Day 1), 3+, n=303, 301 | 0 | 0 |
| Urine leukocyte esterase,Baseline,Trace,n=303,301 | 25 | 18 |
| Urine leukocyte esterase, Baseline, 1+, n=303, 301 | 14 | 16 |
| Urine leukocyte esterase, Baseline, 2+, n=303, 301 | 14 | 8 |
| Urine leukocyte esterase, Baseline, 3+, n=303, 301 | 5 | 5 |
| Urine nitrite, Baseline, positive, n=303, 301 | 11 | 11 |
| Urine occult blood, Baseline, Trace, n=303, 301 | 19 | 12 |
| Urine occult blood, Baseline, 1+, n=303, 301 | 8 | 9 |
| Urine occult blood, Baseline, 2+, n=303, 301 | 7 | 5 |
| Urine occult blood, Baseline, 3+, n=303, 301 | 5 | 3 |
| Urine protein, Baseline, Trace, n=303, 301 | 14 | 20 |
| Urine protein, Baseline, 1+, n=303, 301 | 6 | 12 |
| Urine protein, Baseline, 2+, n=303, 301 | 0 | 1 |
| Urine protein, Baseline, 3+, n=303, 301 | 0 | 0 |
| Urine protein, Baseline, 4+, n=303, 301 | 0 | 0 |
| Urine bilirubin, Week 4, Trace, n=303, 302 | 0 | 0 |
| Urine bilirubin, Week 4, 1+, n=303, 302 | 9 | 5 |
| Urine bilirubin, Week 4, 2+, n=303, 302 | 0 | 0 |
| Urine bilirubin, Week 4, 3+, n=303, 302 | 0 | 0 |
| Urine glucose, Week 4, Trace, n=303, 302 | 3 | 2 |
| Urine glucose, Week 4, 1+, n=303, 302 | 1 | 2 |
| Urine glucose, Week 4, 2+, n=303, 302 | 2 | 0 |
| Urine glucose, Week 4, 3+, n=303, 302 | 0 | 1 |
| Urine ketones, Week 4, Trace, n=303, 302 | 9 | 15 |
| Urine ketones, Week 4, 1+, n=303, 302 | 0 | 2 |
| Urine ketones, Week 4, 2+, n=303, 302 | 1 | 1 |
| Urine ketones, Week 4, 3+, n=303, 302 | 0 | 0 |
| Urine leukocyte esterase, Week 4, Trace,n=303, 302 | 25 | 29 |
| Urine leukocyte esterase, Week 4, 1+, n=303, 302 | 14 | 15 |
| Urine leukocyte esterase, Week 4, 2+, n=303, 302 | 14 | 9 |
| Urine leukocyte esterase, Week 4, 3+, n=303, 302 | 3 | 4 |
| Urine nitrite, Week 4, positive, n=303, 302 | 10 | 12 |
| Urine occult blood, Week 4, Trace, n=303, 302 | 15 | 18 |
| Urine occult blood, Week 4, 1+, n=303, 302 | 9 | 10 |
| Urine occult blood, Week 4, 2+, n=303, 302 | 5 | 5 |
| Urine occult blood, Week 4, 3+, n=303, 302 | 4 | 3 |
| Urine protein, Week 4, Trace, n=303, 302 | 10 | 13 |
| Urine protein, Week 4, 1+, n=303, 302 | 8 | 7 |
| Urine protein, Week 4, 2+, n=303, 302 | 2 | 4 |
| Urine protein, Week 4, 3+, n=303, 302 | 0 | 0 |
| Urine protein, Week 4, 4+, n=303, 302 | 0 | 0 |
| Urine bilirubin, Week 24, Trace, n=279, 298 | 0 | 0 |
| Urine bilirubin, Week 24, 1+, n=279, 298 | 10 | 13 |
| Urine bilirubin, Week 24, 2+, n=279, 298 | 0 | 0 |
| Urine bilirubin, Week 24, 3+, n=279, 298 | 0 | 0 |
| Urine glucose, Week 24, Trace, n=279, 298 | 0 | 1 |
| Urine glucose, Week 24, 1+, n=279, 298 | 2 | 0 |
| Urine glucose, Week 24, 2+, n=279, 298 | 0 | 1 |
| Urine glucose, Week 24, 3+, n=279, 298 | 1 | 1 |
| Urine ketones, Week 24, Trace, n=279, 298 | 16 | 13 |
| Urine ketones, Week 24, 1+, n=279, 298 | 1 | 1 |
| Urine ketones, Week 24, 2+, n=279, 298 | 0 | 0 |
| Urine ketones, Week 24, 3+, n=279, 298 | 0 | 0 |
| Urine leukocyte esterase,Week 24, Trace, n=279,298 | 22 | 17 |
| Urine leukocyte esterase, Week 24, 1+, n=279, 298 | 14 | 14 |
| Urine leukocyte esterase, Week 24, 2+, n=279, 298 | 6 | 14 |
| Urine leukocyte esterase, Week 24, 3+, n=279, 298 | 3 | 7 |
| Urine nitrite, Week 24, positive, n=279, 298 | 9 | 10 |
| Urine occult blood, Week 24, Trace, n=279, 298 | 13 | 10 |
| Urine occult blood, Week 24, 1+, n=279, 298 | 5 | 6 |
| Urine occult blood, Week 24, 2+, n=279, 298 | 6 | 4 |
| Urine occult blood, Week 24, 3+, n=279, 298 | 0 | 6 |
| Urine protein, Week 24, Trace, n=279, 298 | 10 | 21 |
| Urine protein, Week 24, 1+, n=279, 298 | 4 | 12 |
| Urine protein, Week 24, 2+, n=279, 298 | 1 | 3 |
| Urine protein, Week 24, 3+, n=279, 298 | 0 | 0 |
| Urine protein, Week 24, 4+, n=279, 298 | 0 | 0 |
| Urine bilirubin, Week 48, Trace, n=279, 290 | 0 | 0 |
| Urine bilirubin, Week 48, 1+, n=279, 290 | 9 | 8 |
| Urine bilirubin, Week 48, 2+, n=279, 290 | 1 | 0 |
| Urine bilirubin, Week 48, 3+, n=279, 290 | 0 | 0 |
| Urine glucose, Week 48, Trace, n=279, 290 | 0 | 1 |
| Urine glucose, Week 48, 1+, n=279, 290 | 0 | 2 |
| Urine glucose, Week 48, 2+, n=279, 290 | 1 | 0 |
| Urine glucose, Week 48, 3+, n=279, 290 | 0 | 2 |
| Urine ketones, Week 48, Trace, n=279, 290 | 13 | 9 |
| Urine ketones, Week 48, 1+, n=279, 290 | 0 | 0 |
| Urine ketones, Week 48, 2+, n=279, 290 | 0 | 0 |
| Urine ketones, Week 48, 3+, n=279, 290 | 0 | 0 |
| Urine leukocyte esterase, Week 48, Trace,n=279,290 | 24 | 27 |
| Urine leukocyte esterase, Week 48, 1+, n=279, 290 | 13 | 15 |
| Urine leukocyte esterase, Week 48, 2+, n=279, 290 | 7 | 7 |
| Urine leukocyte esterase, Week 48, 3+, n=279, 290 | 5 | 6 |
| Urine nitrite, Week 48, positive, n=279, 290 | 10 | 6 |
| Urine occult blood, Week 48, Trace, n=279, 290 | 11 | 12 |
| Urine occult blood, Week 48, 1+, n=279, 290 | 5 | 5 |
| Urine occult blood, Week 48, 2+, n=279, 290 | 4 | 4 |
| Urine occult blood, Week 48, 3+, n=279, 290 | 6 | 0 |
| Urine protein, Week 48, Trace, n=279, 290 | 10 | 15 |
| Urine protein, Week 48, 1+, n=279, 290 | 4 | 6 |
| Urine protein, Week 48, 2+, n=279, 290 | 3 | 3 |
| Urine protein, Week 48, 3+, n=279, 290 | 0 | 0 |
| Urine protein, Week 48, 4+, n=279, 290 | 0 | 1 |
Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0).
| Participants | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Baseline, pH=5, n=303, 301 | 44 | 42 |
| Baseline, pH=5.5, n=303, 301 | 78 | 80 |
| Baseline, pH=6, n=303, 301 | 85 | 72 |
| Baseline, pH=6.5, n=303, 301 | 47 | 45 |
| Baseline, pH=7, n=303, 301 | 32 | 34 |
| Baseline, pH=7.5, n=303, 301 | 12 | 19 |
| Baseline, pH=8, n=303, 301 | 3 | 7 |
| Baseline, pH=8.5, n=303, 301 | 0 | 1 |
| Baseline, pH>9.0, n=303, 301 | 2 | 1 |
| Week 4, pH=5, n=303, 302 | 41 | 53 |
| Week 4, pH=5.5, n=303, 302 | 78 | 93 |
| Week 4, pH=6, n=303, 302 | 73 | 67 |
| Week 4, pH=6.5, n=303, 302 | 49 | 41 |
| Week 4, pH=7, n=303, 302 | 38 | 28 |
| Week 4, pH=7.5, n=303, 302 | 12 | 14 |
| Week 4, pH=8, n=303, 302 | 8 | 3 |
| Week 4, pH=8.5, n=303, 302 | 3 | 2 |
| Week 4, pH>9.0, n=303, 302 | 1 | 1 |
| Week 24, pH=5, n=279, 298 | 23 | 26 |
| Week 24, pH=5.5, n=279, 298 | 85 | 96 |
| Week 24, pH=6, n=279, 298 | 66 | 67 |
| Week 24, pH=6.5, n=279, 298 | 44 | 52 |
| Week 24, pH=7, n=279, 298 | 32 | 31 |
| Week 24, pH=7.5, n=279, 298 | 16 | 15 |
| Week 24, pH=8, n=279, 298 | 7 | 8 |
| Week 24, pH=8.5, n=279, 298 | 2 | 2 |
| Week 24, pH>9.0, n=279, 298 | 4 | 1 |
| Week 48, pH=5, n=279, 290 | 45 | 43 |
| Week 48, pH=5.5, n=279, 290 | 69 | 83 |
| Week 48, pH=6, n=279, 290 | 61 | 58 |
| Week 48, pH=6.5, n=279, 290 | 47 | 48 |
| Week 48, pH=7, n=279, 290 | 31 | 30 |
| Week 48, pH=7.5, n=279, 290 | 17 | 17 |
| Week 48, pH=8, n=279, 290 | 6 | 5 |
| Week 48, pH=8.5, n=279, 290 | 0 | 4 |
| Week 48, pH>9.0, n=279, 290 | 3 | 2 |
Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK. Baseline values is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| International units per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| ALT, Week 4, n=301, 303 | 0.8 ± 13.98 | 0.1 ± 9.65 |
| ALT, Week 8, n=229, 303 | 0.7 ± 15.35 | 1.6 ± 29.98 |
| ALT, Week 12, n=295, 299 | 5.2 ± 113.34 | 0.4 ± 11.60 |
| ALT, Week 16, n=284, 298 | -0.1 ± 21.80 | -0.6 ± 10.14 |
| ALT, Week 20, n=277, 302 | -0.8 ± 22.62 | -1.1 ± 10.86 |
| ALT, Week 24, n=284, 299 | 2.2 ± 61.65 | -0.6 ± 10.57 |
| ALT, Week 28, n=267, 296 | -2.7 ± 11.14 | -0.2 ± 12.52 |
| ALT, Week 32, n=275, 294 | -1.9 ± 14.44 | -0.5 ± 11.49 |
| ALT, Week 36, n=273, 292 | -0.8 ± 23.51 | 0.1 ± 10.95 |
| ALT, Week 40, n=270, 293 | 0.6 ± 36.29 | -0.2 ± 11.82 |
| ALT, Week 44, n=275, 293 | -2.2 ± 13.97 | -0.2 ± 12.37 |
| ALT, Week 48, n=265, 292 | -1.9 ± 13.43 | -0.6 ± 10.50 |
| ALP, Week 4, n=301, 303 | -6.0 ± 12.74 | -2.2 ± 8.85 |
| ALP, Week 8, n=229, 303 | -6.7 ± 16.59 | 1.1 ± 20.99 |
| ALP, Week 12, n=295, 299 | -8.0 ± 20.87 | 0.9 ± 14.45 |
| ALP, Week 16, n=284, 298 | -9.7 ± 19.47 | -0.5 ± 10.35 |
| ALP, Week 20, n=277, 302 | -9.2 ± 19.05 | -1.0 ± 11.65 |
| ALP, Week 24, n=284, 299 | -9.0 ± 19.02 | -0.1 ± 10.67 |
| ALP, Week 28, n=267, 296 | -10.1 ± 19.08 | -0.2 ± 11.44 |
| ALP, Week 32, n=275, 294 | -9.9 ± 19.10 | -1.7 ± 11.29 |
| ALP, Week 36, n=273, 292 | -10.5 ± 20.41 | -1.1 ± 11.44 |
| ALP, Week 40, n=270, 293 | -10.4 ± 20.71 | -1.1 ± 11.34 |
| ALP, Week 44, n=275, 293 | -11.4 ± 20.64 | -0.7 ± 12.02 |
| ALP, Week 48, n=265, 292 | -10.9 ± 23.27 | -0.3 ± 12.51 |
| AST, Week 4, n=301, 303 | -0.3 ± 12.52 | 0.2 ± 10.02 |
| AST, Week 8, n=229, 303 | 1.2 ± 19.73 | -0.1 ± 13.68 |
| AST, Week 12, n=295, 299 | 2.3 ± 65.03 | 0.6 ± 8.82 |
| AST, Week 16, n=284, 298 | 0.1 ± 18.49 | -0.1 ± 9.71 |
| AST, Week 20, n=277, 302 | -0.5 ± 17.02 | -0.6 ± 9.80 |
| AST, Week 24, n=284, 298 | 0.1 ± 24.12 | 0.0 ± 9.57 |
| AST, Week 28, n=267, 296 | -1.4 ± 8.77 | 0.3 ± 11.19 |
| AST, Week 32, n=275, 294 | -1.2 ± 16.08 | 0.6 ± 13.40 |
| AST, Week 36, n=273, 292 | -1.2 ± 12.95 | 0.1 ± 9.61 |
| AST, Week 40, n=270, 293 | -0.2 ± 17.27 | 0.0 ± 10.64 |
| AST, Week 44, n=275, 293 | -1.1 ± 16.51 | 0.1 ± 11.09 |
| AST Week 48, n=265, 292 | -1.0 ± 12.79 | 0.7 ± 10.75 |
| CK, Week 4, n=301, 303 | -0.1 ± 548.15 | 30.8 ± 435.12 |
| CK, Week 8, n=229, 303 | 98.2 ± 1076.99 | -16.5 ± 344.96 |
| CK, Week 12, n=295, 299 | 6.0 ± 585.45 | 14.9 ± 288.85 |
| CK, Week 16, n=284, 298 | 54.2 ± 882.23 | 5.8 ± 411.52 |
| CK, Week 20, n=277, 302 | 31.2 ± 653.11 | -16.7 ± 363.30 |
| CK, Week 24, n=284, 299 | -9.2 ± 538.95 | -0.7 ± 353.99 |
| CK, Week 28, n=267, 296 | -1.9 ± 213.98 | 20.8 ± 538.83 |
| CK, Week 32, n=275, 294 | 13.3 ± 699.60 | 34.0 ± 597.29 |
| CK, Week 36, n=273, 292 | -18.2 ± 476.64 | -10.8 ± 358.72 |
| CK, Week 40, n=270, 293 | 39.7 ± 704.18 | -0.3 ± 373.96 |
| CK, Week 44, n=275, 293 | 47.4 ± 1185.55 | -10.9 ± 350.64 |
| CK, Week 48, n=265, 292 | -0.6 ± 528.71 | 18.1 ± 463.49 |
Blood samples were collected for the analysis of clinical chemistry parameter-albumin. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Grams per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Week 4, n=301, 303 | -0.5 ± 2.60 | -0.5 ± 2.49 |
| Week 8, n=229, 303 | -0.3 ± 2.76 | -0.7 ± 2.70 |
| Week 12, n=295, 299 | -0.6 ± 2.72 | -0.4 ± 2.63 |
| Week 16, n=284, 298 | -0.6 ± 2.78 | -0.8 ± 2.70 |
| Week 20, n=277, 302 | -0.8 ± 2.78 | -0.8 ± 2.56 |
| Week 24, n=284, 299 | -0.7 ± 2.69 | -0.8 ± 2.59 |
| Week 28, n=267, 296 | -0.7 ± 2.60 | -1.0 ± 2.47 |
| Week 32, n=275, 294 | -0.6 ± 2.78 | -1.0 ± 2.56 |
| Week 36, n=273, 292 | -0.9 ± 2.71 | -0.9 ± 2.65 |
| Week 40, n=270, 293 | -0.5 ± 2.53 | -1.0 ± 2.61 |
| Week 44, n=275, 293 | -0.4 ± 2.58 | -0.8 ± 2.47 |
| Week 48, n=265, 292 | -0.4 ± 2.64 | -0.4 ± 2.55 |
Blood samples were collected for the analysis of clinical chemistry parameters including bilirubin, creatinine and direct bilirubin. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Micromoles per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Bilirubin, Week 4, n=301, 303 | -0.8 ± 9.87 | -0.3 ± 4.17 |
| Bilirubin, Week 8, n=229, 303 | -0.1 ± 6.92 | 0.1 ± 7.66 |
| Bilirubin, Week 12, n=295, 299 | -0.6 ± 10.23 | 0.1 ± 4.56 |
| Bilirubin, Week 16, n=284, 298 | 0.2 ± 14.00 | -0.2 ± 4.12 |
| Bilirubin, Week 20, n=277, 302 | -0.2 ± 10.04 | 0.0 ± 6.10 |
| Bilirubin, Week 24, n=284, 298 | -0.6 ± 9.90 | 0.2 ± 5.90 |
| Bilirubin, Week 28, n=267, 296 | 0.0 ± 10.46 | -0.1 ± 4.76 |
| Bilirubin, Week 32, n=275, 294 | -0.1 ± 10.36 | 0.0 ± 4.94 |
| Bilirubin, Week 36, n=273, 292 | -0.6 ± 10.39 | 0.1 ± 4.55 |
| Bilirubin, Week 40, n=270, 293 | -0.3 ± 10.61 | 0.2 ± 6.28 |
| Bilirubin, Week 44, n=275, 293 | -0.4 ± 10.11 | 0.4 ± 5.24 |
| Bilirubin, Week 48, n=265, 292 | -0.3 ± 10.57 | 0.2 ± 3.91 |
| Direct bilirubin, Week 4, n=301, 303 | -0.1 ± 1.48 | 0.1 ± 1.20 |
| Direct bilirubin, Week 8, n=229, 303 | -0.1 ± 1.42 | 0.2 ± 3.96 |
| Direct bilirubin, Week 12, n=295, 299 | -0.2 ± 1.61 | 0.1 ± 1.21 |
| Direct bilirubin, Week 16, n=284, 298 | 0.1 ± 5.02 | -0.1 ± 1.12 |
| Direct bilirubin, Week 20, n=277, 302 | -0.3 ± 1.52 | -0.2 ± 1.29 |
| Direct bilirubin, Week 24, n=284, 298 | -0.2 ± 1.55 | -0.1 ± 1.24 |
| Direct bilirubin, Week 28, n=267, 296 | -0.3 ± 1.55 | -0.2 ± 1.29 |
| Direct bilirubin, Week 32, n=275, 294 | -0.3 ± 1.61 | -0.2 ± 1.24 |
| Direct bilirubin, Week 36, n=273, 292 | -0.3 ± 1.70 | -0.1 ± 1.20 |
| Direct bilirubin, Week 40, n=270, 293 | -0.3 ± 1.68 | -0.2 ± 1.18 |
| Direct bilirubin, Week 44, n=275, 293 | -0.2 ± 1.55 | -0.1 ± 1.19 |
| Direct bilirubin, Week 48, n=265, 292 | -0.2 ± 1.54 | 0.0 ± 1.23 |
| Creatinine, Week 4, n=301, 301 | 1.15 ± 8.205 | 1.80 ± 8.022 |
| Creatinine, Week 8, n=229, 303 | -0.66 ± 9.042 | 1.23 ± 7.560 |
| Creatinine, Week 12, n=295, 299 | -0.38 ± 9.380 | 1.71 ± 7.638 |
| Creatinine, Week 16, n=284, 298 | -0.60 ± 9.225 | 1.62 ± 8.169 |
| Creatinine, Week 20, n=277, 302 | 0.53 ± 9.390 | 1.80 ± 8.454 |
| Creatinine, Week 24, n=284, 298 | 0.90 ± 12.494 | 1.36 ± 8.038 |
| Creatinine, Week 28, n=267, 296 | 1.14 ± 10.998 | 1.59 ± 8.303 |
| Creatinine, Week 32, n=275, 294 | 0.33 ± 10.102 | 1.95 ± 8.331 |
| Creatinine, Week 36, n=273, 292 | 0.34 ± 10.585 | 1.62 ± 7.891 |
| Creatinine, Week 40, n=270, 293 | 0.88 ± 9.986 | 1.64 ± 8.318 |
| Creatinine, Week 44, n=275, 293 | 1.03 ± 11.253 | 1.40 ± 8.008 |
| Creatinine, Week 48, n=265, 292 | 1.59 ± 11.253 | 0.82 ± 7.846 |
Blood samples were collected for the analysis of clinical chemistry parameters which includes total CO2, chloride, glucose, phosphate, potassium, sodium and urea. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Millimoles per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| CO2, Week 4, n=301, 303 | 1.0 ± 2.53 | 0.7 ± 2.21 |
| CO2, Week 8, n=229, 303 | 0.4 ± 2.31 | 0.6 ± 2.52 |
| CO2, Week 12, n=295, 299 | 0.5 ± 2.42 | 0.3 ± 2.39 |
| CO2, Week 16, n=284, 298 | 0.3 ± 2.42 | 0.5 ± 2.41 |
| CO2, Week 20, n=277, 302 | 0.2 ± 2.26 | 0.3 ± 2.31 |
| CO2, Week 24, n=284, 298 | 0.2 ± 2.46 | 0.2 ± 2.44 |
| CO2, Week 28, n=267, 296 | 0.1 ± 2.47 | 0.1 ± 2.39 |
| CO2, Week 32, n=275, 294 | 0.0 ± 2.37 | 0.2 ± 2.31 |
| CO2, Week 36, n=273, 292 | 0.2 ± 2.37 | 0.3 ± 2.39 |
| CO2, Week 40, n=270, 293 | 0.5 ± 2.49 | 0.4 ± 2.29 |
| CO2, Week 44, n=275, 293 | 0.5 ± 2.34 | 0.5 ± 2.19 |
| CO2, Week 48, n=265, 292 | 0.1 ± 2.41 | 0.2 ± 2.31 |
| Chloride, Week 4, n=301, 303 | 0.4 ± 2.05 | 0.5 ± 2.13 |
| Chloride, Week 8, n=229, 303 | 0.3 ± 2.12 | 0.5 ± 2.19 |
| Chloride, Week 12, n=295, 299 | 0.4 ± 2.30 | 0.5 ± 2.25 |
| Chloride, Week 16, n=284, 298 | 0.6 ± 2.41 | 0.8 ± 2.25 |
| Chloride, Week 20, n=277, 302 | 0.8 ± 2.32 | 0.8 ± 2.38 |
| Chloride, Week 24, n=284, 299 | 0.6 ± 2.48 | 0.9 ± 2.26 |
| Chloride, Week 28, n=267, 296 | 0.9 ± 2.21 | 1.0 ± 2.55 |
| Chloride, Week 32, n=275, 294 | 0.8 ± 2.41 | 0.9 ± 2.33 |
| Chloride, Week 36, n=273, 292 | 0.9 ± 2.18 | 0.9 ± 2.48 |
| Chloride, Week 40, n=270, 293 | 0.8 ± 2.24 | 0.8 ± 2.76 |
| Chloride, Week 44, n=275, 293 | 0.7 ± 2.20 | 0.8 ± 2.28 |
| Chloride, Week 48, n=265, 292 | 0.5 ± 2.36 | 0.3 ± 2.38 |
| Glucose, Week 4, n=218, 226 | 0.17 ± 0.721 | 0.21 ± 0.900 |
| Glucose, Week 8, n=151, 213 | 0.22 ± 0.841 | 0.22 ± 0.832 |
| Glucose, Week 12, n=204, 216 | 0.19 ± 0.855 | 0.19 ± 0.974 |
| Glucose, Week 16, n=207, 211 | 0.23 ± 1.050 | 0.27 ± 1.084 |
| Glucose, Week 20, n=192, 216 | 0.19 ± 0.712 | 0.19 ± 0.961 |
| Glucose, Week 24, n=212, 224 | 0.23 ± 0.710 | 0.16 ± 0.881 |
| Glucose, Week 28, n=188, 225 | 0.17 ± 0.793 | 0.28 ± 0.903 |
| Glucose, Week 32, n=192, 213 | 0.35 ± 0.956 | 0.27 ± 0.939 |
| Glucose, Week 36, n=190, 215 | 0.18 ± 0.803 | 0.26 ± 1.070 |
| Glucose, Week 40, n=193, 213 | 0.27 ± 0.833 | 0.25 ± 0.891 |
| Glucose, Week 44, n=193, 213 | 0.23 ± 0.895 | 0.27 ± 0.898 |
| Glucose, Week 48, n=238, 274 | 0.04 ± 0.693 | 0.02 ± 0.924 |
| Phosphate, Week 4, n=301, 303 | 0.066 ± 0.1666 | 0.015 ± 0.1595 |
| Phosphate, Week 8, n=229, 303 | 0.062 ± 0.1862 | -0.006 ± 0.1609 |
| Phosphate, Week 12, n=295, 299 | 0.041 ± 0.1978 | 0.013 ± 0.1742 |
| Phosphate, Week 16, n=284, 298 | 0.041 ± 0.2012 | 0.003 ± 0.1640 |
| Phosphate, Week 20, n=277, 302 | 0.035 ± 0.1871 | 0.010 ± 0.1839 |
| Phosphate, Week 24, n=284, 299 | 0.042 ± 0.1963 | 0.006 ± 0.1845 |
| Phosphate, Week 28, n=267, 296 | 0.037 ± 0.1822 | 0.004 ± 0.1823 |
| Phosphate, Week 32, n=275, 294 | 0.021 ± 0.1980 | 0.005 ± 0.1886 |
| Phosphate, Week 36, n=273, 292 | 0.011 ± 0.1846 | -0.002 ± 0.1855 |
| Phosphate, Week 40, n=270, 293 | 0.024 ± 0.2035 | -0.004 ± 0.1736 |
| Phosphate, Week 44, n=275, 293 | 0.027 ± 0.1982 | 0.004 ± 0.1811 |
| Phosphate, Week 48, n=265, 292 | 0.034 ± 0.2007 | 0.003 ± 0.1741 |
| Potassium, Week 4, n=301, 303 | 0.05 ± 0.342 | 0.11 ± 0.375 |
| Potassium, Week 8, n=229, 303 | 0.01 ± 0.311 | 0.06 ± 0.393 |
| Potassium, Week 12, n=295, 299 | 0.04 ± 0.341 | 0.08 ± 0.356 |
| Potassium, Week 16, n=284, 298 | 0.01 ± 0.341 | 0.06 ± 0.340 |
| Potassium, Week 20, n=277, 302 | 0.04 ± 0.345 | 0.05 ± 0.359 |
| Potassium, Week 24, n=284, 298 | 0.03 ± 0.325 | 0.07 ± 0.337 |
| Potassium, Week 28, n=267, 296 | 0.04 ± 0.380 | 0.07 ± 0.389 |
| Potassium, Week 32, n=275, 294 | 0.02 ± 0.390 | 0.05 ± 0.347 |
| Potassium, Week 36, n=273, 292 | 0.03 ± 0.356 | 0.07 ± 0.359 |
| Potassium, Week 40, n=270, 293 | 0.04 ± 0.344 | 0.07 ± 0.350 |
| Potassium, Week 44, n=275, 293 | 0.06 ± 0.344 | 0.07 ± 0.372 |
| Potassium, Week 48, n=265, 292 | -0.02 ± 0.299 | 0.00 ± 0.332 |
| Sodium, Week 4, n=301, 303 | 0.3 ± 1.84 | 0.1 ± 1.99 |
| Sodium, Week 8, n=229, 303 | 0.2 ± 1.99 | -0.1 ± 1.92 |
| Sodium, Week 12, n=295, 299 | 0.2 ± 2.07 | 0.2 ± 1.91 |
| Sodium, Week 16, n=284, 298 | 0.1 ± 2.18 | 0.1 ± 2.06 |
| Sodium, Week 20, n=277, 302 | 0.3 ± 2.10 | 0.3 ± 1.95 |
| Sodium, Week 24, n=284, 299 | 0.3 ± 2.07 | 0.2 ± 1.95 |
| Sodium, Week 28, n=267, 296 | 0.5 ± 2.11 | 0.2 ± 2.24 |
| Sodium, Week 32, n=275, 294 | 0.3 ± 2.05 | 0.4 ± 1.89 |
| Sodium, Week 36, n=273, 292 | 0.5 ± 2.01 | 0.5 ± 2.19 |
| Sodium, Week 40, n=270, 293 | 0.4 ± 2.02 | 0.5 ± 2.07 |
| Sodium, Week 44, n=275, 293 | 0.5 ± 2.03 | 0.5 ± 2.05 |
| Sodium, Week 48, n=265, 292 | 0.4 ± 2.20 | 0.3 ± 1.95 |
| Urea, Week 4, n=301, 303 | 0.01 ± 1.369 | 0.08 ± 1.334 |
| Urea, Week 8, n=229, 303 | 0.07 ± 1.453 | 0.00 ± 1.363 |
| Urea, Week 12, n=295, 299 | 0.15 ± 1.409 | 0.09 ± 1.381 |
| Urea, Week 16, n=284, 298 | 0.08 ± 1.387 | 0.19 ± 1.496 |
| Urea, Week 20, n=277, 302 | 0.15 ± 1.399 | 0.11 ± 1.461 |
| Urea, Week 24, n=284, 299 | 0.25 ± 1.420 | 0.15 ± 1.311 |
| Urea, Week 28, n=267, 296 | 0.15 ± 1.524 | 0.00 ± 1.439 |
| Urea, Week 32, n=275, 294 | 0.20 ± 1.511 | 0.06 ± 1.415 |
| Urea, Week 36, n=273, 292 | 0.06 ± 1.420 | -0.02 ± 1.386 |
| Urea, Week 40, n=270, 293 | 0.19 ± 1.400 | 0.09 ± 1.452 |
| Urea, Week 44, n=275, 293 | 0.13 ± 1.426 | 0.02 ± 1.467 |
| Urea, Week 48, n=265, 292 | 0.24 ± 1.465 | -0.01 ± 1.312 |
Blood samples were collected for the analysis of clinical chemistry parameter-lipase. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Units per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Week 4, n=301, 303 | 5.2 ± 41.42 | 1.5 ± 23.88 |
| Week 8, n=227, 303 | 1.2 ± 19.31 | 1.0 ± 17.96 |
| Week 12, n=294, 297 | 2.7 ± 25.12 | -0.8 ± 18.59 |
| Week 16, n=285, 299 | 2.6 ± 24.79 | 3.5 ± 31.03 |
| Week 20, n=278, 302 | 0.9 ± 15.65 | 0.8 ± 28.95 |
| Week 24, n=283, 299 | 2.1 ± 20.79 | 3.0 ± 23.85 |
| Week 28, n=267, 297 | 2.2 ± 24.93 | 2.3 ± 18.96 |
| Week 32, n=274, 294 | 5.2 ± 57.44 | 3.1 ± 21.31 |
| Week 36, n=273, 292 | 5.1 ± 49.92 | 0.7 ± 17.39 |
| Week 40, n=269, 293 | 5.1 ± 33.58 | 0.5 ± 17.60 |
| Week 44, n=274, 293 | 2.0 ± 22.57 | 2.3 ± 21.13 |
| Week 48, n=264, 290 | 3.0 ± 28.26 | 1.5 ± 19.00 |
Blood samples were collected for the analysis of clinical chemistry parameter-creatinine clearance. GFR will be estimated by the central laboratory using the CKD-EPI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Milliliters per minute per 1.73meter^2 | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Week 4, n=301, 301 | -1.8 ± 9.51 | -2.3 ± 9.18 |
| Week 8, n=227, 303 | 0.4 ± 9.88 | -1.5 ± 8.06 |
| Week 12, n=295, 297 | 0.3 ± 10.28 | -1.9 ± 8.02 |
| Week 16, n=284, 297 | 0.4 ± 10.63 | -1.9 ± 8.69 |
| Week 20, n=277, 302 | -1.0 ± 10.37 | -2.4 ± 8.55 |
| Week 24, n=283, 298 | -1.0 ± 10.52 | -2.3 ± 8.76 |
| Week 28, n=267, 296 | -1.8 ± 11.47 | -2.4 ± 8.93 |
| Week 32, n=274, 294 | -1.2 ± 11.11 | -3.0 ± 8.94 |
| Week 36, n=273, 292 | -1.2 ± 11.26 | -2.6 ± 8.52 |
| Week 40, n=268, 293 | -1.7 ± 10.70 | -2.7 ± 9.10 |
| Week 44, n=274, 293 | -2.1 ± 10.45 | -2.3 ± 8.74 |
| Week 48, n=264, 291 | -2.5 ± 11.80 | -1.9 ± 8.50 |
Blood samples were collected for the analysis of fasting lipid parameters- total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Millimoles per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Total cholesterol, Week 48, n=231, 242 | 0.08 ± 0.688 | -0.04 ± 0.665 |
| HDL cholesterol, Week 48, n=231, 242 | 0.040 ± 0.2702 | 0.002 ± 0.2682 |
| LDL cholesterol, Week 48, n=224, 238 | 0.098 ± 0.6105 | -0.017 ± 0.5314 |
| Triglycerides, Week 48, n=231, 242 | -0.159 ± 0.8670 | -0.033 ± 0.7844 |
Urine biomarker samples were collected for the analysis of urine albumin/creatinine ratio and urine protein/creatinine ratio.Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Grams per mole | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Urine albumin/creatinine ratio, Week 4,n=210, 221 | 0.32 ± 3.948 | 0.06 ± 6.383 |
| Urine albumin/creatinine ratio, Week 24,n=198, 208 | -0.08 ± 3.360 | -0.11 ± 8.552 |
| Urine albumin/creatinine ratio, Week 48,n=191, 197 | 0.15 ± 6.049 | -0.14 ± 5.286 |
| Urine protein/creatinine, Week 4, n=234, 236 | -0.66 ± 11.803 | 1.85 ± 31.997 |
| Urine protein/creatinine, Week 24, n=208, 232 | -2.49 ± 8.028 | 1.67 ± 20.505 |
| Urine protein/creatinine, Week 48, n=206, 225 | -1.72 ± 9.551 | 6.70 ± 112.353 |
Urine biomarker samples were collected for the analysis of urine creatinine. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Micromoles per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Week 4, n=304, 302 | -543.9 ± 8693.94 | -305.5 ± 8787.62 |
| Week 24, n=282, 297 | -341.8 ± 9286.26 | -270.4 ± 8437.76 |
| Week 48, n=282, 291 | -342.9 ± 8965.01 | -521.6 ± 7873.28 |
Urine biomarker samples were collected for the analysis of urine phosphate. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Millimoles per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Week 4, n=302, 300 | -0.460 ± 15.2707 | 1.483 ± 15.0378 |
| Week 24, n=281, 294 | 0.286 ± 16.1887 | 0.640 ± 14.4201 |
| Week 48, n=280, 291 | -0.369 ± 14.2441 | 1.254 ± 15.6532 |
Urine biomarker samples were collected for the analysis of urine retinol binding protein. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Nanomoles per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Change From Baseline Values in Urine Retinol Binding Protein Over Time Including Week 48 | -1.8913 ± 14.10125 | 1.4289 ± 15.70559 |
Urine biomarker samples were collected for the analysis of urine specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The dipstick test gives results in a semi-quantitative manner. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. The urine specific gravity was measured as the ratio of urine density compared with water density.
| Ratio of urine density to water density | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Week 4, n=298, 295 | -0.0009 ± 0.00800 | -0.0000 ± 0.00785 |
| Week 24, n=274, 291 | -0.0008 ± 0.00784 | -0.0000 ± 0.00770 |
| Week 48, n=274, 283 | -0.0009 ± 0.00772 | -0.0002 ± 0.00768 |
Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0). The dipstick test gives results in a semi-quantitative manner. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| pH | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Week 4, n=298, 295 | 0.08 ± 0.886 | -0.13 ± 0.935 |
| Week 24, n=274, 291 | 0.18 ± 1.021 | 0.01 ± 0.870 |
| Week 48, n=274, 283 | 0.09 ± 1.036 | -0.02 ± 0.951 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.
| Participants | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Number of Participants Who Discontinued or Withdrawn Due to AEs Over Time Including Week 48 | 13 | 5 |
Blood samples were collected at Baseline and at Week 48 to assess fasting lipids which included total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Percentage change from Baseline is calculated as: value at Week 48 minus Baseline value divided by Baseline value multiplied by 100.
| Percent change | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Cholesterol, Week 48, Overall, n=231, 242 | 3.25 ± 15.563 | 0.13 ± 13.379 |
| HDL cholesterol, Week 48, Overall, n=231, 242 | 5.059 ± 20.5368 | 2.132 ± 18.0473 |
| LDL cholesterol, Week 48, Overall, n=224, 238 | 6.762 ± 31.7209 | 1.029 ± 19.4719 |
| Triglycerides, Week 48, Overall, n=231, 242 | 0.708 ± 43.5160 | 8.203 ± 51.7632 |
Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria.The CVF population comprised of all participants in ITT-E population who met CVF criteria.Phenotypic Resistance data for following drugs:CAB,dolutegravir(DTG),elvitegravir(EVG), raltegravir(RAL),delavirdine(DLV),efavirenz(EFV),etravirine(ETR),nevirapine(NVP),RPV,lamivudine(3TC),abacavir(ABC),emtricitabine(FTC),tenofovir(TDF),zidovudine(ZDV),stavudine(d4T),didanosine(ddI), atazanavir(ATV),darunavir(DRV),fosamprenavir(FPV),indinavir(IDV),lopinavir(LPV),nelfinavir(NFV),rito-navir(RTV),saquinavir(SQV) and tipranavir(TPV) in participants meeting CVF criteria is presented.Phenotypic resistance, partially sensitive, and Sensitive were defined based on fold change(FC) value from Monogram as:resistance(FC\>clinical higher cutoff/biologic cutoff),partially sensitive(FC \<=clinical higher cutoff and \> clinical lower cutoff),sensitive(FC \<= clinical lower cutoff/biologic cutoff).
| Participants | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| INI, CAB, resistant, n=3, 4 | 1 | 0 |
| INI, CAB, sensitive, n=3, 4 | 2 | 4 |
| INI, DTG, resistant, n=3, 4 | 0 | 0 |
| INI, DTG, partially sensitive, n=3, 4 | 0 | 0 |
| INI, DTG, sensitive, n=3, 4 | 3 | 4 |
| INI, EVG, resistant, n=3, 4 | 1 | 0 |
| INI, EVG, sensitive, n=3, 4 | 2 | 4 |
| INI, RAL, resistant, n=3, 4 | 1 | 0 |
| INI, RAL, sensitive, n=3, 4 | 2 | 4 |
| NNRTI, DLV, resistant, n=3, 3 | 2 | 0 |
| NNRTI, DLV, sensitive, n=3, 3 | 1 | 3 |
| NNRTI, EFV, resistant, n=3, 3 | 2 | 0 |
| NNRTI, EFV, sensitive, n=3, 3 | 1 | 3 |
| NNRTI, ETR, resistant, n=3, 3 | 0 | 0 |
| NNRTI, ETR, partially sensitive, n=3, 3 | 2 | 0 |
| NNRTI, ETR, sensitive, n=3, 3 | 1 | 3 |
| NNRTI, NVP, resistant, n=3, 3 | 2 | 0 |
| NNRTI, NVP, sensitive, n=3, 3 | 1 | 3 |
| NNRTI, RPV, resistant, n=3, 3 | 3 | 0 |
| NNRTI, RPV, sensitive, n=3, 3 | 0 | 3 |
| NRTI, 3TC, resistant, n=3, 3 | 0 | 1 |
| NRTI, 3TC, sensitive, n=3, 3 | 3 | 2 |
| NRTI, ABC, resistant, n=3, 3 | 0 | 0 |
| NRTI, ABC, partially sensitive, n=3, 3 | 0 | 0 |
| NRTI, ABC, sensitive, n=3, 3 | 3 | 3 |
| NRTI, FTC, resistant, n=3, 3 | 0 | 1 |
| NRTI, FTC, sensitive, n=3, 3 | 3 | 2 |
| NRTI, TDF, resistant, n=3, 3 | 0 | 0 |
| NRTI, TDF, partially sensitive, n=3, 3 | 0 | 0 |
| NRTI, TDF, sensitive, n=3, 3 | 3 | 3 |
| NRTI, ZDV, resistant, n=3, 3 | 1 | 0 |
| NRTI, ZDV, sensitive, n=3, 3 | 2 | 3 |
| NRTI, d4T, resistant, n=3, 3 | 0 | 0 |
| NRTI, d4T, sensitive, n=3, 3 | 3 | 3 |
| NRTI, ddI, resistant, n=3, 3 | 0 | 0 |
| NRTI, ddI, partially sensitive, n=3, 3 | 0 | 0 |
| NRTI, ddI, sensitive, n=3, 3 | 3 | 3 |
| PI, ATV, resistant, n=3, 3 | 0 | 0 |
| PI, ATV, sensitive, n=3, 3 | 3 | 3 |
| PI, DRV, resistant, n=3, 3 | 0 | 0 |
| PI, DRV, partially sensitive, n=3, 3 | 0 | 0 |
| PI, DRV, sensitive, n=3, 3 | 3 | 3 |
| PI, FPV, resistant, n=3, 3 | 0 | 0 |
| PI, FPV, partially sensitive, n=3, 3 | 0 | 0 |
| PI, FPV, sensitive, n=3, 3 | 3 | 3 |
| PI, IDV, resistant, n=3, 3 | 0 | 0 |
| PI, IDV, sensitive, n=3, 3 | 3 | 3 |
| PI, LPV, resistant, n=3, 3 | 0 | 0 |
| PI, LPV, partially sensitive, n=3, 3 | 0 | 0 |
| PI, LPV, sensitive, n=3, 3 | 3 | 3 |
| PI, NFV, resistant, n=3, 3 | 0 | 0 |
| PI, NFV, sensitive, n=3, 3 | 3 | 3 |
| PI, RTV, resistant, n=3, 3 | 0 | 0 |
| PI, RTV, sensitive, n=3, 3 | 3 | 3 |
| PI, SQV, resistant, n=3, 3 | 0 | 0 |
| PI, SQV, partially sensitive, n=3, 3 | 0 | 0 |
| PI, SQV, sensitive, n=3, 3 | 3 | 3 |
| PI, TPV, resistant, n=3, 3 | 0 | 0 |
| PI, TPV, partially sensitive, n=3, 3 | 0 | 0 |
| PI, TPV, sensitive, n=3, 3 | 3 | 3 |
Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria. Genotypic Resistance data for the following drugs: DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented.
| Participants | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| INI, DTG, resistant | 0 | 0 |
| INI, DTG, resistance possible | 0 | 0 |
| INI, DTG, sensitive | 3 | 4 |
| INI, EVG, resistant | 1 | 0 |
| INI, EVG, resistance possible | 0 | 0 |
| INI, EVG, sensitive | 2 | 4 |
| INI, RAL, resistant | 1 | 0 |
| INI, RAL, resistance possible | 0 | 0 |
| INI, RAL, sensitive | 2 | 4 |
| NNRTI, DLV, resistant | 0 | 0 |
| NNRTI, DLV, resistance possible | 0 | 0 |
| NNRTI, DLV, sensitive | 3 | 4 |
| NNRTI, EFV, resistant | 1 | 1 |
| NNRTI, EFV, resistance possible | 0 | 0 |
| NNRTI, EFV, sensitive | 2 | 3 |
| NNRTI, ETR, resistant | 0 | 0 |
| NNRTI, ETR, resistance possible | 2 | 0 |
| NNRTI, ETR, sensitive | 1 | 4 |
| NNRTI, NVP, resistant | 1 | 1 |
| NNRTI, NVP, resistance possible | 0 | 0 |
| NNRTI, NVP, sensitive | 2 | 3 |
| NNRTI, RPV, resistant | 3 | 1 |
| NNRTI, RPV, resistance possible | 0 | 0 |
| NNRTI, RPV, sensitive | 0 | 3 |
| NRTI, 3TC, resistant | 0 | 2 |
| NNRTI, 3TC, resistance possible | 0 | 0 |
| NRTI, 3TC, sensitive | 3 | 2 |
| NRTI, ABC, resistant | 0 | 0 |
| NRTI, ABC, resistance possible | 0 | 0 |
| NRTI, ABC, sensitive | 3 | 4 |
| NRTI, FTC, resistant | 0 | 2 |
| NRTI, FTC, resistance possible | 0 | 0 |
| NRTI, FTC, sensitive | 3 | 2 |
| NRTI, TDF, resistant | 0 | 0 |
| NRTI, TDF, resistance possible | 0 | 0 |
| NRTI, TDF, sensitive | 3 | 4 |
| NRTI, ZDV, resistant | 0 | 0 |
| NRTI, ZDV, resistance possible | 0 | 0 |
| NRTI, ZDV, sensitive | 3 | 4 |
| NRTI, d4T, resistant | 0 | 0 |
| NRTI, d4T, resistance possible | 0 | 0 |
| NRTI, d4T, sensitive | 3 | 4 |
| NRTI, ddI, resistant | 0 | 0 |
| NRTI, ddI, resistance possible | 0 | 2 |
| NRTI, ddI, sensitive | 3 | 2 |
| PI, ATV, resistant | 1 | 0 |
| PI, ATV, resistance possible | 0 | 0 |
| PI, ATV, sensitive | 2 | 4 |
| PI, ATV/r, resistant | 0 | 0 |
| PI, ATV/r, resistance possible | 1 | 0 |
| PI, ATV/r, sensitive | 2 | 4 |
| PI, DRV/r, resistant | 0 | 0 |
| PI, DRV/r, resistance possible | 0 | 0 |
| PI, DRV/r, sensitive | 3 | 4 |
| PI, FPV/r, resistant | 0 | 0 |
| PI, FPV/r, resistance possible | 0 | 0 |
| PI, FPV/r, sensitive | 3 | 4 |
| PI, IDV/r, resistant | 0 | 0 |
| PI, IDV/r, resistance possible | 0 | 0 |
| PI, IDV/r, sensitive | 3 | 4 |
| PI, LPV/r, resistant | 0 | 0 |
| PI, LPV/r, resistance possible | 0 | 0 |
| PI, LPV/r, sensitive | 3 | 4 |
| PI, NFV, resistant | 1 | 0 |
| PI, NFV, resistance possible | 0 | 0 |
| PI, NFV, sensitive | 2 | 4 |
| PI, RTV, resistant | 0 | 0 |
| PI, RTV, resistance possible | 0 | 0 |
| PI, RTV, sensitive | 3 | 4 |
| PI, SQV/r, resistant | 0 | 0 |
| PI, SQV/r, resistance possible | 0 | 0 |
| PI, SQV/r, sensitive | 3 | 4 |
| PI, TPV/r, resistant | 0 | 0 |
| PI, TPV/r, resistance possible | 0 | 0 |
| PI, TPV/r, sensitive | 3 | 4 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.
| Participants | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Any AE, INI, n=102, 99 | 99 | 68 |
| Any AE, NNRTI, n=155, 155 | 148 | 116 |
| Any AE, PI, n=51, 54 | 47 | 36 |
Blood samples were collected for the analysis of clinical chemistry parameters to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).
| International units per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| PI, ALT, Baseline, n=51, 54 | 19.3 ± 11.23 | 18.7 ± 9.13 |
| PI, ALT, Week 4, n=51, 53 | 28.7 ± 20.12 | 19.8 ± 12.29 |
| PI, ALT, Week 8, n=34, 53 | 25.8 ± 19.28 | 19.6 ± 10.43 |
| PI, ALT, Week 12, n=50, 52 | 24.7 ± 17.09 | 20.1 ± 14.19 |
| PI, ALT, Week 16, n=48, 53 | 26.3 ± 19.89 | 20.0 ± 12.04 |
| PI, ALT, Week 20, n=46, 53 | 24.9 ± 18.46 | 19.0 ± 9.52 |
| PI, ALT, Week 24, n=47, 53 | 24.1 ± 13.75 | 19.1 ± 10.02 |
| PI, ALT, Week 28, n=42, 53 | 22.0 ± 12.42 | 19.4 ± 10.45 |
| PI, ALT, Week 32, n=45, 51 | 22.7 ± 15.18 | 18.8 ± 8.18 |
| PI, ALT, Week 36, n=44, 50 | 22.3 ± 15.09 | 20.7 ± 13.18 |
| PI, ALT, Week 40, n=42, 51 | 24.9 ± 19.63 | 19.5 ± 13.46 |
| PI, ALT, Week 44, n=47, 51 | 23.2 ± 17.05 | 19.3 ± 14.23 |
| PI, ALT, Week 48, n=43, 50 | 22.5 ± 13.28 | 19.0 ± 8.52 |
| INI, ALT, Baseline, n=102, 99 | 24.8 ± 15.23 | 21.2 ± 10.93 |
| INI, ALT, Week 4, n=99, 97 | 26.5 ± 18.35 | 21.7 ± 10.09 |
| INI, ALT, Week 8, n=73, 98 | 28.4 ± 22.77 | 26.8 ± 49.37 |
| INI, ALT, Week 12, n=99, 95 | 23.8 ± 14.21 | 22.9 ± 16.05 |
| INI, ALT, Week 16, n=93, 96 | 23.2 ± 13.62 | 21.2 ± 11.24 |
| INI, ALT, Week 20, n=93, 97 | 23.0 ± 15.29 | 20.7 ± 9.83 |
| INI, ALT, Week 24, n=94, 95 | 25.7 ± 20.09 | 21.0 ± 13.40 |
| INI, ALT, Week 28, n=89, 93 | 21.5 ± 13.06 | 20.9 ± 14.10 |
| INI, ALT, Week 32, n=93, 95 | 22.5 ± 10.95 | 21.1 ± 12.32 |
| INI, ALT, Week 36, n=94, 95 | 26.5 ± 38.41 | 20.5 ± 9.38 |
| INI, ALT, Week 40, n=90, 95 | 30.2 ± 61.80 | 20.6 ± 9.20 |
| INI, ALT, Week 44, n=91, 94 | 23.2 ± 15.03 | 20.7 ± 10.01 |
| INI, ALT, Week 48, n=91, 95 | 24.4 ± 17.58 | 20.3 ± 9.79 |
| NNRTI, ALT, Baseline, n=155, 155 | 24.6 ± 12.67 | 24.4 ± 14.74 |
| NNRTI, ALT, Week 4, n=151, 153 | 21.6 ± 10.72 | 23.7 ± 11.16 |
| NNRTI, ALT, Week 8, n=122, 152 | 20.8 ± 10.13 | 23.7 ± 12.94 |
| NNRTI, ALT, Week 12, n=146, 152 | 33.9 ± 161.81 | 23.6 ± 11.27 |
| NNRTI, ALT, Week 16, n=143, 149 | 23.2 ± 27.18 | 22.8 ± 11.06 |
| NNRTI, ALT, Week 20, n=138, 152 | 22.6 ± 27.36 | 22.3 ± 11.15 |
| NNRTI, ALT, Week 24, n=143, 151 | 27.4 ± 85.70 | 22.9 ± 12.88 |
| NNRTI, ALT, Week 28, n=136, 150 | 20.6 ± 11.45 | 23.8 ± 16.00 |
| NNRTI, ALT, Week 32, n=137, 148 | 21.1 ± 12.69 | 23.4 ± 12.86 |
| NNRTI, ALT, Week 36, n=135, 147 | 21.2 ± 12.38 | 24.1 ± 13.19 |
| NNRTI, ALT, Week 40, n=138, 147 | 20.8 ± 10.63 | 23.9 ± 14.24 |
| NNRTI, ALT, Week 44, n=137, 148 | 20.0 ± 9.61 | 23.9 ± 15.22 |
| NNRTI, ALT, Week 48, n=131, 147 | 19.8 ± 9.62 | 23.5 ± 12.32 |
| PI, ALP, Baseline, n=51, 54 | 73.8 ± 24.90 | 70.2 ± 19.56 |
| PI, ALP, Week 4, n=51, 53 | 70.4 ± 20.03 | 67.7 ± 19.24 |
| PI, ALP, Week 8, n=34, 53 | 72.4 ± 34.86 | 70.9 ± 23.18 |
| PI, ALP, Week 12, n=50, 52 | 68.2 ± 17.49 | 71.6 ± 23.60 |
| PI, ALP, Week 16, n=48, 53 | 66.9 ± 15.70 | 71.2 ± 21.50 |
| PI, ALP, Week 20, n=46, 53 | 67.7 ± 16.36 | 70.8 ± 20.96 |
| PI, ALP, Week 24, n=47, 53 | 67.6 ± 16.14 | 70.3 ± 19.23 |
| PI, ALP, Week 28, n=42, 53 | 67.3 ± 17.71 | 73.7 ± 21.89 |
| PI, ALP, Week 32, n=45, 51 | 63.8 ± 16.09 | 69.8 ± 21.44 |
| PI, ALP, Week 36, n=44, 50 | 64.3 ± 16.50 | 71.7 ± 23.57 |
| PI, ALP, Week 40, n=42, 51 | 65.5 ± 13.63 | 68.5 ± 19.55 |
| PI, ALP, Week 44, n=47, 51 | 63.0 ± 15.76 | 69.1 ± 20.67 |
| PI, ALP, Week 48, n=43, 50 | 63.6 ± 14.22 | 69.9 ± 18.94 |
| INI, ALP, Baseline, n=102, 99 | 66.3 ± 17.31 | 64.9 ± 19.05 |
| INI, ALP, Week 4, n=99, 97 | 65.9 ± 17.25 | 64.4 ± 18.77 |
| INI, ALP, Week 8, n=73, 98 | 64.0 ± 16.21 | 69.7 ± 38.92 |
| INI, ALP, Week 12, n=99, 95 | 64.7 ± 16.33 | 67.7 ± 27.73 |
| INI, ALP, Week 16, n=93, 96 | 65.3 ± 17.01 | 64.4 ± 20.89 |
| INI, ALP, Week 20, n=93, 97 | 64.9 ± 16.80 | 64.2 ± 19.58 |
| INI, ALP, Week 24, n=94, 95 | 65.0 ± 17.08 | 64.4 ± 19.46 |
| INI, ALP, Week 28, n=89, 93 | 65.0 ± 15.81 | 63.3 ± 18.76 |
| INI, ALP, Week 32, n=93, 95 | 64.4 ± 16.12 | 62.3 ± 17.96 |
| INI, ALP, Week 36, n=94, 95 | 64.3 ± 18.15 | 62.2 ± 18.12 |
| INI, ALP, Week 40, n=90, 95 | 65.1 ± 17.07 | 62.2 ± 18.22 |
| INI, ALP, Week 44, n=91, 94 | 64.0 ± 16.71 | 64.1 ± 19.31 |
| INI, ALP, Week 48, n=91, 95 | 65.1 ± 15.98 | 63.0 ± 18.76 |
| NNRTI, ALP, Baseline, n=155, 155 | 84.4 ± 32.47 | 88.1 ± 28.83 |
| NNRTI, ALP, Week 4, n=151, 153 | 73.4 ± 26.16 | 85.6 ± 27.39 |
| NNRTI, ALP, Week 8, n=122, 152 | 70.9 ± 20.00 | 87.4 ± 28.15 |
| NNRTI, ALP, Week 12, n=146, 152 | 72.0 ± 30.68 | 87.8 ± 28.30 |
| NNRTI, ALP, Week 16, n=143, 149 | 69.9 ± 22.37 | 87.7 ± 28.55 |
| NNRTI, ALP, Week 20, n=138, 152 | 69.3 ± 20.51 | 86.7 ± 26.18 |
| NNRTI, ALP, Week 24, n=143, 151 | 70.2 ± 21.08 | 88.3 ± 27.77 |
| NNRTI, ALP, Week 28, n=136, 150 | 69.3 ± 20.91 | 87.0 ± 28.40 |
| NNRTI, ALP, Week 32, n=137, 148 | 69.1 ± 21.60 | 86.5 ± 26.32 |
| NNRTI, ALP, Week 36, n=135, 147 | 69.3 ± 23.22 | 87.1 ± 26.24 |
| NNRTI, ALP, Week 40, n=138, 147 | 67.1 ± 18.98 | 87.8 ± 27.07 |
| NNRTI, ALP, Week 44, n=137, 148 | 68.4 ± 19.94 | 87.5 ± 26.53 |
| NNRTI, ALP, Week 48, n=131, 147 | 68.5 ± 21.69 | 88.6 ± 27.61 |
| PI, AST, Baseline, n=51, 54 | 19.7 ± 6.97 | 20.1 ± 5.66 |
| PI, AST, Week 4, n=51, 53 | 23.5 ± 9.76 | 22.5 ± 17.53 |
| PI, AST, Week 8, n=34, 53 | 23.4 ± 11.04 | 20.0 ± 5.24 |
| PI, AST, Week 12, n=50, 52 | 22.5 ± 11.60 | 21.8 ± 9.63 |
| PI, AST, Week 16, n=48, 53 | 23.7 ± 15.77 | 22.0 ± 10.39 |
| PI, AST, Week 20, n=46, 53 | 24.1 ± 20.53 | 20.6 ± 6.35 |
| PI, AST, Week 24, n=47, 53 | 21.5 ± 7.02 | 21.7 ± 11.65 |
| PI, AST, Week 28, n=42, 53 | 22.9 ± 9.20 | 22.0 ± 8.47 |
| PI, AST, Week 32, n=45, 51 | 23.0 ± 13.51 | 20.3 ± 5.57 |
| PI, AST, Week 36, n=44, 50 | 21.5 ± 7.88 | 21.8 ± 7.04 |
| PI, AST, Week 40, n=42, 51 | 25.1 ± 23.51 | 20.5 ± 7.55 |
| PI, AST, Week 44, n=47, 51 | 21.6 ± 8.80 | 21.4 ± 13.16 |
| PI, AST, Week 48, n=43, 50 | 21.6 ± 7.59 | 22.2 ± 8.85 |
| INI, AST, Baseline, n=102, 99 | 24.5 ± 13.03 | 22.2 ± 13.13 |
| INI, AST, Week 4, n=99, 97 | 24.5 ± 13.22 | 22.0 ± 10.41 |
| INI, AST, Week 8, n=73, 98 | 26.8 ± 25.34 | 23.6 ± 19.30 |
| INI, AST, Week 12, n=99, 95 | 23.2 ± 10.47 | 23.2 ± 13.10 |
| INI, AST, Week 16, n=93, 96 | 22.5 ± 8.78 | 22.5 ± 9.96 |
| INI, AST, Week 20, n=93, 97 | 22.8 ± 10.11 | 21.4 ± 6.12 |
| INI, AST, Week 24, n=94, 95 | 24.4 ± 12.42 | 22.0 ± 9.44 |
| INI, AST, Week 28, n=89, 93 | 21.3 ± 7.14 | 21.6 ± 8.49 |
| INI, AST, Week 32, n=93, 95 | 22.2 ± 7.77 | 21.6 ± 7.87 |
| INI, AST, Week 36, n=94, 95 | 23.9 ± 15.06 | 21.1 ± 5.43 |
| INI, AST, Week 40, n=90, 95 | 25.4 ± 18.01 | 21.8 ± 7.30 |
| INI, AST, Week 44, n=91, 94 | 25.6 ± 23.29 | 21.4 ± 6.51 |
| INI, AST, Week 48, n=91, 95 | 24.9 ± 13.88 | 22.4 ± 9.70 |
| NNRTI, AST, Baseline, n=155, 155 | 24.8 ± 10.99 | 23.6 ± 9.16 |
| NNRTI, AST, Week 4, n=151, 153 | 22.2 ± 11.35 | 23.2 ± 7.95 |
| NNRTI, AST, Week 8, n=122, 152 | 23.0 ± 17.16 | 22.8 ± 7.19 |
| NNRTI, AST, Week 12, n=146, 152 | 29.4 ± 91.34 | 23.6 ± 9.12 |
| NNRTI, AST, Week 16, n=143, 149 | 25.3 ± 22.91 | 22.6 ± 6.80 |
| NNRTI, AST, Week 20, n=138, 152 | 23.8 ± 16.12 | 22.9 ± 7.33 |
| NNRTI, AST, Week 24, n=143, 150 | 25.1 ± 30.40 | 23.1 ± 8.25 |
| NNRTI, AST, Week 28, n=136, 150 | 22.6 ± 9.49 | 24.0 ± 10.53 |
| NNRTI, AST, Week 32, n=137, 148 | 23.2 ± 16.69 | 25.1 ± 15.63 |
| NNRTI, AST, Week 36, n=135, 147 | 22.8 ± 8.90 | 23.9 ± 7.99 |
| NNRTI, AST, Week 40, n=138, 147 | 22.3 ± 7.66 | 23.7 ± 8.01 |
| NNRTI, AST, Week 44, n=137, 148 | 21.7 ± 7.11 | 23.8 ± 10.98 |
| NNRTI, AST, Week 48, n=131, 147 | 22.0 ± 7.86 | 24.2 ± 9.16 |
| PI, CK, Baseline, n=51, 54 | 121.3 ± 173.52 | 111.8 ± 66.03 |
| PI, CK, Week 4, n=51, 53 | 130.0 ± 94.61 | 244.2 ± 908.06 |
| PI, CK, Week 8, n=34, 53 | 157.7 ± 174.37 | 134.2 ± 179.01 |
| PI, CK, Week 12, n=50, 52 | 124.2 ± 71.36 | 168.8 ± 406.86 |
| PI, CK, Week 16, n=48, 53 | 142.3 ± 197.96 | 127.0 ± 82.59 |
| PI, CK, Week 20, n=46, 53 | 227.9 ± 689.65 | 117.5 ± 76.83 |
| PI, CK, Week 24, n=47, 53 | 120.8 ± 72.63 | 128.9 ± 85.38 |
| PI, CK, Week 28, n=42, 53 | 185.9 ± 237.49 | 124.2 ± 96.15 |
| PI, CK, Week 32, n=45, 51 | 282.5 ± 959.49 | 110.1 ± 58.84 |
| PI, CK, Week 36, n=44, 50 | 115.5 ± 81.36 | 130.9 ± 95.59 |
| PI, CK, Week 40, n=42, 51 | 319.4 ± 1169.15 | 109.9 ± 53.99 |
| PI, CK, Week 44, n=47, 51 | 117.2 ± 74.25 | 114.4 ± 62.44 |
| PI, CK, Week 48, n=43, 50 | 123.5 ± 90.77 | 183.1 ± 485.07 |
| INI, CK, Baseline, n=102, 99 | 257.9 ± 565.99 | 214.3 ± 627.94 |
| INI, CK, Week 4, n=99, 97 | 225.9 ± 484.50 | 193.6 ± 415.15 |
| INI, CK, Week 8, n=73, 98 | 306.8 ± 791.76 | 158.0 ± 164.72 |
| INI, CK, Week 12, n=99, 95 | 242.5 ± 649.06 | 195.3 ± 383.74 |
| INI, CK, Week 16, n=93, 96 | 198.6 ± 335.16 | 216.4 ± 422.21 |
| INI, CK, Week 20, n=93, 97 | 200.9 ± 301.61 | 158.8 ± 156.94 |
| INI, CK, Week 24, n=94, 95 | 202.1 ± 276.49 | 178.8 ± 356.60 |
| INI, CK, Week 28, n=89, 93 | 151.1 ± 128.42 | 192.6 ± 463.71 |
| INI, CK, Week 32, n=93, 95 | 182.2 ± 202.28 | 175.1 ± 256.84 |
| INI, CK, Week 36, n=94, 95 | 190.7 ± 268.67 | 153.8 ± 151.29 |
| INI, CK, Week 40, n=90, 95 | 286.9 ± 705.76 | 178.2 ± 200.25 |
| INI, CK, Week 44, n=91, 94 | 457.7 ± 2054.68 | 153.6 ± 139.48 |
| INI, CK, Week 48, n=91, 95 | 278.9 ± 651.96 | 188.7 ± 339.93 |
| NNRTI, CK, Baseline, n=155, 155 | 180.9 ± 210.84 | 143.8 ± 118.05 |
| NNRTI, CK, Week 4, n=151, 153 | 192.5 ± 472.95 | 170.1 ± 226.58 |
| NNRTI, CK, Week 8, n=122, 152 | 290.4 ± 1322.89 | 141.1 ± 106.01 |
| NNRTI, CK, Week 12, n=146, 152 | 198.5 ± 430.65 | 168.5 ± 236.30 |
| NNRTI, CK, Week 16, n=143, 149 | 326.5 ± 1157.93 | 150.4 ± 214.31 |
| NNRTI, CK, Week 20, n=138, 152 | 247.2 ± 661.97 | 144.9 ± 131.72 |
| NNRTI, CK, Week 24, n=143, 151 | 210.9 ± 582.66 | 161.5 ± 182.51 |
| NNRTI, CK, Week 28, n=136, 150 | 175.0 ± 156.46 | 197.3 ± 460.97 |
| NNRTI, CK, Week 32, n=137, 148 | 218.0 ± 617.20 | 238.8 ± 656.12 |
| NNRTI, CK, Week 36, n=135, 147 | 206.4 ± 401.19 | 155.5 ± 134.30 |
| NNRTI, CK, Week 40, n=138, 147 | 175.6 ± 156.39 | 166.9 ± 191.28 |
| NNRTI, CK, Week 44, n=137, 148 | 148.6 ± 94.67 | 159.7 ± 171.66 |
| NNRTI, CK, Week 48, n=131, 147 | 167.8 ± 132.83 | 171.3 ± 256.04 |
Blood samples were collected for the analysis of clinical chemistry parameter: albumin to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).
| Grams per Liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| PI, Baseline, n=51, 54 | 43.9 ± 3.22 | 44.2 ± 3.36 |
| PI, Week 4, n=51, 53 | 44.1 ± 2.90 | 43.9 ± 2.92 |
| PI, Week 8, n=34, 53 | 44.6 ± 3.36 | 44.1 ± 3.32 |
| PI, Week 12, n=50, 52 | 43.7 ± 3.25 | 43.8 ± 3.56 |
| PI, Week 16, n=48, 53 | 43.8 ± 3.19 | 43.4 ± 3.36 |
| PI, Week 20, n=46, 53 | 43.6 ± 2.70 | 43.3 ± 3.57 |
| PI, Week 24, n=47, 53 | 43.5 ± 2.80 | 43.3 ± 3.09 |
| PI, Week 28, n=42, 53 | 43.5 ± 2.74 | 42.8 ± 3.43 |
| PI, Week 32, n=45, 51 | 43.2 ± 2.85 | 43.7 ± 3.31 |
| PI, Week 36, n=44, 50 | 43.5 ± 2.87 | 43.4 ± 3.02 |
| PI, Week 40, n=42, 51 | 44.2 ± 2.64 | 43.9 ± 3.11 |
| PI, Week 44, n=47, 51 | 43.6 ± 2.58 | 43.9 ± 3.03 |
| PI, Week 48, n=43, 50 | 43.9 ± 2.97 | 44.5 ± 2.44 |
| INI, Baseline, n=102, 99 | 44.3 ± 3.08 | 44.9 ± 3.21 |
| INI, Week 4, n=99, 97 | 43.9 ± 2.91 | 43.8 ± 2.57 |
| INI, Week 8, n=73, 98 | 43.7 ± 3.07 | 43.9 ± 3.10 |
| INI, Week 12, n=99, 95 | 44.1 ± 3.01 | 44.3 ± 2.62 |
| INI, Week 16, n=93, 96 | 43.9 ± 2.77 | 43.7 ± 2.76 |
| INI, Week 20, n=93, 97 | 43.6 ± 2.70 | 44.1 ± 2.87 |
| INI, Week 24, n=94, 95 | 43.4 ± 3.03 | 43.9 ± 3.00 |
| INI, Week 28, n=89, 93 | 44.0 ± 2.97 | 43.9 ± 2.87 |
| INI, Week 32, n=93, 95 | 44.1 ± 2.87 | 43.7 ± 2.89 |
| INI, Week 36, n=94, 95 | 43.6 ± 2.74 | 43.7 ± 2.60 |
| INI, Week 40, n=90, 95 | 44.1 ± 2.79 | 43.6 ± 2.70 |
| INI, Week 44, n=91, 94 | 43.6 ± 2.96 | 43.8 ± 2.83 |
| INI, Week 48, n=91, 95 | 44.3 ± 2.58 | 44.3 ± 2.73 |
| NNRTI, Baseline, n=155, 155 | 44.1 ± 3.11 | 44.0 ± 3.10 |
| NNRTI, Week 4, n=151, 153 | 43.4 ± 2.83 | 43.7 ± 3.04 |
| NNRTI, Week 8, n=122, 152 | 43.6 ± 2.96 | 43.4 ± 3.16 |
| NNRTI, Week 12, n=146, 152 | 43.3 ± 2.86 | 43.7 ± 3.25 |
| NNRTI, Week 16, n=143, 149 | 43.3 ± 2.61 | 43.3 ± 3.27 |
| NNRTI, Week 20, n=138, 152 | 43.1 ± 2.75 | 43.2 ± 2.98 |
| NNRTI, Week 24, n=143, 151 | 43.4 ± 2.54 | 43.4 ± 3.01 |
| NNRTI, Week 28, n=136, 150 | 43.3 ± 2.78 | 43.2 ± 3.03 |
| NNRTI, Week 32, n=137, 148 | 43.2 ± 2.74 | 43.1 ± 3.43 |
| NNRTI, Week 36, n=135, 147 | 43.0 ± 2.86 | 43.3 ± 3.37 |
| NNRTI, Week 40, n=138, 147 | 43.3 ± 2.66 | 43.1 ± 3.20 |
| NNRTI, Week 44, n=137, 148 | 43.7 ± 2.74 | 43.2 ± 3.13 |
| NNRTI, Week 48, n=131, 147 | 43.4 ± 2.73 | 43.6 ± 3.14 |
Blood samples were collected for the analysis of clinical chemistry parameter: bilirubin, direct bilirubin and creatinine to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).
| Micromoles per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| PI, Bilirubin, Baseline, n=51, 54 | 18.3 ± 20.54 | 13.9 ± 11.07 |
| PI, Bilirubin, Week 4, n=51, 53 | 9.3 ± 3.81 | 14.4 ± 10.37 |
| PI, Bilirubin, Week 8, n=34, 53 | 8.9 ± 3.45 | 14.2 ± 10.79 |
| PI, Bilirubin, Week 12, n=50, 52 | 8.1 ± 3.44 | 15.6 ± 11.70 |
| PI, Bilirubin, Week 16, n=48, 53 | 8.7 ± 3.95 | 14.7 ± 10.78 |
| PI, Bilirubin, Week 20, n=46, 53 | 9.3 ± 3.60 | 15.6 ± 14.96 |
| PI, Bilirubin, Week 24, n=47, 53 | 9.5 ± 3.42 | 16.8 ± 16.15 |
| PI, Bilirubin, Week 28, n=42, 53 | 9.4 ± 4.29 | 15.0 ± 12.75 |
| PI, Bilirubin, Week 32, n=45, 51 | 9.7 ± 3.66 | 17.1 ± 12.45 |
| PI, Bilirubin, Week 36, n=44, 50 | 8.3 ± 3.17 | 16.0 ± 14.09 |
| PI, Bilirubin, Week 40, n=42, 51 | 9.2 ± 3.51 | 17.9 ± 18.08 |
| PI, Bilirubin, Week 44, n=47, 51 | 9.5 ± 3.41 | 18.1 ± 16.62 |
| PI, Bilirubin, Week 48, n=43, 50 | 9.3 ± 3.77 | 16.7 ± 10.73 |
| INI, Bilirubin, Baseline, n=102, 99 | 9.4 ± 3.94 | 9.7 ± 5.07 |
| INI, Bilirubin, Week 4, n=99, 97 | 9.5 ± 3.88 | 9.0 ± 4.77 |
| INI, Bilirubin, Week 8, n=73, 98 | 10.1 ± 4.29 | 10.7 ± 12.28 |
| INI, Bilirubin, Week 12, n=99, 95 | 9.9 ± 4.50 | 9.2 ± 3.91 |
| INI, Bilirubin, Week 16, n=93, 96 | 9.8 ± 4.29 | 9.6 ± 3.80 |
| INI, Bilirubin, Week 20, n=93, 97 | 10.1 ± 4.05 | 9.3 ± 3.60 |
| INI, Bilirubin, Week 24, n=94, 94 | 9.4 ± 4.11 | 9.1 ± 3.81 |
| INI, Bilirubin, Week 28, n=89, 93 | 10.3 ± 3.53 | 9.5 ± 4.67 |
| INI, Bilirubin, Week 32, n=93, 95 | 9.9 ± 4.42 | 8.8 ± 3.32 |
| INI, Bilirubin, Week 36, n=94, 95 | 9.8 ± 4.09 | 9.1 ± 3.76 |
| INI, Bilirubin, Week 40, n=90, 95 | 9.9 ± 4.12 | 8.9 ± 3.63 |
| INI, Bilirubin, Week 44, n=91, 94 | 10.1 ± 4.75 | 9.0 ± 3.40 |
| INI, Bilirubin, Week 48, n=91, 95 | 10.3 ± 4.37 | 8.9 ± 3.76 |
| NNRTI, Bilirubin, Baseline, n=155, 155 | 7.4 ± 3.30 | 7.2 ± 3.30 |
| NNRTI, Bilirubin, Week 4, n=151, 153 | 8.7 ± 4.10 | 6.9 ± 2.98 |
| NNRTI, Bilirubin, Week 8, n=122, 152 | 8.9 ± 4.01 | 6.8 ± 3.40 |
| NNRTI, Bilirubin, Week 12, n=146, 152 | 9.3 ± 4.66 | 7.1 ± 3.50 |
| NNRTI, Bilirubin, Week 16, n=143, 149 | 10.5 ± 14.51 | 6.8 ± 3.52 |
| NNRTI, Bilirubin, Week 20, n=138, 152 | 9.6 ± 4.63 | 7.1 ± 3.15 |
| NNRTI, Bilirubin, Week 24, n=143, 151 | 9.1 ± 3.93 | 6.9 ± 3.75 |
| NNRTI, Bilirubin, Week 28, n=136, 150 | 9.7 ± 4.17 | 6.9 ± 3.29 |
| NNRTI, Bilirubin, Week 32, n=137, 148 | 9.7 ± 4.55 | 6.9 ± 3.52 |
| NNRTI, Bilirubin, Week 36, n=135, 147 | 9.3 ± 3.72 | 7.0 ± 3.33 |
| NNRTI, Bilirubin, Week 40, n=138, 147 | 9.6 ± 4.21 | 7.0 ± 3.43 |
| NNRTI, Bilirubin, Week 44, n=137, 148 | 9.4 ± 4.03 | 7.1 ± 3.25 |
| NNRTI, Bilirubin, Week 48, n=131, 147 | 9.4 ± 4.28 | 7.3 ± 3.19 |
| PI, Direct bilirubin, Baseline, n=51, 54 | 3.6 ± 2.13 | 2.9 ± 1.68 |
| PI, Direct bilirubin, Week 4, n=51, 53 | 2.4 ± 1.20 | 3.3 ± 1.67 |
| PI, Direct bilirubin, Week 8, n=34, 53 | 2.3 ± 1.12 | 2.8 ± 1.68 |
| PI, Direct bilirubin, Week 12, n=50, 52 | 1.9 ± 0.80 | 3.2 ± 1.95 |
| PI, direct bilirubin, Week 16, n=48, 53 | 2.0 ± 0.87 | 2.9 ± 1.45 |
| PI, Direct bilirubin, Week 20, n=46, 53 | 2.2 ± 0.79 | 2.9 ± 2.17 |
| PI, Direct bilirubin, Week 24, n=47, 53 | 2.2 ± 0.75 | 3.1 ± 2.02 |
| PI, Direct bilirubin, Week 28, n=42, 53 | 2.1 ± 1.08 | 2.7 ± 1.84 |
| PI, Direct bilirubin, Week 32, n=45, 51 | 2.2 ± 0.88 | 3.1 ± 1.84 |
| PI, Direct bilirubin, Week 36, n=44, 50 | 1.9 ± 0.80 | 3.1 ± 1.95 |
| PI, Direct bilirubin, Week 40, n=42, 51 | 2.0 ± 0.77 | 3.2 ± 2.05 |
| PI, Direct bilirubin, Week 44, n=47, 51 | 2.1 ± 0.83 | 3.3 ± 1.99 |
| PI, Direct bilirubin, Week 48, n=43, 50 | 2.3 ± 0.93 | 3.2 ± 1.71 |
| INI, Direct bilirubin, Baseline, n=102, 99 | 2.4 ± 0.96 | 2.3 ± 1.16 |
| INI, Direct bilirubin, Week 4, n=99, 97 | 2.4 ± 0.90 | 2.3 ± 1.18 |
| INI, Direct bilirubin, Week 8, n=73, 98 | 2.4 ± 1.02 | 3.0 ± 6.70 |
| INI, Direct bilirubin, Week 12, n=99, 95 | 2.3 ± 0.98 | 2.3 ± 1.06 |
| INI, Direct bilirubin, Week 16, n=93, 96 | 2.3 ± 1.03 | 2.1 ± 0.87 |
| INI, Direct bilirubin, Week 20, n=93, 97 | 2.2 ± 0.85 | 2.1 ± 0.89 |
| INI, Direct bilirubin, Week 24, n=94, 94 | 2.2 ± 1.02 | 2.0 ± 0.78 |
| INI, Direct bilirubin, Week 28, n=89, 93 | 2.2 ± 0.74 | 2.1 ± 1.12 |
| INI, Direct bilirubin, Week 32, n=93, 95 | 2.2 ± 0.94 | 1.9 ± 0.77 |
| INI, Direct bilirubin, Week 36, n=94, 95 | 2.2 ± 1.25 | 2.0 ± 0.97 |
| INI, Direct bilirubin, Week 40, n=90, 95 | 2.2 ± 1.06 | 2.0 ± 1.11 |
| INI, Direct bilirubin. Week 44, n=91, 94 | 2.3 ± 0.99 | 2.1 ± 0.95 |
| INI, Direct bilirubin, Week 48, n=91, 95 | 2.3 ± 0.82 | 2.2 ± 1.00 |
| NNRTI, Direct bilirubin, Baseline, n=155, 155 | 2.1 ± 1.00 | 1.9 ± 1.00 |
| NNRTI, Direct bilirubin, Week 4, n=151, 153 | 2.2 ± 1.06 | 2.0 ± 0.96 |
| NNRTI, Direct bilirubin, Week 8, n=122, 152 | 2.2 ± 1.10 | 1.9 ± 0.97 |
| NNRTI, Direct bilirubin, Week 12, n=146, 152 | 2.2 ± 1.12 | 1.9 ± 0.98 |
| NNRTI, Direct bilirubin, Week 16, n=143, 149 | 2.7 ± 6.95 | 1.9 ± 0.90 |
| NNRTI, Direct bilirubin, Week 20, n=138, 152 | 2.2 ± 1.07 | 1.7 ± 0.97 |
| NNRTI, Week 24, Direct bilirubin, n=143, 151 | 2.1 ± 1.04 | 1.8 ± 0.95 |
| NNRTI, Direct bilirubin, Week 28, n=136, 150 | 2.1 ± 1.01 | 1.7 ± 1.01 |
| NNRTI, Direct bilirubin, Week 32, n=137, 148 | 2.1 ± 1.08 | 1.7 ± 0.94 |
| NNRTI, Direct bilirubin, Week 36, n=135, 147 | 2.1 ± 1.10 | 1.7 ± 0.94 |
| NNRTI, Direct bilirubin, Week 40, n=138, 147 | 2.1 ± 1.18 | 1.7 ± 1.00 |
| NNRTI, Direct bilirubin, Week 44, n=137, 148 | 2.1 ± 0.96 | 1.8 ± 0.91 |
| NNRTI, Direct bilirubin, Week 48, n=131, 147 | 2.2 ± 0.98 | 1.9 ± 0.96 |
| PI, Creatinine, Baseline, n=51, 54 | 71.41 ± 12.315 | 70.20 ± 13.391 |
| PI, Creatinine, Week 4, n=51, 53 | 72.87 ± 11.632 | 72.53 ± 14.574 |
| PI, Creatinine, Week 8, n=34, 53 | 71.66 ± 13.012 | 71.54 ± 14.362 |
| PI, Creatinine, Week 12, n=50, 52 | 70.05 ± 11.609 | 73.22 ± 14.968 |
| PI, Creatinine, Week 16, n=48, 53 | 71.05 ± 11.778 | 73.25 ± 15.740 |
| PI, Creatinine, Week 20, n=46, 53 | 73.40 ± 12.191 | 75.37 ± 15.799 |
| PI, Creatinine, Week 24, n=47, 53 | 72.75 ± 11.654 | 72.84 ± 14.549 |
| PI, Creatinine, Week 28, n=42, 53 | 75.18 ± 13.118 | 73.42 ± 14.738 |
| PI, Creatinine, Week 32, n=45, 51 | 74.59 ± 13.730 | 73.93 ± 15.399 |
| PI, Creatinine, Week 36, n=44, 50 | 74.41 ± 12.217 | 72.37 ± 14.570 |
| PI, Creatinine, Week 40, n=42, 51 | 74.31 ± 11.749 | 73.73 ± 15.726 |
| PI, Creatinine, Week 44, n=47, 51 | 75.38 ± 13.405 | 73.00 ± 14.885 |
| PI, Creatinine, Week 48, n=43, 50 | 76.95 ± 13.021 | 72.21 ± 15.031 |
| INI, Creatinine, Baseline, n=102, 99 | 88.16 ± 16.835 | 86.34 ± 17.320 |
| INI, Creatinine, Week 4, n=99, 95 | 86.39 ± 14.472 | 87.66 ± 16.208 |
| INI, Creatinine, Week 8, n=73, 98 | 85.52 ± 15.851 | 88.11 ± 17.308 |
| INI, Creatinine, Week 12, n=99, 95 | 85.53 ± 17.539 | 89.36 ± 17.923 |
| INI, Creatinine, Week 16, n=93, 96 | 84.99 ± 15.429 | 86.85 ± 17.320 |
| INI, Creatinine, Week 20, n=93, 97 | 85.01 ± 14.695 | 87.06 ± 16.987 |
| INI, Creatinine, Week 24, n=94, 94 | 84.21 ± 15.039 | 87.02 ± 16.777 |
| INI, Creatinine, Week 28, n=89, 93 | 84.84 ± 15.670 | 87.41 ± 17.065 |
| INI, Creatinine, Week 32, n=93, 95 | 85.42 ± 15.349 | 86.91 ± 15.628 |
| INI, Creatinine, Week 36, n=94, 95 | 84.49 ± 15.189 | 87.20 ± 15.835 |
| INI, Creatinine, Week 40, n=90, 95 | 85.92 ± 14.651 | 87.70 ± 17.119 |
| INI, Creatinine, Week 44, n=91, 94 | 84.66 ± 15.701 | 87.08 ± 16.694 |
| INI, Creatinine, Week 48, n=91, 95 | 85.27 ± 15.683 | 86.64 ± 15.958 |
| NNRTI, Creatinine, Baseline, n=155, 155 | 75.57 ± 14.604 | 75.06 ± 14.671 |
| NNRTI, Creatinine, Week 4, n=151, 153 | 78.57 ± 15.814 | 76.79 ± 14.908 |
| NNRTI, Creatinine, Week 8, n=122, 152 | 76.75 ± 15.759 | 76.17 ± 14.876 |
| NNRTI, Creatinine, Week 12, n=146, 152 | 76.93 ± 15.495 | 75.50 ± 14.723 |
| NNRTI, Creatinine, Week 16, n=143, 149 | 77.22 ± 15.406 | 77.00 ± 16.025 |
| NNRTI, Creatinine, Week 20, n=138, 152 | 78.32 ± 16.372 | 76.36 ± 15.744 |
| NNRTI, Creatinine, Week 24, n=143, 151 | 79.92 ± 21.430 | 76.26 ± 15.534 |
| NNRTI, Creatinine, Week 28, n=136, 150 | 79.13 ± 17.039 | 76.45 ± 15.060 |
| NNRTI, Creatinine, Week 32, n=137, 148 | 77.40 ± 14.117 | 77.05 ± 16.200 |
| NNRTI, Creatinine, Week 36, n=135, 147 | 78.15 ± 16.839 | 76.64 ± 15.734 |
| NNRTI, Creatinine, Week 40, n=138, 147 | 78.42 ± 16.662 | 76.04 ± 15.083 |
| NNRTI, Creatinine, Week 44, n=137, 148 | 78.45 ± 15.909 | 76.25 ± 15.257 |
| NNRTI, Creatinine, Week 48, n=131, 147 | 78.91 ± 17.389 | 75.67 ± 14.794 |
Blood samples were collected for the analysis of clinical chemistry parameter: creatinine clearance to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). GFR will be estimated by the central laboratory using the CKD-EPI.
| Milliliters per minute per 1.73meter^2 | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| PI, Baseline, n=51, 54 | 105.2 ± 15.67 | 104.9 ± 15.22 |
| PI, Week 4, n=51, 53 | 103.0 ± 15.59 | 102.1 ± 15.68 |
| PI, Week 8, n=34, 53 | 104.3 ± 14.52 | 103.5 ± 15.61 |
| PI, Week 12, n=50, 52 | 107.1 ± 14.95 | 101.1 ± 15.94 |
| PI, Week 16, n=48, 53 | 105.4 ± 15.88 | 101.8 ± 15.99 |
| PI, Week 20, n=46, 53 | 102.9 ± 17.17 | 99.8 ± 16.53 |
| PI, Week 24, n=47, 53 | 103.3 ± 14.64 | 101.0 ± 15.54 |
| PI, Week 28, n=42, 53 | 100.6 ± 16.62 | 100.8 ± 14.58 |
| PI, Week 32, n=45, 51 | 101.0 ± 17.38 | 100.4 ± 16.04 |
| PI, Week 36, n=44, 50 | 100.7 ± 16.68 | 101.7 ± 14.42 |
| PI, Week 40, n=42, 51 | 100.2 ± 14.54 | 100.3 ± 15.51 |
| PI, Week 44, n=47, 51 | 99.8 ± 18.00 | 101.0 ± 15.31 |
| PI, Week 48, n=43, 50 | 98.8 ± 17.31 | 102.2 ± 15.45 |
| INI, Baseline, n=102, 99 | 92.3 ± 17.62 | 94.9 ± 18.82 |
| INI, Week 4, n=99, 95 | 93.4 ± 15.07 | 93.1 ± 18.22 |
| INI, Week 8, n=72, 98 | 94.4 ± 17.05 | 93.0 ± 18.12 |
| INI, Week 12, n=99, 93 | 94.5 ± 16.82 | 91.6 ± 18.81 |
| INI, Week 16, n=93, 96 | 94.9 ± 16.02 | 94.4 ± 18.30 |
| INI, Week 20, n=93, 97 | 95.3 ± 15.97 | 93.3 ± 17.48 |
| INI, Week 24, n=94, 94 | 95.6 ± 15.88 | 93.1 ± 17.21 |
| INI, Week 28, n=89, 93 | 95.4 ± 17.00 | 93.6 ± 17.89 |
| INI, Week 32, n=92, 95 | 94.8 ± 17.16 | 93.1 ± 16.94 |
| INI, Week 36, n=94, 95 | 95.6 ± 15.81 | 92.7 ± 15.65 |
| INI, Week 40, n=89, 95 | 94.8 ± 16.32 | 92.9 ± 18.15 |
| INI, Week 44, n=91, 94 | 94.8 ± 15.64 | 93.4 ± 17.94 |
| INI, Week 48, n=90, 94 | 95.4 ± 16.20 | 93.5 ± 17.00 |
| NNRTI, Baseline, n=155, 155 | 104.4 ± 17.78 | 103.7 ± 16.85 |
| NNRTI, Week 4, n=151, 153 | 100.8 ± 18.35 | 101.5 ± 17.72 |
| NNRTI, Week 8, n=121, 152 | 102.3 ± 17.23 | 102.2 ± 16.85 |
| NNRTI, Week 12, n=146, 152 | 103.1 ± 18.02 | 103.2 ± 17.47 |
| NNRTI, Week 16, n=143, 148 | 102.5 ± 17.66 | 101.0 ± 18.66 |
| NNRTI, Week 20, n=138, 152 | 101.0 ± 17.94 | 101.8 ± 17.61 |
| NNRTI, Week 24, n=142, 151 | 99.6 ± 18.18 | 101.7 ± 17.43 |
| NNRTI, Week 28, n=136, 150 | 99.9 ± 18.23 | 101.7 ± 17.20 |
| NNRTI, Week 32, n=137, 148 | 101.3 ± 16.10 | 101.0 ± 17.79 |
| NNRTI, Week 36, n=135, 147 | 100.8 ± 18.02 | 101.4 ± 17.46 |
| NNRTI, Week 40, n=137, 147 | 100.5 ± 18.40 | 101.6 ± 16.68 |
| NNRTI, Week 44, n=136, 148 | 99.9 ± 17.23 | 101.8 ± 16.96 |
| NNRTI, Week 48, n=131, 147 | 98.7 ± 17.35 | 102.1 ± 16.83 |
Blood samples were collected for the analysis of clinical chemistry parameter: lipase to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).
| Units per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| PI, Baseline, n=51, 54 | 27.6 ± 21.69 | 33.0 ± 22.44 |
| PI, Week 4, n=51, 53 | 25.5 ± 14.41 | 34.4 ± 20.77 |
| PI, Week 8, n=34, 53 | 23.4 ± 10.96 | 35.7 ± 28.85 |
| PI, Week 12, n=49, 52 | 26.4 ± 12.00 | 31.2 ± 15.31 |
| PI, Week 16, n=47, 53 | 28.1 ± 13.01 | 34.6 ± 18.14 |
| PI, Week 20, n=46, 53 | 25.8 ± 11.37 | 32.7 ± 16.37 |
| PI, Week 24, n=47, 53 | 25.8 ± 11.74 | 30.5 ± 15.48 |
| PI, Week 28, n=42, 53 | 26.4 ± 10.86 | 33.4 ± 15.92 |
| PI, Week 32, n=45, 51 | 26.9 ± 12.18 | 36.2 ± 24.23 |
| PI, Week 36, n=44, 50 | 27.1 ± 13.69 | 32.7 ± 17.14 |
| PI, Week 40, n=42, 51 | 30.5 ± 19.78 | 32.0 ± 15.16 |
| PI, Week 44, n=47, 51 | 27.1 ± 10.70 | 35.2 ± 18.59 |
| PI, Week 48, n=43, 50 | 26.3 ± 12.02 | 32.7 ± 15.62 |
| INI, Baseline, n=102, 99 | 29.3 ± 20.90 | 28.2 ± 16.64 |
| INI, Week 4, n=99, 97 | 36.8 ± 43.46 | 32.1 ± 31.31 |
| INI, Week 8, n=72, 98 | 28.8 ± 16.80 | 27.7 ± 12.72 |
| INI, Week 12, n=99, 93 | 33.1 ± 20.98 | 29.8 ± 23.81 |
| INI, Week 16, n=93, 97 | 34.4 ± 33.09 | 28.9 ± 14.77 |
| INI, Week 20, n=94, 97 | 32.0 ± 28.19 | 29.1 ± 16.34 |
| INI, Week 24, n=94, 95 | 32.0 ± 19.15 | 30.1 ± 21.56 |
| INI, Week 28, n=89, 94 | 35.1 ± 38.32 | 32.8 ± 24.85 |
| INI, Week 32, n=92, 95 | 32.6 ± 23.00 | 32.7 ± 21.75 |
| INI, Week 36, n=94, 95 | 35.0 ± 32.32 | 27.6 ± 12.20 |
| INI, Week 40, n=89, 95 | 33.8 ± 20.14 | 29.6 ± 14.21 |
| INI, Week 44, n=91, 94 | 34.6 ± 34.66 | 32.8 ± 22.45 |
| INI, Week 48, n=90, 94 | 35.1 ± 36.88 | 31.6 ± 23.18 |
| NNRTI, Baseline, n=155, 155 | 32.1 ± 24.46 | 31.8 ± 19.30 |
| NNRTI, Week 4, n=151, 153 | 37.6 ± 64.95 | 31.7 ± 17.60 |
| NNRTI, Week 8, n=121, 152 | 33.8 ± 27.26 | 33.4 ± 21.17 |
| NNRTI, Week 12, n=146, 152 | 35.6 ± 34.76 | 29.7 ± 14.64 |
| NNRTI, Week 16, n=145, 149 | 35.3 ± 32.66 | 36.8 ± 46.27 |
| NNRTI, Week 20, n=138, 152 | 32.0 ± 19.03 | 32.9 ± 37.34 |
| NNRTI, Week 24, n=142, 151 | 36.2 ± 29.08 | 37.2 ± 36.77 |
| NNRTI, Week 28, n=136, 150 | 33.4 ± 21.71 | 33.1 ± 17.20 |
| NNRTI, Week 32, n=137, 148 | 40.6 ± 83.20 | 33.6 ± 20.70 |
| NNRTI, Week 36, n=135, 147 | 39.9 ± 67.63 | 33.9 ± 21.66 |
| NNRTI, Week 40, n=138, 147 | 38.6 ± 46.34 | 32.3 ± 16.96 |
| NNRTI, Week 44, n=136, 148 | 34.5 ± 23.27 | 32.9 ± 19.81 |
| NNRTI, Week 48, n=131, 146 | 36.3 ± 30.60 | 32.8 ± 20.04 |
Blood samples were collected for the analysis of clinical chemistry parameters: CO2, chloride, glucose, phosphate, potassium, sodium and urea to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).
| Millimoles per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| PI, CO2, Baseline, n=51, 54 | 22.3 ± 2.53 | 22.7 ± 2.17 |
| PI, CO2, Week 4, n=51, 53 | 23.6 ± 2.37 | 23.4 ± 2.28 |
| PI, CO2, Week 8, n=34, 53 | 23.0 ± 1.95 | 23.0 ± 2.53 |
| PI, CO2, Week 12, n=50, 52 | 22.9 ± 2.14 | 22.9 ± 2.41 |
| PI, CO2, Week 16, n=48, 53 | 23.0 ± 2.07 | 22.9 ± 2.32 |
| PI, CO2, Week 20, n=46, 53 | 23.1 ± 2.04 | 22.7 ± 2.59 |
| PI, CO2, Week 24, n=47, 53 | 22.7 ± 1.95 | 22.8 ± 2.62 |
| PI, CO2, Week 28, n=42, 53 | 22.7 ± 2.31 | 22.5 ± 2.48 |
| PI, CO2, Week 32, n=45, 51 | 22.6 ± 2.22 | 22.6 ± 2.84 |
| PI, CO2, Week 36, n=44, 50 | 22.6 ± 2.21 | 22.4 ± 2.36 |
| PI, CO2, Week 40, n=42, 51 | 22.8 ± 2.24 | 23.1 ± 2.37 |
| PI, CO2, Week 44, n=47, 51 | 22.9 ± 1.94 | 23.1 ± 2.37 |
| PI, CO2, Week 48, n=43, 50 | 23.0 ± 2.01 | 22.7 ± 2.19 |
| INI, CO2, Baseline, n=102, 99 | 22.8 ± 2.09 | 22.9 ± 2.08 |
| INI, CO2, Week 4, n=99, 97 | 23.7 ± 2.36 | 23.7 ± 2.28 |
| INI, CO2, Week 8, n=73, 98 | 23.0 ± 2.10 | 23.6 ± 2.20 |
| INI, CO2, Week 12, n=99, 95 | 23.2 ± 2.07 | 23.3 ± 2.26 |
| INI, CO2, Week 16, n=93, 96 | 22.8 ± 2.10 | 23.5 ± 2.39 |
| INI, CO2, Week 20, n=93, 97 | 22.8 ± 2.11 | 23.6 ± 2.14 |
| INI, CO2, Week 24, n=94, 95 | 22.8 ± 2.22 | 23.1 ± 2.21 |
| INI, CO2, Week 28, n=89, 93 | 22.5 ± 2.21 | 23.1 ± 2.14 |
| INI, CO2, Week 32, n=93, 95 | 22.8 ± 2.17 | 23.0 ± 2.09 |
| INI, CO2, Week 36, n=94, 95 | 22.8 ± 1.90 | 23.5 ± 2.12 |
| INI, CO2, Week 40, n=90, 95 | 23.1 ± 2.07 | 23.2 ± 2.09 |
| INI, CO2, Week 44, n=91, 94 | 23.1 ± 2.08 | 23.7 ± 2.11 |
| INI, CO2, Week 48, n=91, 95 | 22.9 ± 1.97 | 23.3 ± 2.32 |
| NNRTI, CO2, Baseline, n=155, 155 | 22.7 ± 2.41 | 22.3 ± 2.35 |
| NNRTI, CO2, Week 4, n=151, 153 | 23.7 ± 2.63 | 23.0 ± 2.24 |
| NNRTI, CO2, Week 8, n=122, 152 | 23.2 ± 2.28 | 23.1 ± 2.61 |
| NNRTI, CO2, Week 12, n=146, 152 | 23.2 ± 2.18 | 22.8 ± 2.39 |
| NNRTI, CO2, Week 16, n=143, 149 | 23.0 ± 2.24 | 22.8 ± 2.23 |
| NNRTI, CO2, Week 20, n=138, 152 | 22.9 ± 2.24 | 22.5 ± 2.20 |
| NNRTI, CO2, Week 24, n=143, 150 | 23.0 ± 2.49 | 22.7 ± 2.45 |
| NNRTI, CO2, Week 28, n=136, 150 | 22.8 ± 2.58 | 22.6 ± 2.27 |
| NNRTI, CO2, Week 32, n=137, 148 | 22.5 ± 2.11 | 22.7 ± 2.29 |
| NNRTI, CO2, Week 36, n=135, 147 | 22.8 ± 2.38 | 22.8 ± 2.27 |
| NNRTI, CO2, Week 40, n=138, 147 | 23.1 ± 2.40 | 22.8 ± 2.68 |
| NNRTI, CO2, Week 44, n=137, 148 | 23.0 ± 2.35 | 22.8 ± 2.38 |
| NNRTI, CO2, Week 48, n=131, 147 | 22.5 ± 2.55 | 22.6 ± 2.29 |
| PI, Chloride, Baseline, n=51, 54 | 104.0 ± 1.46 | 103.5 ± 2.61 |
| PI, Chloride, Week 4, n=51, 53 | 104.5 ± 1.80 | 104.0 ± 2.10 |
| PI, Chloride, Week 8, n=34, 53 | 104.4 ± 2.35 | 104.2 ± 2.28 |
| PI, Chloride, Week 12, n=50, 52 | 104.4 ± 2.02 | 104.3 ± 2.13 |
| PI, Chloride, Week 16, n=48, 53 | 104.4 ± 2.08 | 104.5 ± 2.10 |
| PI, Chloride, Week 20, n=46, 53 | 104.8 ± 1.98 | 104.2 ± 1.97 |
| PI, Chloride, Week 24, n=47, 53 | 105.1 ± 1.85 | 104.7 ± 2.02 |
| PI, Chloride, Week 28, n=42, 53 | 105.3 ± 1.88 | 104.6 ± 2.47 |
| PI, Chloride, Week 32, n=45, 51 | 105.0 ± 2.32 | 104.4 ± 1.92 |
| PI, Chloride, Week 36, n=44, 50 | 105.0 ± 2.17 | 104.4 ± 2.27 |
| PI, Chloride, Week 40, n=42, 51 | 105.2 ± 2.27 | 104.5 ± 2.31 |
| PI, Chloride, Week 44, n=47, 51 | 105.1 ± 1.84 | 104.5 ± 1.88 |
| PI, Chloride, Week 48, n=43, 50 | 104.4 ± 1.72 | 104.3 ± 1.88 |
| INI, Chloride, Baseline, n=102, 99 | 103.6 ± 2.03 | 103.5 ± 2.26 |
| INI, Chloride, Week 4, n=99, 97 | 104.0 ± 2.17 | 104.0 ± 2.15 |
| INI, Chloride, Week 8, n=73, 98 | 104.1 ± 2.16 | 103.5 ± 2.58 |
| INI, Chloride, Week 12, n=99, 95 | 104.1 ± 2.31 | 104.0 ± 2.32 |
| INI, Chloride, Week 16, n=93, 96 | 104.7 ± 2.05 | 104.2 ± 2.26 |
| INI, Chloride, Week 20, n=93, 97 | 104.8 ± 2.39 | 103.8 ± 2.36 |
| INI, Chloride, Week 24, n=94, 95 | 104.3 ± 2.30 | 104.1 ± 2.50 |
| INI, Chloride, Week 28, n=89, 93 | 104.7 ± 1.92 | 104.0 ± 2.16 |
| INI, Chloride, Week 32, n=93, 95 | 104.5 ± 2.33 | 104.2 ± 2.47 |
| INI, Chloride, Week 36, n=94, 95 | 104.6 ± 2.04 | 104.1 ± 2.40 |
| INI, Chloride, Week 40, n=90, 95 | 104.4 ± 1.94 | 103.9 ± 2.48 |
| INI, Chloride, Week 44, n=91, 94 | 104.5 ± 2.12 | 104.0 ± 2.27 |
| INI, Chloride, Week 48, n=91, 95 | 104.2 ± 2.43 | 103.2 ± 2.26 |
| NNRTI, Chloride, Baseline, n=155, 155 | 103.9 ± 2.18 | 104.0 ± 2.37 |
| NNRTI, Chloride, Week 4, n=151, 153 | 104.3 ± 2.21 | 104.6 ± 2.29 |
| NNRTI, Chloride, Week 8, n=122, 152 | 104.4 ± 2.31 | 104.7 ± 2.22 |
| NNRTI, Chloride, Week 12, n=146, 152 | 104.3 ± 2.33 | 104.5 ± 2.23 |
| NNRTI, Chloride, Week 16, n=143, 149 | 104.4 ± 2.37 | 104.8 ± 2.34 |
| NNRTI, Chloride, Week 20, n=138, 152 | 104.6 ± 2.55 | 105.1 ± 2.38 |
| NNRTI, Chloride, Week 24, n=143, 151 | 104.4 ± 2.52 | 105.1 ± 2.18 |
| NNRTI, Chloride, Week 28, n=136, 150 | 104.7 ± 2.41 | 105.3 ± 2.31 |
| NNRTI, Chloride, Week 32, n=137, 148 | 104.7 ± 2.68 | 105.1 ± 2.26 |
| NNRTI, Chloride, Week 36, n=135, 147 | 105.0 ± 2.28 | 105.1 ± 2.30 |
| NNRTI, Chloride, Week 40, n=138, 147 | 104.7 ± 2.36 | 105.0 ± 2.70 |
| NNRTI, Chloride, Week 44, n=137, 148 | 104.6 ± 2.17 | 105.0 ± 2.32 |
| NNRTI, Chloride, Week 48, n=131, 147 | 104.6 ± 2.54 | 104.5 ± 2.46 |
| PI, Glucose, Baseline, n=51, 53 | 5.11 ± 0.878 | 5.03 ± 0.505 |
| PI, Glucose, Week 4, n=43, 43 | 5.06 ± 0.481 | 5.29 ± 0.452 |
| PI, Glucose, Week 8, n=25, 41 | 5.11 ± 0.456 | 5.18 ± 0.462 |
| PI, Glucose, Week 12, n=40, 43 | 5.21 ± 0.533 | 5.25 ± 0.535 |
| PI, Glucose, Week 16, n=39, 44 | 5.24 ± 0.800 | 5.26 ± 0.614 |
| PI, Glucose, Week 20, n=35, 42 | 5.11 ± 0.580 | 5.29 ± 0.718 |
| PI, Glucose, Week 24, n=38, 43 | 5.31 ± 0.526 | 5.29 ± 0.747 |
| PI, Glucose, Week 28, n=32, 43 | 5.16 ± 0.651 | 5.12 ± 0.512 |
| PI, Glucose, Week 32, n=36, 42 | 5.37 ± 0.700 | 5.31 ± 0.643 |
| PI, Glucose, Week 36, n=35, 42 | 5.13 ± 0.525 | 5.23 ± 0.513 |
| PI, Glucose, Week 40, n=34, 41 | 5.31 ± 0.464 | 5.17 ± 0.555 |
| PI, Glucose, Week 44, n=40, 40 | 5.13 ± 0.681 | 5.20 ± 0.408 |
| PI, Glucose, Week 48, n=39, 48 | 5.16 ± 0.647 | 5.18 ± 0.661 |
| INI, Glucose, Baseline, n=98, 96 | 5.06 ± 0.638 | 5.25 ± 0.801 |
| INI, Glucose, Week 4, n=55, 54 | 5.39 ± 0.771 | 5.37 ± 1.043 |
| INI, Glucose, Week 8, n=36, 58 | 5.16 ± 0.584 | 5.49 ± 1.307 |
| INI, Glucose, Week 12, n=53, 56 | 5.50 ± 1.317 | 5.51 ± 1.414 |
| INI, Glucose, Week 16, n=54, 53 | 5.41 ± 1.727 | 5.25 ± 0.624 |
| INI, Glucose, Week 20, n=52, 58 | 5.36 ± 0.674 | 5.21 ± 0.793 |
| INI, Glucose, Week 24, n=61, 62 | 5.34 ± 0.660 | 5.36 ± 0.753 |
| INI, Glucose, Week 28, n=53, 63 | 5.32 ± 0.817 | 5.45 ± 0.940 |
| INI, Glucose, Week 32, n=54, 56 | 5.57 ± 1.260 | 5.52 ± 0.839 |
| INI, Glucose, Week 36, n=53, 58 | 5.46 ± 0.697 | 5.34 ± 1.142 |
| INI, Glucose, Week 40, n=59, 63 | 5.53 ± 0.931 | 5.46 ± 0.765 |
| INI, Glucose, Week 44, n=54, 57 | 5.40 ± 1.020 | 5.43 ± 0.637 |
| INI, Glucose, Week 48, n=84, 91 | 5.16 ± 0.549 | 5.24 ± 0.752 |
| NNRTI, Glucose, Baseline, n=152, 150 | 4.93 ± 0.697 | 5.17 ± 1.201 |
| NNRTI, Glucose, Week 4, n=118, 129 | 5.11 ± 0.798 | 5.48 ± 1.490 |
| NNRTI, Glucose, Week 8, n=92, 119 | 5.17 ± 1.204 | 5.35 ± 1.030 |
| NNRTI, Glucose, Week 12, n=113, 122 | 5.04 ± 0.856 | 5.30 ± 1.067 |
| NNRTI, Glucose, Week 16, n=116, 119 | 5.12 ± 0.914 | 5.45 ± 1.683 |
| NNRTI, Glucose, Week 20, n=107, 121 | 5.16 ± 0.802 | 5.48 ± 1.476 |
| NNRTI, Glucose, Week 24, n=116, 124 | 5.16 ± 0.944 | 5.36 ± 0.914 |
| NNRTI, Glucose, Week 28, n=105, 120 | 5.08 ± 0.635 | 5.40 ± 0.934 |
| NNRTI, Glucose, Week 32, n=104, 121 | 5.18 ± 1.000 | 5.47 ± 1.316 |
| NNRTI, Glucose, Week 36, n=103, 120 | 5.07 ± 0.856 | 5.49 ± 1.857 |
| NNRTI, Glucose, Week 40, n=102, 114 | 5.16 ± 0.776 | 5.53 ± 1.558 |
| NNRTI, Glucose, Week 44, n=99, 116 | 5.15 ± 0.877 | 5.53 ± 1.708 |
| NNRTI, Glucose, Week 48, n=119, 138 | 5.01 ± 0.640 | 5.23 ± 1.160 |
| PI, Phosphate, Baseline, n=51, 54 | 1.048 ± 0.1523 | 1.060 ± 0.1719 |
| PI, Phosphate, Week 4, n=51, 53 | 1.116 ± 0.1648 | 1.069 ± 0.1647 |
| PI, Phosphate, Week 8, n=34, 53 | 1.119 ± 0.1891 | 1.041 ± 0.1664 |
| PI, Phosphate, Week 12, n=50, 52 | 1.073 ± 0.1788 | 1.064 ± 0.1872 |
| PI, Phosphate, Week 16, n=48, 53 | 1.111 ± 0.2006 | 1.051 ± 0.1849 |
| PI, Phosphate, Week 20, n=46, 53 | 1.119 ± 0.1689 | 1.076 ± 0.2187 |
| PI, Phosphate, Week 24, n=47, 53 | 1.086 ± 0.1647 | 1.077 ± 0.1631 |
| PI, Phosphate, Week 28, n=42, 53 | 1.085 ± 0.1803 | 1.076 ± 0.1970 |
| PI, Phosphate, Week 32, n=45, 51 | 1.109 ± 0.1869 | 1.081 ± 0.1769 |
| PI, Phosphate, Week 36, n=44, 50 | 1.084 ± 0.1659 | 1.058 ± 0.1830 |
| PI, Phosphate, Week 40, n=42, 51 | 1.067 ± 0.2020 | 1.053 ± 0.1932 |
| PI, Phosphate, Week 44, n=47, 51 | 1.084 ± 0.1785 | 1.063 ± 0.2227 |
| PI, Phosphate, Week 48, n=43, 50 | 1.095 ± 0.1636 | 1.070 ± 0.1804 |
| INI, Phosphate, Baseline, n=102, 99 | 1.045 ± 0.1687 | 1.063 ± 0.1700 |
| INI, Phosphate, Week 4, n=99, 97 | 1.080 ± 0.1725 | 1.082 ± 0.1857 |
| INI, Phosphate, Week 8, n=73, 98 | 1.086 ± 0.1901 | 1.071 ± 0.2001 |
| INI, Phosphate, Week 12, n=99, 95 | 1.068 ± 0.1970 | 1.078 ± 0.1823 |
| INI, Phosphate, Week 16, n=93, 96 | 1.063 ± 0.1623 | 1.061 ± 0.1702 |
| INI, Phosphate, Week 20, n=93, 97 | 1.046 ± 0.1717 | 1.091 ± 0.1757 |
| INI, Phosphate, Week 24, n=94, 95 | 1.066 ± 0.1661 | 1.052 ± 0.1921 |
| INI, Phosphate, Week 28, n=89, 93 | 1.060 ± 0.1602 | 1.065 ± 0.1835 |
| INI, Phosphate, Week 32, n=93, 95 | 1.045 ± 0.1649 | 1.045 ± 0.1569 |
| INI, Phosphate, Week 36, n=94, 95 | 1.032 ± 0.1572 | 1.059 ± 0.1800 |
| INI, Phosphate, Week 40, n=90, 95 | 1.054 ± 0.1838 | 1.062 ± 0.1731 |
| INI, Phosphate, Week 44, n=91, 94 | 1.043 ± 0.1805 | 1.066 ± 0.2029 |
| INI, Phosphate, Week 48, n=91, 95 | 1.072 ± 0.1721 | 1.066 ± 0.1918 |
| NNRTI, Phosphate, Baseline, n=155, 155 | 1.038 ± 0.1905 | 1.040 ± 0.1741 |
| NNRTI, Phosphate, Week 4, n=151, 153 | 1.128 ± 0.1867 | 1.056 ± 0.1764 |
| NNRTI, Phosphate, Week 8, n=122, 152 | 1.097 ± 0.1994 | 1.024 ± 0.1784 |
| NNRTI, Phosphate, Week 12, n=146, 152 | 1.091 ± 0.1838 | 1.051 ± 0.2002 |
| NNRTI, Phosphate, Week 16, n=143, 149 | 1.082 ± 0.1827 | 1.046 ± 0.1700 |
| NNRTI, Phosphate, Week 20, n=138, 152 | 1.076 ± 0.1763 | 1.037 ± 0.1806 |
| NNRTI, Phosphate, Week 24, n=143, 151 | 1.091 ± 0.1914 | 1.052 ± 0.1882 |
| NNRTI, Phosphate, Week 28, n=136, 150 | 1.076 ± 0.1764 | 1.038 ± 0.1585 |
| NNRTI, Phosphate, Week 32, n=137, 148 | 1.057 ± 0.1722 | 1.050 ± 0.1874 |
| NNRTI, Phosphate, Week 36, n=135, 147 | 1.055 ± 0.1790 | 1.039 ± 0.1793 |
| NNRTI, Phosphate, Week 40, n=138, 147 | 1.071 ± 0.1689 | 1.033 ± 0.1724 |
| NNRTI, Phosphate, Week 44, n=137, 148 | 1.076 ± 0.1795 | 1.040 ± 0.1693 |
| NNRTI, Phosphate, Week 48, n=131, 147 | 1.075 ± 0.1941 | 1.037 ± 0.1789 |
| PI, Potassium, Baseline, n=51, 54 | 4.13 ± 0.288 | 4.10 ± 0.308 |
| PI, Potassium, Week 4, n=51, 53 | 4.25 ± 0.355 | 4.31 ± 0.395 |
| PI, Potassium, Week 8, n=34, 53 | 4.18 ± 0.283 | 4.19 ± 0.331 |
| PI, Potassium, Week 12, n=50, 52 | 4.25 ± 0.335 | 4.31 ± 0.364 |
| PI, Potassium, Week 16, n=48, 53 | 4.16 ± 0.322 | 4.30 ± 0.359 |
| PI, Potassium, Week 20, n=46, 53 | 4.18 ± 0.291 | 4.29 ± 0.314 |
| PI, Potassium, Week 24, n=47, 53 | 4.15 ± 0.335 | 4.30 ± 0.379 |
| PI, Potassium, Week 28, n=42, 53 | 4.21 ± 0.342 | 4.26 ± 0.348 |
| PI, Potassium, Week 32, n=45, 51 | 4.15 ± 0.326 | 4.31 ± 0.367 |
| PI, Potassium, Week 36, n=44, 50 | 4.25 ± 0.345 | 4.26 ± 0.378 |
| PI, Potassium, Week 40, n=42, 51 | 4.23 ± 0.293 | 4.26 ± 0.363 |
| PI, Potassium, Week 44, n=47, 51 | 4.24 ± 0.348 | 4.32 ± 0.375 |
| PI, Potassium, Week 48, n=43, 50 | 4.15 ± 0.292 | 4.12 ± 0.320 |
| INI, Potassium, Baseline, n=102, 99 | 4.17 ± 0.245 | 4.18 ± 0.289 |
| INI, Potassium, Week 4, n=99, 97 | 4.20 ± 0.311 | 4.26 ± 0.359 |
| INI, Potassium, Week 8, n=73, 98 | 4.14 ± 0.306 | 4.24 ± 0.462 |
| INI, Potassium, Week 12, n=99, 95 | 4.19 ± 0.340 | 4.18 ± 0.291 |
| INI, Potassium, Week 16, n=93, 96 | 4.15 ± 0.317 | 4.19 ± 0.297 |
| INI, Potassium, Week 20, n=93, 97 | 4.20 ± 0.299 | 4.18 ± 0.289 |
| INI, Potassium, Week 24, n=94, 95 | 4.19 ± 0.304 | 4.21 ± 0.304 |
| INI, Potassium,Week 28, n=89, 93 | 4.19 ± 0.412 | 4.22 ± 0.341 |
| INI, Potassium, Week 32, n=93, 95 | 4.20 ± 0.358 | 4.19 ± 0.307 |
| INI, Potassium, Week 36, n=94, 95 | 4.19 ± 0.365 | 4.23 ± 0.332 |
| INI, Potassium, Week 40, n=90, 95 | 4.18 ± 0.332 | 4.19 ± 0.297 |
| INI, Potassium, Week 44, n=91, 94 | 4.18 ± 0.309 | 4.17 ± 0.314 |
| INI, Potassium, Week 48, n=91, 95 | 4.15 ± 0.266 | 4.16 ± 0.305 |
| NNRTI, Potassium, Baseline, n=155, 155 | 4.16 ± 0.302 | 4.18 ± 0.331 |
| NNRTI, Potassium, Week 4, n=151, 153 | 4.21 ± 0.287 | 4.28 ± 0.333 |
| NNRTI, Potassium, Week 8, n=122, 152 | 4.17 ± 0.295 | 4.23 ± 0.366 |
| NNRTI, Potassium, Week 12, n=146, 152 | 4.18 ± 0.322 | 4.26 ± 0.341 |
| NNRTI, Potassium, Week 16, n=143, 149 | 4.20 ± 0.313 | 4.23 ± 0.320 |
| NNRTI, Potassium,Week 20, n=138, 152 | 4.20 ± 0.326 | 4.21 ± 0.337 |
| NNRTI, Potassium, Week 24, n=143, 150 | 4.19 ± 0.259 | 4.22 ± 0.341 |
| NNRTI, Potassium, Week 28, n=136, 150 | 4.18 ± 0.301 | 4.25 ± 0.434 |
| NNRTI, Potassium, Week 32, n=137, 148 | 4.17 ± 0.388 | 4.20 ± 0.349 |
| NNRTI, Potassium, Week 36, n=135, 147 | 4.17 ± 0.289 | 4.22 ± 0.343 |
| NNRTI, Potassium, Week 40, n=138, 147 | 4.20 ± 0.283 | 4.26 ± 0.321 |
| NNRTI, Potassium, Week 44, n=137, 148 | 4.23 ± 0.324 | 4.24 ± 0.374 |
| NNRTI, Potassium, Week 48, n=131, 147 | 4.14 ± 0.271 | 4.17 ± 0.352 |
| PI, Sodium, Baseline, n=51, 54 | 138.9 ± 2.15 | 138.7 ± 2.10 |
| PI, Sodium, Week 4, n=51, 53 | 139.3 ± 1.64 | 139.0 ± 2.08 |
| PI, Sodium, Week 8, n=34, 53 | 139.6 ± 2.10 | 139.0 ± 1.95 |
| PI, Sodium, Week 12, n=50, 52 | 139.3 ± 1.76 | 139.4 ± 2.03 |
| PI, Sodium, Week 16, n=48, 53 | 139.4 ± 2.18 | 139.0 ± 1.75 |
| PI, Sodium, Week 20, n=46, 53 | 139.6 ± 1.71 | 139.1 ± 1.97 |
| PI, Sodium, Week 24, n=47, 53 | 139.4 ± 2.08 | 139.1 ± 2.07 |
| PI, Sodium, Week 28, n=42, 53 | 140.3 ± 1.59 | 139.5 ± 2.49 |
| PI, Sodium, Week 32, n=45, 51 | 139.4 ± 2.14 | 139.3 ± 2.28 |
| PI, Sodium, Week 36, n=44, 50 | 139.7 ± 1.63 | 139.4 ± 2.32 |
| PI, Sodium, Week 40, n=42, 51 | 139.8 ± 1.94 | 139.4 ± 1.93 |
| PI, Sodium, Week 44, n=47, 51 | 139.7 ± 1.78 | 139.4 ± 2.09 |
| PI, Sodium, Week 48, n=43, 50 | 139.8 ± 1.86 | 139.6 ± 1.90 |
| INI, Sodium, Baseline, n=102, 99 | 138.8 ± 1.62 | 139.0 ± 1.67 |
| INI, Sodium, Week 4, n=99, 97 | 139.2 ± 1.58 | 139.1 ± 1.72 |
| INI, Sodium, Week 8, n=73, 98 | 138.8 ± 2.00 | 138.8 ± 1.79 |
| INI, Sodium, Week 12, n=99, 95 | 139.1 ± 1.97 | 139.0 ± 1.88 |
| INI, Sodium, Week 16, n=93, 96 | 139.1 ± 1.87 | 139.4 ± 1.89 |
| INI, Sodium, Week 20, n=93, 97 | 139.4 ± 1.92 | 139.2 ± 1.67 |
| INI, Sodium, Week 24, n=94, 95 | 139.3 ± 1.86 | 139.1 ± 1.91 |
| INI, Sodium, Week 28, n=89, 93 | 139.4 ± 1.65 | 138.8 ± 1.67 |
| INI, Sodium, Week 32, n=93, 95 | 139.4 ± 1.63 | 139.2 ± 1.68 |
| INI, Sodium, Week 36, n=94, 95 | 139.2 ± 1.84 | 139.4 ± 1.99 |
| INI, Sodium, Week 40, n=90, 95 | 139.3 ± 2.01 | 139.3 ± 1.83 |
| INI, Sodium, Week 44, n=91, 94 | 139.3 ± 1.67 | 139.4 ± 1.88 |
| INI, Sodium, Week 48, n=91, 95 | 139.3 ± 1.98 | 139.0 ± 1.76 |
| NNRTI, Sodium, Baseline, n=155, 155 | 139.1 ± 2.00 | 139.2 ± 1.68 |
| NNRTI, Sodium, Week 4, n=151, 153 | 139.4 ± 1.79 | 139.2 ± 1.90 |
| NNRTI, Sodium, Week 8, n=122, 152 | 139.1 ± 1.91 | 139.2 ± 1.76 |
| NNRTI, Sodium, Week 12, n=146, 152 | 139.2 ± 1.78 | 139.2 ± 1.77 |
| NNRTI, Sodium, Week 16, n=143, 149 | 139.0 ± 1.99 | 139.0 ± 2.06 |
| NNRTI, Sodium, Week 20, n=138, 152 | 139.0 ± 1.87 | 139.5 ± 1.83 |
| NNRTI, Sodium, Week 24, n=143, 151 | 139.2 ± 1.83 | 139.4 ± 1.94 |
| NNRTI, Sodium, Week 28, n=136, 150 | 139.3 ± 1.84 | 139.4 ± 1.99 |
| NNRTI, Sodium, Week 32, n=137, 148 | 139.2 ± 1.68 | 139.7 ± 1.75 |
| NNRTI, Sodium, Week 36, n=135, 147 | 139.4 ± 1.80 | 139.7 ± 2.19 |
| NNRTI, Sodium, Week 40, n=138, 147 | 139.4 ± 1.87 | 139.7 ± 2.06 |
| NNRTI, Sodium, Week 44, n=137, 148 | 139.5 ± 1.88 | 139.7 ± 1.92 |
| NNRTI, Sodium, Week 48, n=131, 147 | 139.4 ± 1.93 | 139.5 ± 1.82 |
| PI, Urea, Baseline, n=51, 54 | 4.97 ± 1.409 | 4.89 ± 1.316 |
| PI, Urea, Week 4, n=51, 53 | 4.99 ± 1.210 | 4.91 ± 1.455 |
| PI, Urea, Week 8, n=34, 53 | 5.10 ± 1.353 | 4.88 ± 1.447 |
| PI, Urea, Week 12, n=50, 52 | 5.03 ± 1.368 | 4.85 ± 1.480 |
| PI, Urea, Week 16, n=48, 53 | 5.20 ± 1.295 | 5.09 ± 1.754 |
| PI, Urea, Week 20, n=46, 53 | 5.18 ± 1.216 | 5.07 ± 1.535 |
| PI, Urea, Week 24, n=47, 53 | 5.44 ± 1.587 | 5.00 ± 1.414 |
| PI, Urea, Week 28, n=42, 53 | 5.21 ± 1.358 | 4.90 ± 1.530 |
| PI, Urea, Week 32, n=45, 51 | 5.13 ± 1.135 | 5.09 ± 1.482 |
| PI, Urea, Week 36, n=44, 50 | 4.99 ± 1.310 | 4.78 ± 1.411 |
| PI, Urea, Week 40, n=42, 51 | 5.35 ± 1.227 | 5.30 ± 1.758 |
| PI, Urea, Week 44, n=47, 51 | 5.38 ± 1.483 | 5.10 ± 1.517 |
| PI, Urea, Week 48, n=43, 50 | 5.22 ± 1.469 | 5.11 ± 1.489 |
| INI, Urea, Baseline, n=102, 99 | 5.76 ± 1.528 | 5.61 ± 1.894 |
| INI, Urea, Week 4, n=99, 97 | 5.63 ± 1.471 | 5.77 ± 1.676 |
| INI, Urea, Week 8, n=73, 98 | 5.80 ± 1.617 | 5.60 ± 1.607 |
| INI, Urea, Week 12, n=99, 95 | 5.81 ± 1.536 | 5.83 ± 1.724 |
| INI, Urea, Week 16, n=93, 96 | 5.76 ± 1.577 | 5.70 ± 1.574 |
| INI, Urea, Week 20, n=93, 97 | 5.75 ± 1.640 | 5.76 ± 1.580 |
| INI, Urea, Week 24, n=94, 95 | 5.84 ± 1.578 | 5.72 ± 1.774 |
| INI, Urea, Week 28, n=89, 93 | 5.76 ± 1.593 | 5.65 ± 1.435 |
| INI, Urea, Week 32, n=93, 95 | 5.67 ± 1.537 | 5.63 ± 1.477 |
| INI, Urea, Week 36, n=94, 95 | 5.67 ± 1.670 | 5.53 ± 1.456 |
| INI, Urea, Week 40, n=90, 95 | 5.81 ± 1.669 | 5.66 ± 1.593 |
| INI, Urea, Week 44, n=91, 94 | 5.59 ± 1.607 | 5.46 ± 1.368 |
| INI, Urea, Week 48, n=91, 95 | 5.83 ± 1.654 | 5.50 ± 1.468 |
| NNRTI, Urea, Baseline, n=155, 155 | 4.96 ± 1.519 | 5.10 ± 1.510 |
| NNRTI, Urea, Week 4, n=151, 153 | 5.08 ± 1.556 | 5.09 ± 1.426 |
| NNRTI, Urea, Week 8, n=122, 152 | 5.09 ± 1.675 | 5.10 ± 1.465 |
| NNRTI, Urea, Week 12, n=146, 152 | 5.20 ± 1.684 | 5.13 ± 1.583 |
| NNRTI, Urea, Week 16, n=143, 149 | 5.03 ± 1.768 | 5.34 ± 1.660 |
| NNRTI, Urea, Week 20, n=138, 152 | 5.18 ± 1.709 | 5.15 ± 1.713 |
| NNRTI, Urea, Week 24, n=143, 151 | 5.29 ± 1.878 | 5.26 ± 1.591 |
| NNRTI, Urea, Week 28, n=136, 150 | 5.20 ± 1.931 | 5.10 ± 1.537 |
| NNRTI, Urea, Week 32, n=137, 148 | 5.38 ± 1.796 | 5.14 ± 1.687 |
| NNRTI, Urea, Week 36, n=135, 147 | 5.07 ± 1.719 | 5.13 ± 1.493 |
| NNRTI, Urea, Week 40, n=138, 147 | 5.30 ± 1.616 | 5.07 ± 1.377 |
| NNRTI, Urea, Week 44, n=137, 148 | 5.23 ± 1.489 | 5.18 ± 1.613 |
| NNRTI, Urea, Week 48, n=131, 147 | 5.32 ± 1.671 | 5.06 ± 1.380 |
Blood samples were collected for the analysis of fasting lipid panel: triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).
| Millimoles per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| PI, Triglycerides, Baseline, n=46, 50 | 1.951 ± 1.8801 | 1.894 ± 1.4058 |
| PI, Triglycerides, Week 48, n=40, 45 | 1.309 ± 0.7647 | 1.772 ± 1.1828 |
| INI, Triglycerides, Baseline, n=82, 84 | 1.470 ± 1.0152 | 1.426 ± 0.8720 |
| INI, Triglycerides, Week 48, n=72, 77 | 1.405 ± 0.9068 | 1.307 ± 0.7427 |
| NNRTI, Triglycerides, Baseline, n=136, 140 | 1.322 ± 0.7986 | 1.506 ± 1.4388 |
| NNRTI, Triglycerides, Week 48, n=119, 120 | 1.305 ± 0.8771 | 1.316 ± 0.7914 |
| PI, Cholesterol, Baseline, n=46, 50 | 4.98 ± 0.960 | 5.14 ± 1.152 |
| PI, Cholesterol, Week 48, n=40, 45 | 5.07 ± 0.775 | 5.16 ± 1.130 |
| INI, Cholesterol, Baseline, n=82, 84 | 4.81 ± 1.077 | 5.01 ± 1.080 |
| INI, Cholesterol, Week 48, n=72, 77 | 4.90 ± 0.881 | 4.87 ± 0.997 |
| NNRTI, Cholesterol, Baseline, n=136, 140 | 4.87 ± 0.958 | 4.98 ± 1.007 |
| NNRTI, Cholesterol, Week 48, n=119, 120 | 4.93 ± 0.904 | 4.91 ± 1.007 |
| PI, HDL cholesterol, Baseline, n=46, 50 | 1.389 ± 0.4943 | 1.537 ± 0.6096 |
| PI, HDL cholesterol, Week 48, n=40, 45 | 1.505 ± 0.5459 | 1.550 ± 0.5950 |
| INI, HDL cholesterol, Baseline, n=82, 84 | 1.257 ± 0.3450 | 1.383 ± 0.3890 |
| INI, HDL cholesterol, Week 48, n=72, 77 | 1.288 ± 0.3664 | 1.323 ± 0.3588 |
| NNRTI, HDL cholesterol, Baseline, n=136, 140 | 1.449 ± 0.4756 | 1.405 ± 0.4401 |
| NNRTI, HDL cholesterol, Week 48, n=119, 120 | 1.442 ± 0.4413 | 1.471 ± 0.4226 |
| PI, LDL cholesterol, Baseline, n=43, 48 | 2.734 ± 0.7891 | 2.743 ± 0.7948 |
| PI, LDL cholesterol, Week 48, n=37, 43 | 2.944 ± 0.7175 | 2.784 ± 0.8477 |
| INI, LDL cholesterol, Basline, n=81, 83 | 2.881 ± 0.9196 | 2.946 ± 0.8614 |
| INI, LDL cholesterol, Week 48, n=71, 76 | 2.975 ± 0.8787 | 2.939 ± 0.8591 |
| NNRTI, LDL cholesterol, Baseline, n=134, 137 | 2.834 ± 0.8442 | 2.901 ± 0.8714 |
| NNRTI, LDL cholesterol, Week 48, n=116, 119 | 2.900 ± 0.8415 | 2.834 ± 0.8763 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.
| Participants | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| PI | 2 | 2 |
| INI | 6 | 0 |
| NNRTI | 5 | 3 |
Blood samples will be collected at indicated time points for pharmacokinetic (PK) analysis of CAB LA. PK population includes all participants who received CAB and / or RPV and underwent PK sampling during the study, and provided CAB and /or RPV plasma concentration data.
| Micrograms per milliliter | CAB LA |
|---|---|
| Pre-dose, Week 8, n=252 | 1.2277 (1.1293 to 1.3346) |
| Pre-dose, Week 12, n=261 | 1.6925 (1.6005 to 1.7897) |
| Pre-dose, Week 16, n=248 | 1.9533 (1.8492 to 2.0632) |
| Pre-dose, Week 20, n=233 | 2.1036 (1.9924 to 2.2209) |
| Pre-dose, Week 24, n=234 | 2.2537 (2.1177 to 2.3984) |
| Pre-dose, Week 28, n=232 | 2.4300 (2.3093 to 2.5569) |
| Pre-dose, Week 32, n=219 | 2.4483 (2.3321 to 2.5703) |
| Pre-dose, Week 36, n=209 | 2.4681 (2.3377 to 2.6057) |
| Pre-dose, Week 40, n=209 | 2.5126 (2.3477 to 2.6890) |
| Pre-dose, Week 44, n=221 | 2.7748 (2.6323 to 2.9250) |
| Pre-dose, Week 48, n=217 | 2.8378 (2.6763 to 3.0090) |
Blood samples will be collected at indicated time points for PK analysis of RPV LA.
| Nanograms per milliliter | RPV LA |
|---|---|
| Pre-dose, Week 8, n=251 | 38.58 (35.96 to 41.39) |
| Pre-dose, Week 12, n=261 | 47.00 (44.50 to 49.64) |
| Pre-dose, Week 16, n=247 | 53.87 (50.92 to 56.98) |
| Pre-dose, Week 20, n=233 | 54.14 (51.13 to 57.34) |
| Pre-dose, Week 24, n=231 | 61.26 (57.80 to 64.93) |
| Pre-dose, Week 28, n=232 | 66.53 (62.87 to 70.40) |
| Pre-dose, Week 32, n=218 | 70.93 (66.97 to 75.11) |
| Pre-dose, Week 36, n=209 | 73.00 (68.54 to 77.75) |
| Pre-dose, Week 40, n=208 | 76.24 (71.71 to 81.07) |
| Pre-dose, Week 44, n=223 | 83.65 (78.94 to 88.63) |
| Pre-dose, Week 48, n=216 | 90.28 (84.92 to 95.98) |
AUC values are Bayesian PK parameter estimates obtained from a population PK meta-analysis of the data collected from studies 201585 and 201584 # NCT02938520. Blood samples from the current study 201585 were collected at indicated time points to analyze concentration in plasma for CAB LA.
| Hours*microgram per milliliter | CAB LA |
|---|---|
| Area Under the Curve (AUC) for CAB LA | 2324.29 (2249.850 to 2401.187) |
AUC values are Bayesian PK parameter estimates obtained from a population PK meta-analysis of the data collected from studies 201585 and 201584 # NCT02938520. Blood samples from the current study 201585 were collected at indicated time points to analyze concentration in plasma for RPV LA.
| Hours*nanogram per milliliter | RPV LA |
|---|---|
| AUC for RPV LA | 67119.84 (64426.092 to 69926.208) |
Blood samples will be collected at indicated time points for PK analysis of CAB LA.
| Micrograms per milliliter | CAB LA |
|---|---|
| Maximum Concentration (Cmax) in Plasma for CAB LA Evaluable at Week 41 | 3.3862 (3.1804 to 3.6054) |
Blood samples will be collected at indicated time points for PK analysis of RPV LA.
| Nanograms per milliliter | RPV LA |
|---|---|
| Cmax in Plasma for RPV LA Evaluable at Week 41 | 110.36 (103.28 to 117.93) |
Percentage of participants with virologic failure endpoint as per FDA snapshot algorithm at Week 48 was assessed based on the non-inferior antiviral activity of switching IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART regimen over 48 weeks in HIV-1 infected ART-experienced participants. The HIV-RNA \>=50 copies/mL per snapshot algorithm was determined using a Cochran-Mantel Haenszel test stratified by baseline third agent class: INI, NNRTI, or PI.
| Percentage of participants | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| PI, n=51, 54 | 2.0 | 0 |
| INI, n=102, 99 | 0 | 2.0 |
| NNRTI, n=155, 155 | 2.6 | 0.6 |
Percentage of participants with HIV-1 RNA \< 50copies/mL endpoint as per FDA snapshot algorithm at Week 48 was assessed based on the non-inferior antiviral activity of switching IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART regimen over 48 weeks in HIV-1 infected ART-experienced participants. The HIV-RNA \<50 copies/mL per snapshot algorithm was determined using a Cochran-Mantel Haenszel test stratified by baseline third agent class: INI, NNRTI, or PI.
| Percentage of participants | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| PI, n=51, 54 | 92 | 94 |
| INI, n=102, 99 | 94 | 96 |
| NNRTI, n=155, 155 | 92 | 95 |
Severity of AEs were defined as per The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table). Severity grades for AEs were as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 were all deaths related to an AE.
| Participants | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| PI, Grade 1 | 22 | 20 |
| PI, Grade 2 | 20 | 11 |
| PI, Grade 3 | 4 | 4 |
| PI, Grade 4 | 1 | 0 |
| PI, Grade 5 | 0 | 1 |
| INI, Grade 1 | 40 | 40 |
| INI, Grade 2 | 50 | 23 |
| INI, Grade 3 | 8 | 3 |
| INI, Grade 4 | 1 | 2 |
| INI, Grade 5 | 0 | 0 |
| NNRTI, Grade 1 | 39 | 55 |
| NNRTI, Grade 2 | 88 | 47 |
| NNRTI, Grade 3 | 15 | 12 |
| NNRTI, Grade 4 | 6 | 2 |
| NNRTI, Grade 5 | 0 | 0 |
Blood samples were collected for the analysis of clinical chemistry parameters: ALT, ALP, AST and CK to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| International units per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| PI, ALT, Week 4, n=51, 53 | 9.4 ± 17.93 | 1.1 ± 9.99 |
| PI, ALT, Week 8, n=34, 53 | 7.9 ± 17.19 | 0.9 ± 7.20 |
| PI, ALT, Week 12, n=50, 52 | 5.3 ± 17.31 | 1.4 ± 9.76 |
| PI, ALT, Week 16, n=48, 53 | 6.5 ± 20.92 | 1.4 ± 8.75 |
| PI, ALT, Week 20, n=46, 53 | 4.9 ± 18.06 | 0.3 ± 7.34 |
| PI, ALT, Week 24, n=47, 53 | 4.1 ± 14.42 | 0.5 ± 7.30 |
| PI, ALT, Week 28, n=42, 53 | 2.6 ± 11.47 | 0.8 ± 7.46 |
| PI, ALT, Week 32, n=45, 51 | 3.5 ± 14.88 | 0.5 ± 7.36 |
| PI, ALT, Week 36, n=44, 50 | 3.3 ± 13.55 | 2.0 ± 9.78 |
| PI, ALT, Week 40, n=42, 51 | 5.4 ± 17.81 | 1.1 ± 10.52 |
| PI, ALT, Week 44, n=47, 51 | 4.0 ± 15.83 | 0.9 ± 11.97 |
| PI, ALT, Week 48, n=43, 50 | 2.9 ± 10.69 | 0.5 ± 8.04 |
| INI, ALT, Week 4, n=99, 97 | 1.7 ± 15.15 | 0.7 ± 7.20 |
| INI, ALT, Week 8, n=73, 98 | 3.3 ± 18.20 | 5.4 ± 50.20 |
| INI, ALT, Week 12, n=99, 95 | -1.0 ± 12.48 | 1.7 ± 10.63 |
| INI, ALT, Week 16, n=93, 96 | -1.8 ± 12.27 | -0.1 ± 8.58 |
| INI, ALT, Week 20, n=93, 97 | -1.9 ± 13.60 | -0.5 ± 9.38 |
| INI, ALT, Week 24, n=94, 95 | 0.6 ± 17.33 | 0.1 ± 9.95 |
| INI, ALT, Week 28, n=89, 93 | -2.4 ± 9.70 | -0.4 ± 12.31 |
| INI, ALT, Week 32, n=93, 95 | -1.8 ± 12.87 | -0.3 ± 7.79 |
| INI, ALT, Week 36, n=94, 95 | 1.5 ± 35.82 | -0.4 ± 8.79 |
| INI, ALT, Week 40, n=90, 95 | 5.0 ± 59.10 | -0.6 ± 9.62 |
| INI, ALT, Week 44, n=91, 94 | -1.6 ± 13.90 | -0.4 ± 7.91 |
| INI, ALT, Week 48, n=91, 95 | -0.2 ± 15.17 | -0.8 ± 7.41 |
| NNRTI, ALT, Week 4, n=151, 153 | -2.6 ± 9.82 | -0.7 ± 10.80 |
| NNRTI, ALT, Week 8, n=122, 152 | -2.9 ± 11.62 | -0.8 ± 12.06 |
| NNRTI, ALT, Week 12, n=146, 152 | 9.5 ± 160.61 | -0.8 ± 12.66 |
| NNRTI, ALT, Week 16, n=143, 149 | -1.3 ± 26.21 | -1.6 ± 11.39 |
| NNRTI, ALT, Week 20, n=138, 152 | -2.0 ± 28.04 | -2.0 ± 12.61 |
| NNRTI, ALT, Week 24, n=143, 151 | 2.6 ± 85.48 | -1.3 ± 11.85 |
| NNRTI, ALT, Week 28, n=136, 150 | -4.5 ± 11.46 | -0.5 ± 14.03 |
| NNRTI, ALT, Week 32, n=137, 148 | -3.8 ± 14.93 | -0.9 ± 14.33 |
| NNRTI, ALT, Week 36, n=135, 147 | -3.8 ± 12.44 | -0.1 ± 12.48 |
| NNRTI, ALT, Week 40, n=138, 147 | -3.8 ± 13.48 | -0.4 ± 13.47 |
| NNRTI, ALT, Week 44, n=137, 148 | -4.7 ± 12.67 | -0.4 ± 14.67 |
| NNRTI, ALT, Week 48, n=131, 147 | -4.6 ± 12.38 | -0.9 ± 12.75 |
| PI, ALP, Week 4, n=51, 53 | -3.5 ± 11.63 | -2.9 ± 8.07 |
| PI, ALP, Week 8, n=34, 53 | -2.1 ± 24.59 | 0.2 ± 11.37 |
| PI, ALP, Week 12, n=50, 52 | -5.7 ± 14.40 | 0.9 ± 10.22 |
| PI, ALP, Week 16, n=48, 53 | -7.3 ± 17.09 | 0.6 ± 8.68 |
| PI, ALP, Week 20, n=46, 53 | -6.8 ± 16.71 | 0.1 ± 10.70 |
| PI, ALP, Week 24, n=47, 53 | -7.5 ± 17.90 | -0.4 ± 7.67 |
| PI, ALP, Week 28, n=42, 53 | -7.3 ± 17.23 | 3.0 ± 9.69 |
| PI, ALP, Week 32, n=45, 51 | -9.3 ± 16.47 | -0.7 ± 8.50 |
| PI, ALP, Week 36, n=44, 50 | -10.2 ± 18.52 | 0.6 ± 13.52 |
| PI, ALP, Week 40, n=42, 51 | -8.7 ± 17.37 | -1.4 ± 8.79 |
| PI, ALP, Week 44, n=47, 51 | -11.5 ± 17.49 | -0.9 ± 9.05 |
| PI, ALP, Week 48, n=43, 50 | -8.0 ± 16.05 | -0.2 ± 9.08 |
| INI, ALP, Week 4, n=99, 97 | -0.5 ± 10.59 | -0.9 ± 7.92 |
| INI, ALP, Week 8, n=73, 98 | -1.8 ± 8.55 | 4.9 ± 33.17 |
| INI, ALP, Week 12, n=99, 95 | -1.6 ± 8.57 | 3.5 ± 19.97 |
| INI, ALP, Week 16, n=93, 96 | -1.7 ± 10.53 | -0.2 ± 10.93 |
| INI, ALP, Week 20, n=93, 97 | -2.0 ± 10.23 | -0.4 ± 7.93 |
| INI, ALP, Week 24, n=94, 95 | -1.4 ± 10.23 | -0.6 ± 8.25 |
| INI, ALP, Week 28, n=89, 93 | -2.1 ± 10.83 | -0.8 ± 8.80 |
| INI, ALP, Week 32, n=93, 95 | -1.6 ± 11.08 | -2.0 ± 8.23 |
| INI, ALP, Week 36, n=94, 95 | -2.4 ± 12.03 | -2.2 ± 9.41 |
| INI, ALP, Week 40, n=90, 95 | -0.9 ± 13.77 | -1.9 ± 9.33 |
| INI, ALP, Week 44, n=91, 94 | -2.6 ± 13.69 | -0.4 ± 11.60 |
| INI, ALP, Week 48, n=91, 95 | -1.9 ± 13.29 | -1.2 ± 10.26 |
| NNRTI, ALP, Week 4, n=151, 153 | -10.4 ± 12.81 | -2.7 ± 9.60 |
| NNRTI, ALP, Week 8, n=122, 152 | -10.9 ± 16.50 | -1.0 ± 10.77 |
| NNRTI, ALP, Week 12, n=146, 152 | -13.0 ± 26.62 | -0.7 ± 11.04 |
| NNRTI, ALP, Week 16, n=143, 149 | -15.7 ± 22.52 | -1.0 ± 10.54 |
| NNRTI, ALP, Week 20, n=138, 152 | -14.9 ± 22.35 | -1.8 ± 13.77 |
| NNRTI, ALP, Week 24, n=143, 151 | -14.5 ± 21.88 | 0.4 ± 12.75 |
| NNRTI, ALP, Week 28, n=136, 150 | -16.2 ± 21.66 | -1.0 ± 13.18 |
| NNRTI, ALP, Week 32, n=137, 148 | -15.8 ± 21.98 | -1.8 ± 13.63 |
| NNRTI, ALP, Week 36, n=135, 147 | -16.1 ± 23.60 | -1.0 ± 11.86 |
| NNRTI, ALP, Week 40, n=138, 147 | -17.2 ± 22.83 | -0.4 ± 13.19 |
| NNRTI, ALP, Week 44, n=137, 148 | -17.3 ± 23.32 | -0.8 ± 13.20 |
| NNRTI, ALP, Week 48, n=131, 147 | -18.0 ± 27.97 | 0.2 ± 14.69 |
| PI, AST, Week 4, n=51, 53 | 3.8 ± 9.18 | 2.3 ± 16.78 |
| PI, AST, Week 8, n=34, 53 | 5.1 ± 8.35 | -0.1 ± 4.60 |
| PI, AST, Week 12, n=50, 52 | 2.7 ± 11.49 | 1.7 ± 7.21 |
| PI, AST, Week 16, n=48, 53 | 3.9 ± 16.81 | 1.8 ± 10.69 |
| PI, AST, Week 20, n=46, 53 | 4.1 ± 20.85 | 0.5 ± 4.29 |
| PI, AST, Week 24, n=47, 53 | 1.5 ± 7.76 | 1.6 ± 9.93 |
| PI, AST, Week 28, n=42, 53 | 2.9 ± 8.86 | 1.9 ± 7.45 |
| PI, AST, Week 32, n=45, 51 | 3.1 ± 14.13 | 0.6 ± 4.93 |
| PI, AST, Week 36, n=44, 50 | 1.7 ± 8.04 | 1.9 ± 6.24 |
| PI, AST, Week 40, n=42, 51 | 5.7 ± 24.61 | 0.5 ± 6.05 |
| PI, AST, Week 44, n=47, 51 | 1.7 ± 9.71 | 1.4 ± 11.60 |
| PI, AST, Week 48, n=43, 50 | 1.7 ± 7.09 | 2.1 ± 8.74 |
| INI, AST, Week 4, n=99, 97 | 0.0 ± 15.36 | -0.1 ± 6.29 |
| INI, AST, Week 8, n=73, 98 | 3.3 ± 25.01 | 1.2 ± 21.48 |
| INI, AST, Week 12, n=99, 95 | -1.3 ± 14.22 | 0.8 ± 7.35 |
| INI, AST, Week 16, n=93, 96 | -2.1 ± 12.73 | 0.1 ± 10.96 |
| INI, AST, Week 20, n=93, 97 | -1.7 ± 13.77 | -0.9 ± 12.67 |
| INI, AST, Week 24, n=94, 95 | -0.4 ± 14.88 | -0.2 ± 10.40 |
| INI, AST, Week 28, n=89, 93 | -1.4 ± 7.74 | -0.9 ± 13.48 |
| INI, AST, Week 32, n=93, 95 | -2.1 ± 13.06 | -0.8 ± 10.01 |
| INI, AST, Week 36, n=94, 95 | -0.7 ± 17.34 | -1.1 ± 11.70 |
| INI, AST, Week 40, n=90, 95 | 1.0 ± 20.11 | -0.4 ± 13.96 |
| INI, AST, Week 44, n=91, 94 | 1.0 ± 24.54 | -0.7 ± 10.69 |
| INI, AST, Week 48, n=91, 95 | 0.4 ± 16.57 | 0.2 ± 11.91 |
| NNRTI, AST, Week 4, n=151, 153 | -1.9 ± 11.09 | -0.5 ± 8.73 |
| NNRTI, AST, Week 8, n=122, 152 | -1.3 ± 18.14 | -0.9 ± 8.31 |
| NNRTI, AST, Week 12, n=146, 152 | 4.7 ± 91.54 | 0.0 ± 10.08 |
| NNRTI, AST, Week 16, n=143, 149 | 0.3 ± 21.80 | -1.0 ± 8.37 |
| NNRTI, AST, Week 20, n=138, 152 | -1.2 ± 17.47 | -0.7 ± 9.09 |
| NNRTI, AST, Week 24, n=143, 150 | -0.1 ± 31.53 | -0.4 ± 8.87 |
| NNRTI, AST, Week 28, n=136, 150 | -2.8 ± 9.02 | 0.4 ± 10.70 |
| NNRTI, AST, Week 32, n=137, 148 | -2.0 ± 18.27 | 1.5 ± 16.84 |
| NNRTI, AST, Week 36, n=135, 147 | -2.5 ± 10.33 | 0.2 ± 9.00 |
| NNRTI, AST, Week 40, n=138, 147 | -2.7 ± 11.14 | 0.1 ± 9.40 |
| NNRTI, AST, Week 44, n=137, 148 | -3.4 ± 10.38 | 0.1 ± 11.20 |
| NNRTI, AST, Week 48, n=131, 147 | -2.9 ± 10.87 | 0.5 ± 10.60 |
| PI, CK, Week 4, n=51, 53 | 8.6 ± 182.21 | 133.5 ± 907.82 |
| PI, CK, Week 8, n=34, 53 | 67.9 ± 176.14 | 23.5 ± 174.40 |
| PI, CK, Week 12, n=50, 52 | 3.1 ± 162.71 | 57.9 ± 406.52 |
| PI, CK, Week 16, n=48, 53 | 19.4 ± 253.86 | 16.3 ± 66.34 |
| PI, CK, Week 20, n=46, 53 | 103.6 ± 696.54 | 6.8 ± 72.86 |
| PI, CK, Week 24, n=47, 53 | -3.0 ± 181.03 | 18.2 ± 86.69 |
| PI, CK, Week 28, n=42, 53 | 60.3 ± 299.83 | 13.5 ± 93.14 |
| PI, CK, Week 32, n=45, 51 | 157.1 ± 988.65 | 1.5 ± 64.94 |
| PI, CK, Week 36, n=44, 50 | -9.0 ± 191.25 | 22.3 ± 62.09 |
| PI, CK, Week 40, n=42, 51 | 193.7 ± 1188.89 | 0.3 ± 48.24 |
| PI, CK, Week 44, n=47, 51 | -6.3 ± 185.69 | 4.8 ± 62.91 |
| PI, CK, Week 48, n=43, 50 | -1.0 ± 158.33 | 72.9 ± 478.94 |
| INI, CK, Week 4, n=99, 97 | -32.7 ± 717.86 | -17.9 ± 260.84 |
| INI, CK, Week 8, n=73, 98 | 95.6 ± 801.75 | -58.0 ± 577.11 |
| INI, CK, Week 12, n=99, 95 | -16.1 ± 852.44 | -23.9 ± 304.61 |
| INI, CK, Week 16, n=93, 96 | -59.5 ± 629.54 | -1.9 ± 686.38 |
| INI, CK, Week 20, n=93, 97 | -55.7 ± 623.92 | -58.1 ± 622.84 |
| INI, CK, Week 24, n=94, 95 | -63.1 ± 549.02 | -40.7 ± 588.24 |
| INI, CK Week 28, n=89, 93 | -17.4 ± 224.35 | -27.4 ± 759.07 |
| INI, CK, Week 32, n=93, 95 | -82.8 ± 587.51 | -42.1 ± 637.00 |
| INI, CK, Week 36, n=94, 95 | -76.1 ± 602.03 | -60.9 ± 603.48 |
| INI, CK, Week 40, n=90, 95 | 40.3 ± 864.00 | -36.2 ± 609.80 |
| INI, CK, Week 44, n=91, 94 | 199.8 ± 2043.35 | -60.2 ± 576.84 |
| INI, CK, Week 48, n=91, 95 | 20.5 ± 861.55 | -25.0 ± 653.03 |
| NNRTI, CK, Week 4, n=151, 153 | 18.2 ± 502.12 | 26.0 ± 214.58 |
| NNRTI, CK, Week 8, n=122, 152 | 108.2 ± 1339.52 | -3.6 ± 108.28 |
| NNRTI, CK, Week 12, n=146, 152 | 21.9 ± 440.81 | 24.5 ± 222.26 |
| NNRTI, CK, Week 16, n=143, 149 | 139.9 ± 1121.08 | 7.0 ± 189.21 |
| NNRTI, CK, Week 20, n=138, 152 | 65.5 ± 656.11 | 1.6 ± 114.05 |
| NNRTI, CK, Week 24, n=143, 151 | 24.1 ± 606.47 | 17.7 ± 167.38 |
| NNRTI, CK, Week 28, n=136, 150 | -10.9 ± 169.29 | 53.2 ± 462.07 |
| NNRTI, CK, Week 32, n=137, 148 | 31.3 ± 650.27 | 94.0 ± 665.17 |
| NNRTI, CK, Week 36, n=135, 147 | 19.0 ± 440.56 | 10.3 ± 135.08 |
| NNRTI, CK, Week 40, n=138, 147 | -7.7 ± 237.00 | 22.6 ± 195.23 |
| NNRTI, CK, Week 44, n=137, 148 | -35.4 ± 183.15 | 14.9 ± 173.39 |
| NNRTI, CK, Week 48, n=131, 147 | -15.1 ± 212.52 | 27.3 ± 272.59 |
Blood samples were collected for the analysis of clinical chemistry parameter: albumin to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Grams per Liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| PI, Week 4, n=51, 53 | 0.2 ± 2.21 | -0.2 ± 2.41 |
| PI, Week 8, n=34, 53 | 0.7 ± 2.73 | -0.1 ± 2.74 |
| PI, Week 12, n=50, 52 | -0.2 ± 2.67 | -0.3 ± 2.81 |
| PI, Week 16, n=48, 53 | -0.2 ± 2.77 | -0.8 ± 2.72 |
| PI, Week 20, n=46, 53 | -0.4 ± 2.35 | -0.8 ± 2.82 |
| PI, Week 24, n=47, 53 | -0.6 ± 2.24 | -0.8 ± 2.40 |
| PI, Week 28, n=42, 53 | -0.6 ± 2.26 | -1.4 ± 2.08 |
| PI, Week 32, n=45, 51 | -0.7 ± 2.39 | -0.5 ± 2.42 |
| PI, Week 36, n=44, 50 | -0.6 ± 2.44 | -0.9 ± 2.48 |
| PI, Week 40, n=42, 51 | -0.1 ± 2.72 | -0.5 ± 2.37 |
| PI, Week 44, n=47, 51 | -0.5 ± 2.15 | -0.5 ± 2.60 |
| PI, Week 48, n=43, 50 | -0.3 ± 2.74 | -0.1 ± 2.44 |
| INI, Week 4, n=99, 97 | -0.4 ± 2.56 | -0.9 ± 2.62 |
| INI, Week 8, n=73, 98 | -0.5 ± 2.59 | -1.0 ± 2.89 |
| INI, Week 12, n=99, 95 | -0.3 ± 2.92 | -0.5 ± 2.59 |
| INI, Week 16, n=93, 96 | -0.5 ± 2.78 | -1.1 ± 2.80 |
| INI, Week 20, n=93, 97 | -0.7 ± 2.71 | -0.7 ± 2.77 |
| INI, Week 24, n=94, 95 | -0.8 ± 2.86 | -1.0 ± 2.74 |
| INI, Week 28, n=89, 93 | -0.3 ± 2.55 | -1.1 ± 2.87 |
| INI, Week 32, n=93, 95 | -0.2 ± 2.70 | -1.3 ± 2.77 |
| INI, Week 36, n=94, 95 | -0.8 ± 2.67 | -1.1 ± 2.54 |
| INI, Week 40, n=90, 95 | -0.3 ± 2.40 | -1.3 ± 2.84 |
| INI, Week 44, n=91, 94 | -0.5 ± 2.77 | -1.0 ± 2.76 |
| INI, Week 48, n=91, 95 | -0.1 ± 2.69 | -0.5 ± 2.69 |
| NNRTI, Week 4, n=151, 153 | -0.8 ± 2.70 | -0.3 ± 2.42 |
| NNRTI, Week 8, n=122, 152 | -0.4 ± 2.83 | -0.6 ± 2.53 |
| NNRTI, Week 12, n=146, 152 | -0.8 ± 2.59 | -0.3 ± 2.61 |
| NNRTI, Week 16, n=143, 149 | -0.8 ± 2.79 | -0.7 ± 2.63 |
| NNRTI, Week 20, n=138, 152 | -0.9 ± 2.96 | -0.9 ± 2.33 |
| NNRTI, Week 24, n=143, 151 | -0.7 ± 2.73 | -0.7 ± 2.57 |
| NNRTI, Week 28, n=136, 150 | -0.9 ± 2.72 | -0.9 ± 2.34 |
| NNRTI, Week 32, n=137, 148 | -0.9 ± 2.94 | -1.0 ± 2.45 |
| NNRTI, Week 36, n=135, 147 | -1.0 ± 2.83 | -0.8 ± 2.79 |
| NNRTI, Week 40, n=138, 147 | -0.7 ± 2.54 | -1.0 ± 2.52 |
| NNRTI, Week 44, n=137, 148 | -0.3 ± 2.60 | -0.8 ± 2.22 |
| NNRTI, Week 48, n=131, 147 | -0.6 ± 2.57 | -0.5 ± 2.49 |
Blood samples were collected for the analysis of clinical chemistry parameter: bilirubin, direct bilirubin and creatinine to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Micromoles per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| PI, Bilirubin, Week 4, n=51, 53 | -9.0 ± 20.62 | 0.3 ± 6.95 |
| PI, Bilirubin, Week 8, n=34, 53 | -6.6 ± 13.76 | 0.1 ± 5.76 |
| PI, Bilirubin, Week 12, n=50, 52 | -10.2 ± 20.18 | 1.7 ± 7.11 |
| PI, Bilirubin, Week 16, n=48, 53 | -10.0 ± 20.13 | 0.6 ± 6.42 |
| PI, Bilirubin, Week 20, n=46, 53 | -9.2 ± 20.21 | 1.5 ± 12.45 |
| PI, Bilirubin, Week 24, n=47, 53 | -9.6 ± 20.64 | 2.7 ± 11.87 |
| PI, Bilirubin, Week 28, n=42, 53 | -10.0 ± 22.42 | 0.9 ± 7.70 |
| PI, Bilirubin, Week 32, n=45, 51 | -8.9 ± 21.34 | 2.7 ± 8.64 |
| PI, Bilirubin, Week 36, n=44, 50 | -10.5 ± 21.75 | 2.6 ± 7.35 |
| PI, Bilirubin, Week 40, n=42, 51 | -11.0 ± 22.20 | 3.5 ± 12.74 |
| PI, Bilirubin, Week 44, n=47, 51 | -9.6 ± 20.32 | 3.7 ± 9.10 |
| PI, Bilirubin, Week 48, n=43, 50 | -10.7 ± 21.77 | 2.3 ± 5.23 |
| INI, Bilirubin, Week 4, n=99, 97 | 0.2 ± 3.92 | -0.7 ± 3.93 |
| INI, Bilirubin, Week 8, n=73, 98 | 0.4 ± 3.96 | 0.9 ± 12.43 |
| INI, Bilirubin, Week 12, n=99, 95 | 0.6 ± 4.41 | -0.5 ± 4.69 |
| INI, Bilirubin, Week 16, n=93, 96 | 0.6 ± 4.30 | -0.2 ± 4.35 |
| INI, Bilirubin, Week 20, n=93, 97 | 0.9 ± 4.08 | -0.5 ± 4.32 |
| INI, Bilirubin, Week 24, n=94, 94 | 0.2 ± 3.72 | -0.5 ± 3.88 |
| INI, Bilirubin, Week 28, n=89, 93 | 1.1 ± 3.58 | -0.4 ± 4.85 |
| INI, Bilirubin, Week 32, n=93, 95 | 0.7 ± 4.67 | -1.1 ± 4.54 |
| INI, Bilirubin, Week 36, n=94, 95 | 0.5 ± 4.07 | -0.6 ± 4.62 |
| INI, Bilirubin, Week 40, n=90, 95 | 0.6 ± 4.28 | -1.0 ± 4.26 |
| INI, Bilirubin, Week 44, n=91, 94 | 0.9 ± 4.34 | -0.7 ± 4.72 |
| INI, Bilirubin, Week 48, n=91, 95 | 1.1 ± 3.72 | -0.9 ± 3.96 |
| NNRTI, Bilirubin, Week 4, n=151, 153 | 1.4 ± 3.87 | -0.4 ± 2.85 |
| NNRTI, Bilirubin, Week 8, n=122, 152 | 1.4 ± 3.84 | -0.4 ± 2.43 |
| NNRTI, Bilirubin, Week 12, n=146, 152 | 2.0 ± 4.69 | -0.2 ± 3.01 |
| NNRTI, Bilirubin, Week 16, n=143, 149 | 3.3 ± 14.12 | -0.5 ± 2.66 |
| NNRTI, Bilirubin, Week 20, n=138, 152 | 2.1 ± 4.90 | -0.1 ± 2.81 |
| NNRTI, Bilirubin, Week 24, n=143, 151 | 1.8 ± 3.91 | -0.3 ± 2.84 |
| NNRTI, Bilirubin, Week 28, n=136, 150 | 2.4 ± 4.11 | -0.4 ± 3.04 |
| NNRTI, Bilirubin, Week 32, n=137, 148 | 2.2 ± 4.76 | -0.3 ± 2.57 |
| NNRTI, Bilirubin, Week 36, n=135, 147 | 1.8 ± 4.14 | -0.2 ± 2.61 |
| NNRTI, Bilirubin, Week 40, n=138, 147 | 2.2 ± 4.43 | -0.2 ± 2.61 |
| NNRTI, Bilirubin, Week 44, n=137, 148 | 2.0 ± 4.15 | -0.1 ± 2.72 |
| NNRTI, Bilirubin, Week 48, n=131, 147 | 2.2 ± 4.59 | 0.1 ± 2.98 |
| PI, Direct bilirubin, Week 4, n=51, 53 | -1.2 ± 2.34 | 0.3 ± 1.40 |
| PI, Direct bilirubin, Week 8, n=34, 53 | -0.9 ± 2.16 | -0.1 ± 1.44 |
| PI, Direct bilirubin, Week 12, n=50, 52 | -1.6 ± 2.16 | 0.3 ± 1.39 |
| PI, direct bilirubin, Week 16, n=48, 53 | -1.7 ± 2.12 | 0.0 ± 1.30 |
| PI, Direct bilirubin, Week 20, n=46, 53 | -1.5 ± 2.27 | 0.0 ± 1.86 |
| PI, Direct bilirubin, Week 24, n=47, 53 | -1.4 ± 2.27 | 0.2 ± 1.72 |
| PI, Direct bilirubin, Week 28, n=42, 53 | -1.6 ± 2.43 | -0.3 ± 1.52 |
| PI, Direct bilirubin, Week 32, n=45, 51 | -1.4 ± 2.48 | 0.2 ± 1.74 |
| PI, Direct bilirubin, Week 36, n=44, 50 | -1.8 ± 2.29 | 0.2 ± 1.49 |
| PI, Direct bilirubin, Week 40, n=42, 51 | -1.8 ± 2.29 | 0.2 ± 1.43 |
| PI, Direct bilirubin, Week 44, n=47, 51 | -1.5 ± 2.22 | 0.3 ± 1.52 |
| PI, Direct bilirubin, Week 48, n=43, 50 | -1.5 ± 2.35 | 0.2 ± 1.36 |
| INI, Direct bilirubin, Week 4, n=99, 97 | 0.0 ± 1.11 | 0.0 ± 1.19 |
| INI, Direct bilirubin, Week 8, n=73, 98 | 0.0 ± 1.13 | 0.7 ± 6.76 |
| INI, Direct bilirubin, Week 12, n=99, 95 | 0.0 ± 1.14 | 0.0 ± 1.29 |
| INI, Direct bilirubin, Week 16, n=93, 96 | 0.0 ± 1.14 | -0.3 ± 1.06 |
| INI, Direct bilirubin, Week 20, n=93, 97 | -0.2 ± 0.96 | -0.2 ± 1.23 |
| INI, Direct bilirubin, Week 24, n=94, 94 | -0.1 ± 1.07 | -0.3 ± 1.16 |
| INI, Direct bilirubin, Week 28, n=89, 93 | -0.1 ± 0.97 | -0.2 ± 1.30 |
| INI, Direct bilirubin, Week 32, n=93, 95 | -0.2 ± 1.24 | -0.4 ± 1.15 |
| INI, Direct bilirubin, Week 36, n=94, 95 | -0.2 ± 1.33 | -0.3 ± 1.18 |
| INI, Direct bilirubin, Week 40, n=90, 95 | -0.1 ± 1.10 | -0.4 ± 1.24 |
| INI, Direct bilirubin. Week 44, n=91, 94 | 0.0 ± 1.14 | -0.3 ± 1.11 |
| INI, Direct bilirubin, Week 48, n=91, 95 | 0.0 ± 1.01 | -0.1 ± 1.28 |
| NNRTI, Direct bilirubin, Week 4, n=151, 153 | 0.1 ± 1.14 | 0.1 ± 1.12 |
| NNRTI, Direct bilirubin, Week 8, n=122, 152 | 0.1 ± 1.24 | 0.0 ± 1.03 |
| NNRTI, Direct bilirubin, Week 12, n=146, 152 | 0.2 ± 1.38 | 0.0 ± 1.08 |
| NNRTI, Direct bilirubin, Week 16, n=143, 149 | 0.7 ± 6.82 | -0.1 ± 1.09 |
| NNRTI, Direct bilirubin, Week 20, n=138, 152 | 0.1 ± 1.32 | -0.2 ± 1.08 |
| NNRTI, Direct bilirubin, Week 24, n=143, 151 | 0.1 ± 1.34 | -0.1 ± 1.06 |
| NNRTI, Direct bilirubin, Week 28, n=136, 150 | 0.1 ± 1.29 | -0.2 ± 1.19 |
| NNRTI, Direct bilirubin, Week 32, n=137, 148 | 0.0 ± 1.31 | -0.2 ± 1.06 |
| NNRTI, Direct bilirubin, Week 36, n=135, 147 | 0.0 ± 1.47 | -0.2 ± 1.09 |
| NNRTI, Direct bilirubin, Week 40, n=138, 147 | 0.0 ± 1.55 | -0.2 ± 1.01 |
| NNRTI, Direct bilirubin, Week 44, n=137, 148 | 0.1 ± 1.28 | -0.1 ± 1.08 |
| NNRTI, Direct bilirubin, Week 48, n=131, 147 | 0.1 ± 1.27 | 0.0 ± 1.16 |
| PI, Creatinine, Week 4, n=51, 53 | 1.46 ± 7.726 | 2.16 ± 6.737 |
| PI, Creatinine, Week 8, n=34, 53 | 0.87 ± 7.777 | 1.17 ± 5.605 |
| PI, Creatinine, Week 12, n=50, 52 | -1.66 ± 8.971 | 3.01 ± 5.406 |
| PI, Creatinine, Week 16, n=48, 53 | -0.90 ± 8.658 | 2.88 ± 5.918 |
| PI, Creatinine, Week 20, n=46, 53 | 1.63 ± 8.709 | 5.00 ± 9.336 |
| PI, Creatinine, Week 24, n=47, 53 | 0.48 ± 7.143 | 2.47 ± 6.821 |
| PI, Creatinine, Week 28, n=42, 53 | 3.06 ± 9.741 | 3.05 ± 6.908 |
| PI, Creatinine, Week 32, n=45, 51 | 2.29 ± 10.124 | 3.79 ± 6.540 |
| PI, Creatinine, Week 36, n=44, 50 | 2.20 ± 7.347 | 2.36 ± 6.291 |
| PI, Creatinine, Week 40, n=42, 51 | 1.10 ± 9.155 | 3.46 ± 6.166 |
| PI, Creatinine, Week 44, n=47, 51 | 3.01 ± 8.981 | 2.73 ± 6.169 |
| PI, Creatinine, Week 48, n=43, 50 | 4.41 ± 10.009 | 1.86 ± 5.575 |
| INI, Creatinine, Week 4, n=99, 95 | -1.61 ± 8.848 | 1.64 ± 10.592 |
| INI, Creatinine, Week 8, n=73, 98 | -3.93 ± 10.030 | 1.56 ± 9.444 |
| INI, Creatinine, Week 12, n=99, 95 | -2.47 ± 10.973 | 3.03 ± 10.203 |
| INI, Creatinine, Week 16, n=93, 96 | -3.93 ± 9.000 | 0.36 ± 8.651 |
| INI, Creatinine, Week 20, n=93, 97 | -3.73 ± 9.101 | 0.86 ± 9.608 |
| INI, Creatinine, Week 24, n=94, 94 | -4.25 ± 8.281 | 0.87 ± 10.493 |
| INI, Creatinine, Week 28, n=89, 93 | -3.54 ± 10.713 | 0.92 ± 10.086 |
| INI, Creatinine, Week 32, n=93, 95 | -3.48 ± 10.591 | 0.86 ± 9.754 |
| INI, Creatinine, Week 36, n=94, 95 | -4.31 ± 10.360 | 1.34 ± 9.369 |
| INI, Creatinine, Week 40, n=90, 95 | -3.08 ± 9.913 | 1.66 ± 10.272 |
| INI, Creatinine, Week 44, n=91, 94 | -3.33 ± 9.165 | 0.98 ± 10.443 |
| INI, Creatinine, Week 48, n=91, 95 | -2.99 ± 9.442 | 0.47 ± 9.602 |
| NNRTI, Creatinine, Week 4, n=151, 153 | 2.86 ± 7.456 | 1.77 ± 6.484 |
| NNRTI, Creatinine, Week 8, n=122, 152 | 0.86 ± 8.263 | 1.05 ± 6.790 |
| NNRTI, Creatinine, Week 12, n=146, 152 | 1.47 ± 7.928 | 0.44 ± 6.096 |
| NNRTI, Creatinine, Week 16, n=143, 149 | 1.67 ± 8.934 | 1.98 ± 8.475 |
| NNRTI, Creatinine, Week 20, n=138, 152 | 3.04 ± 8.836 | 1.27 ± 7.023 |
| NNRTI, Creatinine, Week 24, n=143, 151 | 4.42 ± 14.819 | 1.28 ± 6.553 |
| NNRTI, Creatinine, Week 28, n=136, 150 | 3.61 ± 10.627 | 1.50 ± 7.483 |
| NNRTI, Creatinine, Week 32, n=137, 148 | 2.26 ± 9.033 | 2.01 ± 7.811 |
| NNRTI, Creatinine, Week 36, n=135, 147 | 2.98 ± 10.596 | 1.54 ± 7.354 |
| NNRTI, Creatinine, Week 40, n=138, 147 | 3.39 ± 9.496 | 0.99 ± 7.471 |
| NNRTI, Creatinine, Week 44, n=137, 148 | 3.24 ± 8.892 | 1.21 ± 6.686 |
| NNRTI, Creatinine, Week 48, n=131, 147 | 3.84 ± 11.860 | 0.69 ± 7.241 |
Blood samples were collected for the analysis of clinical chemistry parameter: creatinine clearance to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). GFR will be estimated by the central laboratory using the CKD-EPI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Milliliters per minute per 1.73meter^2 | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| PI, Week 4, n=51, 53 | -2.2 ± 9.77 | -2.8 ± 8.02 |
| PI, Week 8, n=34, 53 | -1.1 ± 10.19 | -1.3 ± 6.58 |
| PI, Week 12, n=50, 52 | 2.2 ± 11.04 | -3.7 ± 6.99 |
| PI, Week 16, n=48, 53 | 0.9 ± 11.02 | -3.1 ± 7.63 |
| PI, Week 20, n=46, 53 | -2.2 ± 10.80 | -5.0 ± 9.26 |
| PI, Week 24, n=47, 53 | -1.0 ± 8.60 | -3.8 ± 8.51 |
| PI, Week 28, n=42, 53 | -4.2 ± 11.82 | -4.0 ± 8.46 |
| PI, Week 32, n=45, 51 | -3.2 ± 12.30 | -5.2 ± 7.56 |
| PI, Week 36, n=44, 50 | -3.8 ± 8.68 | -3.6 ± 8.08 |
| PI, Week 40, n=42, 51 | -2.4 ± 10.71 | -4.9 ± 7.25 |
| PI, Week 44, n=47, 51 | -4.5 ± 10.63 | -4.2 ± 7.58 |
| PI, Week 48, n=43, 50 | -5.6 ± 12.22 | -3.1 ± 6.54 |
| INI, Week 4, n=99, 95 | 1.0 ± 9.51 | -2.0 ± 11.28 |
| INI, Week 8, n=72, 98 | 3.9 ± 9.84 | -1.9 ± 9.28 |
| INI, Week 12, n=99, 93 | 2.1 ± 11.32 | -3.1 ± 9.60 |
| INI, Week 16, n=93, 96 | 3.6 ± 9.71 | -0.7 ± 8.59 |
| INI, Week 20, n=93, 97 | 3.5 ± 9.77 | -1.7 ± 9.58 |
| INI, Week 24, n=94, 94 | 3.9 ± 9.26 | -1.8 ± 10.38 |
| INI, Week 28, n=89, 93 | 3.1 ± 11.02 | -1.6 ± 9.55 |
| INI, Week 32, n=92, 95 | 3.0 ± 10.40 | -2.0 ± 9.69 |
| INI, Week 36, n=94, 95 | 3.7 ± 11.19 | -2.3 ± 9.30 |
| INI, Week 40, n=89, 95 | 2.7 ± 10.45 | -2.6 ± 10.14 |
| INI, Week 44, n=91, 94 | 2.6 ± 9.88 | -1.6 ± 10.90 |
| INI, Week 48, n=90, 94 | 3.0 ± 9.74 | -1.6 ± 9.73 |
| NNRTI, Week 4, n=151, 153 | -3.4 ± 9.06 | -2.3 ± 8.10 |
| NNRTI, Week 8, n=121, 152 | -1.1 ± 9.35 | -1.3 ± 7.72 |
| NNRTI, Week 12, n=146, 152 | -1.7 ± 8.90 | -0.5 ± 7.03 |
| NNRTI, Week 16, n=143, 148 | -1.8 ± 10.60 | -2.3 ± 9.06 |
| NNRTI, Week 20, n=138, 152 | -3.7 ± 9.64 | -1.9 ± 7.41 |
| NNRTI, Week 24, n=142, 151 | -4.3 ± 10.67 | -2.0 ± 7.67 |
| NNRTI, Week 28, n=136, 150 | -4.3 ± 10.68 | -2.4 ± 8.67 |
| NNRTI, Week 32, n=137, 148 | -3.3 ± 10.42 | -2.8 ± 8.80 |
| NNRTI, Week 36, n=135, 147 | -3.8 ± 10.97 | -2.5 ± 8.16 |
| NNRTI, Week 40, n=137, 147 | -4.4 ± 9.97 | -2.0 ± 8.90 |
| NNRTI, Week 44, n=136, 148 | -4.4 ± 9.75 | -2.0 ± 7.45 |
| NNRTI, Week 48, n=131, 147 | -5.2 ± 11.72 | -1.6 ± 8.25 |
Blood samples were collected for the analysis of clinical chemistry parameter: lipase to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Units per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| PI, Week 4, n=51, 53 | -2.2 ± 16.83 | 1.2 ± 19.34 |
| PI, Week 8, n=34, 53 | -2.6 ± 6.71 | 2.5 ± 25.36 |
| PI, Week 12, n=49, 52 | -1.4 ± 17.24 | -2.2 ± 15.95 |
| PI, Week 16, n=47, 53 | -0.5 ± 18.71 | 1.4 ± 17.40 |
| PI, Week 20, n=46, 53 | -2.5 ± 17.90 | -0.6 ± 17.49 |
| PI, Week 24, n=47, 53 | -2.0 ± 16.61 | -2.7 ± 16.30 |
| PI, Week 28, n=42, 53 | -0.7 ± 18.60 | 0.2 ± 16.18 |
| PI, Week 32, n=45, 51 | -2.2 ± 19.27 | 2.5 ± 18.35 |
| PI, Week 36, n=44, 50 | -0.8 ± 17.96 | -1.2 ± 18.18 |
| PI, Week 40, n=42, 51 | 2.2 ± 26.77 | -1.8 ± 19.40 |
| PI, Week 44, n=47, 51 | -1.2 ± 18.28 | 1.4 ± 17.94 |
| PI, Week 48, n=43, 50 | -1.5 ± 19.38 | -1.3 ± 15.73 |
| INI, Week 4, n=99, 97 | 8.1 ± 34.32 | 3.8 ± 30.44 |
| INI, Week 8, n=72, 98 | 0.7 ± 9.79 | -0.5 ± 14.46 |
| INI, Week 12, n=99, 93 | 4.3 ± 17.70 | 1.8 ± 21.29 |
| INI, Week 16, n=93, 97 | 4.4 ± 22.42 | 0.6 ± 16.13 |
| INI, Week 20, n=94, 97 | 2.5 ± 17.23 | 0.9 ± 17.07 |
| INI, Week 24, n=94, 95 | 2.2 ± 15.17 | 2.2 ± 18.91 |
| INI, Week 28, n=89, 94 | 5.6 ± 28.06 | 5.1 ± 24.20 |
| INI, Week 32, n=92, 95 | 3.2 ± 18.68 | 5.4 ± 22.79 |
| INI, Week 36, n=94, 95 | 5.2 ± 21.04 | 0.1 ± 13.82 |
| INI, Week 40, n=89, 95 | 3.5 ± 11.71 | 1.7 ± 16.60 |
| INI, Week 44, n=91, 94 | 4.3 ± 21.59 | 4.8 ± 23.54 |
| INI, Week 48, n=90, 94 | 5.0 ± 24.95 | 3.9 ± 23.48 |
| NNRTI, Week 4, n=151, 153 | 5.7 ± 50.44 | 0.1 ± 20.35 |
| NNRTI, Week 8, n=121, 152 | 2.6 ± 25.04 | 1.5 ± 16.94 |
| NNRTI, Week 12, n=146, 152 | 3.0 ± 30.94 | -1.9 ± 17.59 |
| NNRTI, Week 16, n=145, 149 | 2.5 ± 27.82 | 6.1 ± 40.62 |
| NNRTI, Week 20, n=138, 152 | 0.9 ± 13.53 | 1.3 ± 37.14 |
| NNRTI, Week 24, n=142, 151 | 3.4 ± 24.81 | 5.4 ± 28.22 |
| NNRTI, Week 28, n=136, 150 | 0.8 ± 24.38 | 1.2 ± 15.79 |
| NNRTI, Week 32, n=137, 148 | 9.1 ± 78.96 | 1.9 ± 21.30 |
| NNRTI, Week 36, n=135, 147 | 6.9 ± 68.07 | 1.7 ± 19.14 |
| NNRTI, Week 40, n=138, 147 | 7.1 ± 43.53 | 0.5 ± 17.62 |
| NNRTI, Week 44, n=136, 148 | 1.6 ± 24.46 | 1.1 ± 20.52 |
| NNRTI, Week 48, n=131, 146 | 3.1 ± 32.54 | 0.9 ± 16.60 |
Blood samples were collected for the analysis of clinical chemistry parameters: CO2, chloride, glucose, phosphate, potassium, sodium and urea to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Millimoles per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| PI, CO2, Week 4, n=51, 53 | 1.3 ± 2.63 | 0.7 ± 2.34 |
| PI, CO2, Week 8, n=34, 53 | 0.4 ± 2.36 | 0.3 ± 2.65 |
| PI, CO2, Week 12, n=50, 52 | 0.7 ± 2.84 | 0.2 ± 2.23 |
| PI, CO2, Week 16, n=48, 53 | 0.8 ± 2.60 | 0.2 ± 2.32 |
| PI, CO2, Week 20, n=46, 53 | 0.9 ± 2.53 | 0.0 ± 2.26 |
| PI, CO2, Week 24, n=47, 53 | 0.4 ± 2.23 | 0.1 ± 1.94 |
| PI, CO2, Week 28, n=42, 53 | 0.6 ± 2.54 | -0.2 ± 2.37 |
| PI, CO2, Week 32, n=45, 51 | 0.5 ± 2.35 | -0.2 ± 2.36 |
| PI, CO2, Week 36, n=44, 50 | 0.5 ± 2.38 | -0.4 ± 1.98 |
| PI, CO2, Week 40, n=42, 51 | 0.5 ± 2.10 | 0.3 ± 2.26 |
| PI, CO2, Week 44, n=47, 51 | 0.7 ± 2.29 | 0.3 ± 2.18 |
| PI, CO2, Week 48, n=43, 50 | 0.9 ± 2.69 | -0.1 ± 1.87 |
| INI, CO2, Week 4, n=99, 97 | 1.0 ± 2.37 | 0.8 ± 2.21 |
| INI, CO2, Week 8, n=73, 98 | 0.5 ± 2.29 | 0.6 ± 2.46 |
| INI, CO2, Week 12, n=99, 95 | 0.4 ± 2.27 | 0.3 ± 2.31 |
| INI, CO2, Week 16, n=93, 96 | 0.1 ± 2.56 | 0.6 ± 2.53 |
| INI, CO2, Week 20, n=93, 97 | 0.1 ± 2.07 | 0.7 ± 2.25 |
| INI, CO2, Week 24, n=94, 95 | 0.1 ± 2.32 | 0.2 ± 2.49 |
| INI, CO2, Week 28, n=89, 93 | -0.3 ± 2.30 | 0.2 ± 2.41 |
| INI, CO2, Week 32, n=93, 95 | 0.2 ± 2.33 | 0.1 ± 2.34 |
| INI, CO2, Week 36, n=94, 95 | 0.0 ± 2.36 | 0.5 ± 2.58 |
| INI, CO2, Week 40, n=90, 95 | 0.5 ± 2.43 | 0.3 ± 2.18 |
| INI, CO2, Week 44, n=91, 94 | 0.5 ± 2.36 | 0.7 ± 2.45 |
| INI, CO2, Week 48, n=91, 95 | 0.1 ± 2.12 | 0.3 ± 2.53 |
| NNRTI, CO2, Week 4, n=151, 153 | 0.9 ± 2.60 | 0.7 ± 2.18 |
| NNRTI, CO2, Week 8, n=122, 152 | 0.4 ± 2.32 | 0.8 ± 2.52 |
| NNRTI, CO2, Week 12, n=146, 152 | 0.5 ± 2.38 | 0.4 ± 2.51 |
| NNRTI, CO2, Week 16, n=143, 149 | 0.3 ± 2.25 | 0.5 ± 2.37 |
| NNRTI, CO2, Week 20, n=138, 152 | 0.1 ± 2.27 | 0.2 ± 2.35 |
| NNRTI, CO2, Week 24, n=143, 150 | 0.3 ± 2.63 | 0.3 ± 2.57 |
| NNRTI, CO2, Week 28, n=136, 150 | 0.1 ± 2.54 | 0.2 ± 2.40 |
| NNRTI, CO2, Week 32, n=137, 148 | -0.2 ± 2.39 | 0.4 ± 2.27 |
| NNRTI, CO2, Week 36, n=135, 147 | 0.1 ± 2.38 | 0.5 ± 2.37 |
| NNRTI, CO2, Week 40, n=138, 147 | 0.4 ± 2.64 | 0.5 ± 2.38 |
| NNRTI, CO2, Week 44, n=137, 148 | 0.4 ± 2.35 | 0.5 ± 2.01 |
| NNRTI, CO2, Week 48, n=131, 147 | -0.1 ± 2.47 | 0.3 ± 2.30 |
| PI, Chloride, Week 4, n=51, 53 | 0.5 ± 1.80 | 0.5 ± 2.34 |
| PI, Chloride, Week 8, n=34, 53 | 0.2 ± 2.59 | 0.7 ± 2.42 |
| PI, Chloride, Week 12, n=50, 52 | 0.5 ± 2.39 | 0.8 ± 2.20 |
| PI, Chloride, Week 16, n=48, 53 | 0.5 ± 2.46 | 1.0 ± 2.31 |
| PI, Chloride, Week 20, n=46, 53 | 0.8 ± 2.20 | 0.7 ± 2.30 |
| PI, Chloride, Week 24, n=47, 53 | 1.1 ± 2.07 | 1.3 ± 2.36 |
| PI, Chloride, Week 28, n=42, 53 | 1.5 ± 2.19 | 1.2 ± 3.06 |
| PI, Chloride, Week 32, n=45, 51 | 0.9 ± 2.43 | 0.9 ± 2.60 |
| PI, Chloride, Week 36, n=44, 50 | 1.0 ± 2.28 | 1.0 ± 3.00 |
| PI, Chloride, Week 40, n=42, 51 | 1.3 ± 2.35 | 1.1 ± 2.60 |
| PI, Chloride, Week 44, n=47, 51 | 1.1 ± 2.21 | 1.1 ± 2.57 |
| PI, Chloride, Week 48, n=43, 50 | 0.5 ± 2.10 | 0.9 ± 2.29 |
| INI, Chloride, Week 4, n=99, 97 | 0.3 ± 2.02 | 0.5 ± 1.96 |
| INI, Chloride, Week 8, n=73, 98 | 0.2 ± 2.02 | 0.1 ± 2.42 |
| INI, Chloride, Week 12, n=99, 95 | 0.4 ± 2.53 | 0.5 ± 2.27 |
| INI, Chloride, Week 16, n=93, 96 | 0.9 ± 2.45 | 0.7 ± 2.32 |
| INI, Chloride, Week 20, n=93, 97 | 1.0 ± 2.44 | 0.2 ± 2.31 |
| INI, Chloride, Week 24, n=94, 95 | 0.6 ± 2.46 | 0.5 ± 2.19 |
| INI, Chloride, Week 28, n=89, 93 | 0.8 ± 1.92 | 0.3 ± 2.37 |
| INI, Chloride, Week 32, n=93, 95 | 0.7 ± 2.39 | 0.7 ± 2.45 |
| INI, Chloride, Week 36, n=94, 95 | 0.8 ± 2.20 | 0.5 ± 2.32 |
| INI, Chloride, Week 40, n=90, 95 | 0.7 ± 2.24 | 0.4 ± 2.69 |
| INI, Chloride, Week 44, n=91, 94 | 0.7 ± 2.38 | 0.5 ± 2.41 |
| INI, Chloride, Week 48, n=91, 95 | 0.4 ± 2.37 | -0.3 ± 2.36 |
| NNRTI, Chloride, Week 4, n=151, 153 | 0.4 ± 2.15 | 0.6 ± 2.17 |
| NNRTI, Chloride, Week 8, n=122, 152 | 0.4 ± 2.05 | 0.7 ± 1.91 |
| NNRTI, Chloride, Week 12, n=146, 152 | 0.4 ± 2.12 | 0.5 ± 2.27 |
| NNRTI, Chloride, Week 16, n=143, 149 | 0.5 ± 2.37 | 0.8 ± 2.20 |
| NNRTI, Chloride, Week 20, n=138, 152 | 0.7 ± 2.27 | 1.1 ± 2.40 |
| NNRTI, Chloride, Week 24, n=143, 151 | 0.5 ± 2.60 | 1.1 ± 2.24 |
| NNRTI, Chloride, Week 28, n=136, 150 | 0.8 ± 2.38 | 1.3 ± 2.39 |
| NNRTI, Chloride, Week 32, n=137, 148 | 0.8 ± 2.44 | 1.1 ± 2.15 |
| NNRTI, Chloride, Week 36, n=135, 147 | 1.0 ± 2.15 | 1.1 ± 2.37 |
| NNRTI, Chloride, Week 40, n=138, 147 | 0.6 ± 2.20 | 1.0 ± 2.84 |
| NNRTI, Chloride, Week 44, n=137, 148 | 0.6 ± 2.07 | 1.0 ± 2.08 |
| NNRTI, Chloride, Week 48, n=131, 147 | 0.6 ± 2.45 | 0.5 ± 2.36 |
| PI, Glucose, Week 4, n=43, 43 | -0.08 ± 0.922 | 0.32 ± 0.401 |
| PI, Glucose, Week 8, n=25, 41 | 0.17 ± 0.513 | 0.22 ± 0.466 |
| PI, Glucose, Week 12, n=40, 42 | 0.03 ± 0.925 | 0.27 ± 0.494 |
| PI, Glucose, Week 16, n=39, 43 | 0.11 ± 1.163 | 0.28 ± 0.704 |
| PI, Glucose, Week 20, n=35, 41 | -0.07 ± 1.058 | 0.30 ± 0.799 |
| PI, Glucose, Week 24, n=38, 42 | 0.11 ± 0.705 | 0.32 ± 0.636 |
| PI, Glucose, Week 28, n=32, 43 | -0.03 ± 1.342 | 0.16 ± 0.441 |
| PI, Glucose, Week 32, n=36, 41 | 0.23 ± 1.148 | 0.29 ± 0.600 |
| PI, Glucose, Week 36, n=35, 41 | -0.01 ± 1.014 | 0.22 ± 0.483 |
| PI, Glucose, Week 40, n=34, 40 | 0.11 ± 1.035 | 0.18 ± 0.497 |
| PI, Glucose, Week 44, n=40, 40 | 0.01 ± 1.008 | 0.20 ± 0.278 |
| PI, Glucose, Week 48, n=39, 48 | -0.01 ± 0.977 | 0.11 ± 0.663 |
| INI, Glucose, Week 4, n=55, 52 | 0.30 ± 0.613 | 0.07 ± 0.774 |
| INI, Glucose, Week 8, n=36, 57 | 0.12 ± 0.595 | 0.21 ± 1.083 |
| INI, Glucose, Week 12, n=52, 55 | 0.36 ± 0.996 | 0.30 ± 1.357 |
| INI, Glucose, Week 16, n=53, 52 | 0.35 ± 1.437 | 0.13 ± 0.557 |
| INI, Glucose, Week 20, n=51, 57 | 0.25 ± 0.515 | -0.06 ± 0.676 |
| INI, Glucose, Week 24, n=59, 61 | 0.24 ± 0.596 | 0.04 ± 0.652 |
| INI, Glucose, Week 28, n=52, 62 | 0.17 ± 0.681 | 0.33 ± 0.763 |
| INI, Glucose, Week 32, n=53, 55 | 0.48 ± 1.071 | 0.32 ± 0.876 |
| INI, Glucose, Week 36, n=53, 57 | 0.34 ± 0.642 | 0.19 ± 1.063 |
| INI, Glucose, Week 40, n=59, 62 | 0.36 ± 0.922 | 0.14 ± 0.566 |
| INI, Glucose, Week 44, n=54, 57 | 0.33 ± 0.971 | 0.16 ± 0.626 |
| INI, Glucose, Week 48, n=81, 90 | 0.04 ± 0.577 | -0.03 ± 0.796 |
| NNRTI, Glucose, Week 4, n=116, 124 | 0.20 ± 0.666 | 0.24 ± 1.055 |
| NNRTI, Glucose, Week 8, n=90, 116 | 0.27 ± 0.987 | 0.23 ± 0.795 |
| NNRTI, Glucose, Week 12, n=112, 119 | 0.16 ± 0.746 | 0.11 ± 0.887 |
| NNRTI, Glucose, Week 16, n=115, 116 | 0.22 ± 0.767 | 0.33 ± 1.347 |
| NNRTI, Glucose, Week 20, n=106, 118 | 0.25 ± 0.636 | 0.28 ± 1.104 |
| NNRTI, Glucose, Week 24, n=115, 121 | 0.27 ± 0.763 | 0.16 ± 1.037 |
| NNRTI, Glucose, Week 28, n=104, 120 | 0.23 ± 0.596 | 0.30 ± 1.077 |
| NNRTI, Glucose, Week 32, n=103, 117 | 0.32 ± 0.811 | 0.24 ± 1.062 |
| NNRTI, Glucose, Week 36, n=102, 117 | 0.17 ± 0.789 | 0.31 ± 1.217 |
| NNRTI, Glucose, Week 40, n=100, 111 | 0.27 ± 0.692 | 0.33 ± 1.118 |
| NNRTI, Glucose, Week 44, n=99, 116 | 0.26 ± 0.793 | 0.35 ± 1.121 |
| NNRTI, Glucose, Week 48, n=118, 136 | 0.06 ± 0.659 | 0.02 ± 1.074 |
| PI, Phosphate, Week 4, n=51, 53 | 0.068 ± 0.1513 | 0.009 ± 0.1682 |
| PI, Phosphate, Week 8, n=34, 53 | 0.076 ± 0.2023 | -0.019 ± 0.1752 |
| PI, Phosphate, Week 12, n=50, 52 | 0.025 ± 0.1794 | 0.007 ± 0.1524 |
| PI, Phosphate, Week 16, n=48, 53 | 0.056 ± 0.2028 | -0.008 ± 0.1610 |
| PI, Phosphate, Week 20, n=46, 53 | 0.069 ± 0.1864 | 0.017 ± 0.1924 |
| PI, Phosphate, Week 24, n=47, 53 | 0.037 ± 0.1971 | 0.018 ± 0.1735 |
| PI, Phosphate, Week 28, n=42, 53 | 0.035 ± 0.2140 | 0.017 ± 0.1971 |
| PI, Phosphate, Week 32, n=45, 51 | 0.053 ± 0.2191 | 0.032 ± 0.1545 |
| PI, Phosphate, Week 36, n=44, 50 | 0.032 ± 0.1818 | -0.001 ± 0.1828 |
| PI, Phosphate, Week 40, n=42, 51 | 0.027 ± 0.2392 | 0.001 ± 0.1657 |
| PI, Phosphate, Week 44, n=47, 51 | 0.033 ± 0.2107 | 0.011 ± 0.1736 |
| PI, Phosphate, Week 48, n=43, 50 | 0.048 ± 0.1994 | 0.017 ± 0.1387 |
| INI, Phosphate, Week 4, n=99, 97 | 0.036 ± 0.1518 | 0.017 ± 0.1588 |
| INI, Phosphate, Week 8, n=73, 98 | 0.056 ± 0.1532 | 0.010 ± 0.1676 |
| INI, Phosphate, Week 12, n=99, 95 | 0.024 ± 0.2108 | 0.017 ± 0.1808 |
| INI, Phosphate, Week 16, n=93, 96 | 0.031 ± 0.1895 | 0.001 ± 0.1708 |
| INI, Phosphate, Week 20, n=93, 97 | 0.012 ± 0.1764 | 0.025 ± 0.1823 |
| INI, Phosphate, Week 24, n=94, 95 | 0.031 ± 0.1501 | -0.011 ± 0.1785 |
| INI, Phosphate, Week 28, n=89, 93 | 0.032 ± 0.1628 | 0.006 ± 0.1806 |
| INI, Phosphate, Week 32, n=93, 95 | 0.012 ± 0.1751 | -0.017 ± 0.1827 |
| INI, Phosphate, Week 36, n=94, 95 | -0.002 ± 0.1496 | -0.001 ± 0.1979 |
| INI, Phosphate, Week 40, n=90, 95 | 0.018 ± 0.1766 | -0.002 ± 0.1721 |
| INI, Phosphate, Week 44, n=91, 94 | 0.005 ± 0.1695 | 0.005 ± 0.1977 |
| INI, Phosphate, Week 48, n=91, 95 | 0.028 ± 0.1684 | 0.002 ± 0.2072 |
| NNRTI, Phosphate, Week 4, n=151, 153 | 0.085 ± 0.1785 | 0.016 ± 0.1580 |
| NNRTI, Phosphate, Week 8, n=122, 152 | 0.061 ± 0.2002 | -0.012 ± 0.1515 |
| NNRTI, Phosphate, Week 12, n=146, 152 | 0.057 ± 0.1946 | 0.012 ± 0.1780 |
| NNRTI, Phosphate, Week 16, n=143, 149 | 0.043 ± 0.2088 | 0.008 ± 0.1613 |
| NNRTI, Phosphate, Week 20, n=138, 152 | 0.039 ± 0.1935 | -0.002 ± 0.1823 |
| NNRTI, Phosphate, Week 24, n=143, 151 | 0.050 ± 0.2220 | 0.012 ± 0.1923 |
| NNRTI, Phosphate, Week 28, n=136, 150 | 0.040 ± 0.1850 | -0.003 ± 0.1789 |
| NNRTI, Phosphate, Week 32, n=137, 148 | 0.018 ± 0.2056 | 0.011 ± 0.2020 |
| NNRTI, Phosphate, Week 36, n=135, 147 | 0.014 ± 0.2069 | -0.002 ± 0.1794 |
| NNRTI, Phosphate, Week 40, n=138, 147 | 0.026 ± 0.2095 | -0.006 ± 0.1783 |
| NNRTI, Phosphate, Week 44, n=137, 148 | 0.041 ± 0.2112 | 0.000 ± 0.1735 |
| NNRTI, Phosphate, Week 48, n=131, 147 | 0.034 ± 0.2220 | -0.001 ± 0.1619 |
| PI, Potassium, Week 4, n=51, 53 | 0.12 ± 0.369 | 0.20 ± 0.447 |
| PI, Potassium, Week 8, n=34, 53 | 0.05 ± 0.245 | 0.08 ± 0.307 |
| PI, Potassium, Week 12, n=50, 52 | 0.12 ± 0.353 | 0.19 ± 0.388 |
| PI, Potassium, Week 16, n=48, 53 | 0.02 ± 0.343 | 0.19 ± 0.398 |
| PI, Potassium, Week 20, n=46, 53 | 0.05 ± 0.338 | 0.18 ± 0.420 |
| PI, Potassium, Week 24, n=47, 53 | 0.01 ± 0.354 | 0.19 ± 0.384 |
| PI, Potassium, Week 28, n=42, 53 | 0.09 ± 0.338 | 0.15 ± 0.342 |
| PI, Potassium, Week 32, n=45, 51 | 0.02 ± 0.356 | 0.19 ± 0.408 |
| PI, Potassium, Week 36, n=44, 50 | 0.12 ± 0.363 | 0.14 ± 0.371 |
| PI, Potassium, Week 40, n=42, 51 | 0.09 ± 0.348 | 0.15 ± 0.394 |
| PI, Potassium, Week 44, n=47, 51 | 0.10 ± 0.409 | 0.21 ± 0.433 |
| PI, Potassium, Week 48, n=43, 50 | 0.02 ± 0.359 | 0.01 ± 0.409 |
| INI, Potassium, Week 4, n=99, 97 | 0.03 ± 0.308 | 0.08 ± 0.335 |
| INI, Potassium, Week 8, n=73, 98 | -0.02 ± 0.282 | 0.06 ± 0.483 |
| INI, Potassium, Week 12, n=99, 95 | 0.02 ± 0.316 | 0.01 ± 0.329 |
| INI, Potassium, Week 16, n=93, 96 | -0.01 ± 0.286 | 0.01 ± 0.319 |
| INI, Potassium, Week 20, n=93, 97 | 0.03 ± 0.333 | 0.00 ± 0.313 |
| INI, Potassium, Week 24, n=94, 95 | 0.02 ± 0.304 | 0.04 ± 0.315 |
| INI, Potassium,Week 28, n=89, 93 | 0.02 ± 0.422 | 0.03 ± 0.372 |
| INI, Potassium, Week 32, n=93, 95 | 0.02 ± 0.322 | 0.01 ± 0.289 |
| INI, Potassium, Week 36, n=94, 95 | 0.01 ± 0.345 | 0.05 ± 0.349 |
| INI, Potassium, Week 40, n=90, 95 | 0.01 ± 0.288 | 0.01 ± 0.329 |
| INI, Potassium, Week 44, n=91, 94 | 0.01 ± 0.265 | 0.00 ± 0.327 |
| INI, Potassium, Week 48, n=91, 95 | -0.03 ± 0.249 | -0.01 ± 0.292 |
| NNRTI, Potassium, Week 4, n=151, 153 | 0.05 ± 0.354 | 0.10 ± 0.368 |
| NNRTI, Potassium, Week 8, n=122, 152 | 0.02 ± 0.342 | 0.05 ± 0.355 |
| NNRTI, Potassium, Week 12, n=146, 152 | 0.02 ± 0.351 | 0.08 ± 0.353 |
| NNRTI, Potassium, Week 16, n=143, 149 | 0.03 ± 0.373 | 0.05 ± 0.320 |
| NNRTI, Potassium,Week 20, n=138, 152 | 0.04 ± 0.358 | 0.03 ± 0.355 |
| NNRTI, Potassium, Week 24, n=143, 150 | 0.04 ± 0.329 | 0.04 ± 0.324 |
| NNRTI, Potassium, Week 28, n=136, 150 | 0.03 ± 0.364 | 0.08 ± 0.412 |
| NNRTI, Potassium, Week 32, n=137, 148 | 0.01 ± 0.442 | 0.02 ± 0.348 |
| NNRTI, Potassium, Week 36, n=135, 147 | 0.02 ± 0.359 | 0.05 ± 0.360 |
| NNRTI, Potassium, Week 40, n=138, 147 | 0.05 ± 0.375 | 0.08 ± 0.342 |
| NNRTI, Potassium, Week 44, n=137, 148 | 0.08 ± 0.364 | 0.07 ± 0.366 |
| NNRTI, Potassium, Week 48, n=131, 147 | -0.02 ± 0.311 | 0.00 ± 0.329 |
| PI, Sodium, Week 4, n=51, 53 | 0.4 ± 1.93 | 0.3 ± 2.11 |
| PI, Sodium, Week 8, n=34, 53 | 0.9 ± 2.21 | 0.3 ± 2.25 |
| PI, Sodium, Week 12, n=50, 52 | 0.5 ± 2.09 | 0.7 ± 1.97 |
| PI, Sodium, Week 16, n=48, 53 | 0.5 ± 2.30 | 0.3 ± 2.24 |
| PI, Sodium, Week 20, n=46, 53 | 0.6 ± 2.15 | 0.4 ± 2.12 |
| PI, Sodium, Week 24, n=47, 53 | 0.5 ± 2.33 | 0.4 ± 2.30 |
| PI, Sodium, Week 28, n=42, 53 | 1.3 ± 2.06 | 0.8 ± 2.75 |
| PI, Sodium, Week 32, n=45, 51 | 0.5 ± 2.47 | 0.5 ± 2.26 |
| PI, Sodium, Week 36, n=44, 50 | 0.8 ± 2.21 | 0.6 ± 2.63 |
| PI, Sodium, Week 40, n=42, 51 | 0.8 ± 2.20 | 0.7 ± 2.03 |
| PI, Sodium, Week 44, n=47, 51 | 0.8 ± 2.10 | 0.7 ± 2.49 |
| PI, Sodium, Week 48, n=43, 50 | 0.9 ± 1.98 | 0.8 ± 1.95 |
| INI, Sodium, Week 4, n=99, 97 | 0.3 ± 1.62 | 0.0 ± 1.97 |
| INI, Sodium, Week 8, n=73, 98 | 0.1 ± 1.98 | -0.3 ± 1.87 |
| INI, Sodium, Week 12, n=99, 95 | 0.3 ± 2.11 | 0.0 ± 1.69 |
| INI, Sodium, Week 16, n=93, 96 | 0.3 ± 1.95 | 0.4 ± 1.97 |
| INI, Sodium, Week 20, n=93, 97 | 0.5 ± 1.94 | 0.1 ± 1.86 |
| INI, Sodium, Week 24, n=94, 95 | 0.5 ± 1.79 | 0.0 ± 1.73 |
| INI, Sodium, Week 28, n=89, 93 | 0.5 ± 1.74 | -0.3 ± 1.93 |
| INI, Sodium, Week 32, n=93, 95 | 0.5 ± 1.87 | 0.2 ± 1.75 |
| INI, Sodium, Week 36, n=94, 95 | 0.4 ± 1.86 | 0.3 ± 1.88 |
| INI, Sodium, Week 40, n=90, 95 | 0.5 ± 1.91 | 0.2 ± 2.01 |
| INI, Sodium, Week 44, n=91, 94 | 0.5 ± 1.77 | 0.3 ± 1.93 |
| INI, Sodium, Week 48, n=91, 95 | 0.4 ± 2.00 | -0.1 ± 1.85 |
| NNRTI, Sodium, Week 4, n=151, 153 | 0.2 ± 1.95 | 0.1 ± 1.98 |
| NNRTI, Sodium, Week 8, n=122, 152 | 0.2 ± 1.91 | 0.0 ± 1.82 |
| NNRTI, Sodium, Week 12, n=146, 152 | 0.1 ± 2.04 | 0.1 ± 2.01 |
| NNRTI, Sodium, Week 16, n=143, 149 | -0.1 ± 2.28 | -0.2 ± 2.04 |
| NNRTI, Sodium, Week 20, n=138, 152 | -0.1 ± 2.14 | 0.3 ± 1.95 |
| NNRTI, Sodium, Week 24, n=143, 151 | 0.1 ± 2.14 | 0.3 ± 1.95 |
| NNRTI, Sodium, Week 28, n=136, 150 | 0.3 ± 2.29 | 0.2 ± 2.18 |
| NNRTI, Sodium, Week 32, n=137, 148 | 0.1 ± 2.01 | 0.5 ± 1.84 |
| NNRTI, Sodium, Week 36, n=135, 147 | 0.4 ± 2.05 | 0.5 ± 2.22 |
| NNRTI, Sodium, Week 40, n=138, 147 | 0.3 ± 2.04 | 0.5 ± 2.12 |
| NNRTI, Sodium, Week 44, n=137, 148 | 0.5 ± 2.17 | 0.5 ± 1.96 |
| NNRTI, Sodium, Week 48, n=131, 147 | 0.3 ± 2.39 | 0.4 ± 1.97 |
| PI, Urea, Week 4, n=51, 53 | 0.02 ± 1.449 | 0.01 ± 1.124 |
| PI, Urea, Week 8, n=34, 53 | 0.21 ± 1.142 | -0.02 ± 1.205 |
| PI, Urea, Week 12, n=50, 52 | 0.04 ± 1.446 | -0.01 ± 1.312 |
| PI, Urea, Week 16, n=48, 53 | 0.25 ± 1.309 | 0.20 ± 1.377 |
| PI, Urea, Week 20, n=46, 53 | 0.18 ± 1.425 | 0.17 ± 1.275 |
| PI, Urea, Week 24, n=47, 53 | 0.41 ± 1.248 | 0.10 ± 1.182 |
| PI, Urea, Week 28, n=42, 53 | 0.18 ± 1.352 | 0.00 ± 1.236 |
| PI, Urea, Week 32, n=45, 51 | 0.12 ± 1.567 | 0.16 ± 1.210 |
| PI, Urea, Week 36, n=44, 50 | 0.01 ± 1.449 | -0.13 ± 1.190 |
| PI, Urea, Week 40, n=42, 51 | 0.17 ± 1.291 | 0.33 ± 1.714 |
| PI, Urea, Week 44, n=47, 51 | 0.36 ± 1.258 | 0.13 ± 1.276 |
| PI, Urea, Week 48, n=43, 50 | 0.10 ± 1.303 | 0.13 ± 1.305 |
| INI, Urea, Week 4, n=99, 97 | -0.14 ± 1.477 | 0.19 ± 1.635 |
| INI, Urea, Week 8, n=73, 98 | -0.14 ± 1.799 | 0.01 ± 1.601 |
| INI, Urea, Week 12, n=99, 95 | 0.05 ± 1.554 | 0.21 ± 1.481 |
| INI, Urea, Week 16, n=93, 96 | 0.01 ± 1.402 | 0.05 ± 1.375 |
| INI, Urea, Week 20, n=93, 97 | 0.01 ± 1.531 | 0.15 ± 1.495 |
| INI, Urea, Week 24, n=94, 95 | 0.04 ± 1.367 | 0.12 ± 1.441 |
| INI, Urea, Week 28, n=89, 93 | 0.01 ± 1.570 | -0.02 ± 1.579 |
| INI, Urea, Week 32, n=93, 95 | -0.09 ± 1.592 | 0.01 ± 1.522 |
| INI, Urea, Week 36, n=94, 95 | -0.10 ± 1.514 | -0.05 ± 1.478 |
| INI, Urea, Week 40, n=90, 95 | 0.01 ± 1.519 | 0.12 ± 1.469 |
| INI, Urea, Week 44, n=91, 94 | -0.16 ± 1.583 | -0.19 ± 1.721 |
| INI, Urea, Week 48, n=91, 95 | 0.11 ± 1.633 | -0.05 ± 1.304 |
| NNRTI, Urea, Week 4, n=151, 153 | 0.10 ± 1.265 | 0.04 ± 1.185 |
| NNRTI, Urea, Week 8, n=122, 152 | 0.16 ± 1.286 | 0.01 ± 1.252 |
| NNRTI, Urea, Week 12, n=146, 152 | 0.26 ± 1.290 | 0.06 ± 1.344 |
| NNRTI, Urea, Week 16, n=143, 149 | 0.07 ± 1.407 | 0.28 ± 1.609 |
| NNRTI, Urea, Week 20, n=138, 152 | 0.25 ± 1.296 | 0.07 ± 1.507 |
| NNRTI, Urea, Week 24, n=143, 151 | 0.33 ± 1.499 | 0.18 ± 1.276 |
| NNRTI, Urea, Week 28, n=136, 150 | 0.22 ± 1.549 | 0.02 ± 1.422 |
| NNRTI, Urea, Week 32, n=137, 148 | 0.41 ± 1.410 | 0.06 ± 1.416 |
| NNRTI, Urea, Week 36, n=135, 147 | 0.19 ± 1.339 | 0.04 ± 1.392 |
| NNRTI, Urea, Week 40, n=138, 147 | 0.32 ± 1.347 | -0.01 ± 1.339 |
| NNRTI, Urea, Week 44, n=137, 148 | 0.25 ± 1.346 | 0.10 ± 1.344 |
| NNRTI, Urea, Week 48, n=131, 147 | 0.37 ± 1.389 | -0.02 ± 1.325 |
Blood samples were collected for the analysis of fasting lipid panel: triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Millimoles per liter | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| PI, Triglycerides, Week 48, n=40, 45 | -0.733 ± 1.5612 | 0.060 ± 0.9960 |
| INI, Triglycerides, Week 48, n=72, 77 | -0.078 ± 0.4964 | -0.117 ± 0.8052 |
| NNRTI, Triglycerides, Week 48, n=119, 120 | -0.015 ± 0.6121 | -0.014 ± 0.6761 |
| PI, Cholesterol, Week 48, n=40, 45 | -0.06 ± 0.629 | 0.06 ± 0.744 |
| INI, Cholesterol, Week 48, n=72, 77 | 0.18 ± 0.614 | -0.12 ± 0.674 |
| NNRTI, Cholesterol, Week 48, n=119, 120 | 0.06 ± 0.743 | -0.02 ± 0.626 |
| PI, HDL cholesterol, Week 48, n=40, 45 | 0.130 ± 0.2272 | 0.001 ± 0.3429 |
| INI, HDL cholesterol, Week 48, n=72, 77 | 0.074 ± 0.2339 | -0.038 ± 0.2308 |
| NNRTI, HDL cholesterol, Week 48, n=119, 120 | -0.011 ± 0.2936 | 0.028 ± 0.2577 |
| PI, LDL cholesterol, Week 48, n=37, 43 | 0.075 ± 0.5774 | 0.043 ± 0.5545 |
| INI, LDL cholesterol, Week 48, n=71, 76 | 0.144 ± 0.4840 | -0.015 ± 0.5333 |
| NNRTI, LDL cholesterol, Week 48, n=116, 119 | 0.078 ± 0.6885 | -0.040 ± 0.5246 |
Plasma samples were collected from participants who met confirmed virologic withdrawal criteria to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Genotypic Resistance data for the following drugs: DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented.
| Participants | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| PI, INI, DTG, resistant, n=1, 0 | 0 | 0 |
| PI, INI, DTG, resistance possible, n=1, 0 | 0 | 0 |
| PI, INI, DTG, sensitive, n=1, 0 | 1 | 0 |
| PI, INI, EVG, resistant, n=1, 0 | 0 | 0 |
| PI, INI, EVG, resistance possible, n=1, 0 | 0 | 0 |
| PI, INI, EVG, sensitive, n=1, 0 | 1 | 0 |
| PI, INI, RAL, resistant, n=1, 0 | 0 | 0 |
| PI, INI, RAL, resistance possible, n=1, 0 | 0 | 0 |
| PI, INI, RAL, sensitive, n=1, 0 | 1 | 0 |
| PI, NNRTI, DLV, resistant, n=1, 0 | 0 | 0 |
| PI, NNRTI, DLV, resistance possible, n=1, 0 | 0 | 0 |
| PI, NNRTI, DLV, sensitive, n=1, 0 | 1 | 0 |
| PI, NNRTI, EFV, resistant, n=1, 0 | 0 | 0 |
| PI, NNRTI, EFV, resistance possible, n=1, 0 | 0 | 0 |
| PI, NNRTI, EFV, sensitive, n=1, 0 | 1 | 0 |
| PI, NNRTI, ETR, resistant, n=1, 0 | 0 | 0 |
| PI, NNRTI, ETR, resistance possible, n=1, 0 | 0 | 0 |
| PI, NNRTI, ETR, sensitive, n=1, 0 | 1 | 0 |
| PI, NNRTI, NVP, resistant, n=1, 0 | 0 | 0 |
| PI, NNRTI, NVP, resistance possible, n=1, 0 | 0 | 0 |
| PI, NNRTI, NVP, sensitive, n=1, 0 | 1 | 0 |
| PI, NNRTI, RPV, resistant, n=1, 0 | 1 | 0 |
| PI, NNRTI, RPV, resistance possible, n=1, 0 | 0 | 0 |
| PI, NNRTI, RPV, sensitive, n=1, 0 | 0 | 0 |
| PI, NRTI, 3TC, resistant, n=1, 0 | 0 | 0 |
| PI, NNRTI, 3TC, resistance possible, n=1, 0 | 0 | 0 |
| PI, NRTI, 3TC, sensitive, n=1, 0 | 1 | 0 |
| PI, NRTI, ABC, resistant, n=1, 0 | 0 | 0 |
| PI, NRTI, ABC, resistance possible, n=1, 0 | 0 | 0 |
| PI, NRTI, ABC, sensitive, n=1, 0 | 1 | 0 |
| PI, NRTI, FTC, resistant, n=1, 0 | 0 | 0 |
| PI, NRTI, FTC, resistance possible, n=1, 0 | 0 | 0 |
| PI, NRTI, FTC, sensitive, n=1, 0 | 1 | 0 |
| PI, NRTI, TDF, resistant, n=1, 0 | 0 | 0 |
| PI, NRTI, TDF, resistance possible, n=1, 0 | 0 | 0 |
| PI, NRTI, TDF, sensitive, n=1, 0 | 1 | 0 |
| PI, NRTI, ZDV, resistant, n=1, 0 | 0 | 0 |
| PI, NRTI, ZDV, resistance possible, n=1, 0 | 0 | 0 |
| PI, NRTI, ZDV, sensitive, n=1, 0 | 1 | 0 |
| PI, NRTI, d4T, resistant, n=1, 0 | 0 | 0 |
| PI, NRTI, d4T, resistance possible, n=1, 0 | 0 | 0 |
| PI, NRTI, d4T, sensitive, n=1, 0 | 1 | 0 |
| PI, NRTI, ddI, resistant, n=1, 0 | 0 | 0 |
| PI, NRTI, ddI, resistance possible, n=1, 0 | 0 | 0 |
| PI, NRTI, ddI, sensitive, n=1, 0 | 1 | 0 |
| PI, PI, ATV, resistant, n=1, 0 | 0 | 0 |
| PI, PI, ATV, resistance possible, n=1, 0 | 0 | 0 |
| PI, PI, ATV, sensitive, n=1, 0 | 1 | 0 |
| PI, PI, ATV/r, resistant, n=1, 0 | 0 | 0 |
| PI, PI, ATV/r, resistance possible, n=1, 0 | 0 | 0 |
| PI, PI, ATV/r, sensitive, n=1, 0 | 1 | 0 |
| PI, PI, DRV/r, resistant, n=1, 0 | 0 | 0 |
| PI, PI, DRV/r, resistance possible, n=1, 0 | 0 | 0 |
| PI, PI, DRV/r, sensitive, n=1, 0 | 1 | 0 |
| PI, PI, FPV/r, resistant, n=1, 0 | 0 | 0 |
| PI, PI, FPV/r, resistance possible, n=1, 0 | 0 | 0 |
| PI, PI, FPV/r, sensitive, n=1, 0 | 1 | 0 |
| PI, PI, IDV/r, resistant, n=1, 0 | 0 | 0 |
| PI, PI, IDV/r, resistance possible, n=1, 0 | 0 | 0 |
| PI, PI, IDV/r, sensitive, n=1, 0 | 1 | 0 |
| PI, PI, LPV/r, resistant, n=1, 0 | 0 | 0 |
| PI, PI, LPV/r, resistance possible, n=1, 0 | 0 | 0 |
| PI, PI, LPV/r, sensitive, n=1, 0 | 1 | 0 |
| PI, PI, NFV, resistant, n=1, 0 | 0 | 0 |
| PI, PI, NFV, resistance possible, n=1, 0 | 0 | 0 |
| PI, PI, NFV, sensitive, n=1, 0 | 1 | 0 |
| PI, PI, RTV, resistant, n=1, 0 | 0 | 0 |
| PI, PI, RTV, resistance possible, n=1, 0 | 0 | 0 |
| PI, PI, RTV, sensitive, n=1, 0 | 1 | 0 |
| PI, PI, SQV/r, resistant, n=1, 0 | 0 | 0 |
| PI, PI, SQV/r, resistance possible, n=1, 0 | 0 | 0 |
| PI, PI, SQV/r, sensitive, n=1, 0 | 1 | 0 |
| PI, PI, TPV/r, resistant, n=1, 0 | 0 | 0 |
| PI, PI, TPV/r, resistance possible, n=1, 0 | 0 | 0 |
| PI, PI, TPV/r, sensitive, n=1, 0 | 1 | 0 |
| INI, INI, DTG, resistant, n=0, 3 | 0 | 0 |
| INI, INI, DTG, resistance possible, n=0, 3 | 0 | 0 |
| INI, INI, DTG, sensitive, n=0, 3 | 0 | 3 |
| INI, INI, EVG, resistant, n=0, 3 | 0 | 0 |
| INI, INI, EVG, resistance possible, n=0, 3 | 0 | 0 |
| INI, INI, EVG, sensitive, n=0, 3 | 0 | 3 |
| INI, INI, RAL, resistant, n=0, 3 | 0 | 0 |
| INI, INI, RAL, resistance possible, n=0, 3 | 0 | 0 |
| INI, INI, RAL, sensitive, n=0, 3 | 0 | 3 |
| INI, NNRTI, DLV, resistant, n=0, 3 | 0 | 0 |
| INI, INI, DLV, resistance possible, n=0, 3 | 0 | 0 |
| INI, NNRTI, DLV, sensitive, n=0, 3 | 0 | 3 |
| INI, NNRTI, EFV, resistant, n=0, 3 | 0 | 0 |
| INI, INI, EFV, resistance possible, n=0, 3 | 0 | 0 |
| INI, NNRTI, EFV, sensitive, n=0, 3 | 0 | 3 |
| INI, NNRTI, ETR, resistant,, n=0, 3 | 0 | 0 |
| INI, NNRTI, ETR, resistance possible, n=0, 3 | 0 | 0 |
| INI, NNRTI, ETR, sensitive, n=0, 3 | 0 | 3 |
| INI, NNRTI, NVP, resistant, n=0, 3 | 0 | 0 |
| INI, NNRTI, NVP, resistance possible, n=0, 3 | 0 | 0 |
| INI, NNRTI, NVP, sensitive, n=0, 3 | 0 | 3 |
| INI, NNRTI, RPV, resistant, n=0, 3 | 0 | 1 |
| INI, NNRTI, RPV, resistance possible, n=0, 3 | 0 | 0 |
| INI, NNRTI, RPV, sensitive, n=0, 3 | 0 | 2 |
| INI, NRTI, 3TC, resistant, n=0, 3 | 0 | 1 |
| INI, NNRTI, 3TC, resistance possible, n=0, 3 | 0 | 0 |
| INI, NRTI, 3TC, sensitive, n=0, 3 | 0 | 2 |
| INI, NRTI, ABC, resistant, n=0, 3 | 0 | 0 |
| INI, NRTI, ABC, resistance possible,, n=0, 3 | 0 | 0 |
| INI, NRTI, ABC, sensitive, n=0, 3 | 0 | 3 |
| INI, NRTI, FTC, resistant, n=0, 3 | 0 | 1 |
| INI, NRTI, FTC, resistance possible, n=0, 3 | 0 | 0 |
| INI, NRTI, FTC, sensitive, n=0, 3 | 0 | 2 |
| INI, NRTI, TDF, resistant, n=0, 3 | 0 | 0 |
| INI, NRTI, TDF, resistance possible, n=0, 3 | 0 | 0 |
| INI, NRTI, TDF, sensitive, n=0, 3 | 0 | 3 |
| INI, NRTI, ZDV, resistant, n=0, 3 | 0 | 0 |
| INI, NRTI, ZDV, resistance possible, n=0, 3 | 0 | 0 |
| INI, NRTI, ZDV, sensitive, n=0, 3 | 0 | 3 |
| INI, NRTI, d4T, resistant, n=0, 3 | 0 | 0 |
| INI, NRTI, d4T, resistance possible, n=0, 3 | 0 | 0 |
| INI, NRTI, d4T, sensitive, n=0, 3 | 0 | 3 |
| INI, NRTI, ddI, resistant, n=0, 3 | 0 | 0 |
| INI, NRTI, ddI, resistance possible, n=0, 3 | 0 | 1 |
| INI, NRTI, ddI, sensitive, n=0, 3 | 0 | 2 |
| INI, PI, ATV, resistant, n=0, 3 | 0 | 0 |
| INI, PI, ATV, resistance possible, n=0, 3 | 0 | 0 |
| INI, PI, ATV, sensitive, n=0, 3 | 0 | 3 |
| INI, PI, ATV/r, n=0, 3 | 0 | 0 |
| INI, PI, ATV/r, resistance possible, n=0, 3 | 0 | 0 |
| INI, PI, ATV/r, sensitive, n=0, 3 | 0 | 3 |
| INI, PI, DRV/r, resistant, n=0, 3 | 0 | 0 |
| INI, PI, DRV/r, resistance possible, n=0, 3 | 0 | 0 |
| INI, PI, DRV/r, sensitive, n=0, 3 | 0 | 3 |
| INI, PI, FPV/r, resistant, n=0, 3 | 0 | 0 |
| INI, PI, FPV/r, resistance possible, n=0, 3 | 0 | 0 |
| INI, PI, FPV/r, sensitive, n=0, 3 | 0 | 3 |
| INI, PI, IDV/r, resistant, n=0, 3 | 0 | 0 |
| INI, PI, IDV/r, resistance possible, n=0, 3 | 0 | 0 |
| INI, PI, IDV/r, sensitive, n=0, 3 | 0 | 3 |
| INI, PI, LPV/r, resistant, n=0, 3 | 0 | 0 |
| INI, PI, LPV/r, resistance possible, n=0, 3 | 0 | 0 |
| INI, PI, LPV/r, sensitive, n=0, 3 | 0 | 3 |
| INI, PI, NFV, resistant, n=0, 3 | 0 | 0 |
| INI, PI, NFV, resistance possible, n=0, 3 | 0 | 0 |
| INI, PI, NFV, sensitive, n=0, 3 | 0 | 3 |
| INI, PI, RTV, resistant, n=0, 3 | 0 | 0 |
| INI, PI, RTV, resistance possible, n=0, 3 | 0 | 0 |
| INI, PI, RTV, sensitive, n=0, 3 | 0 | 3 |
| INI, PI, SQV/r, resistant, n=0, 3 | 0 | 0 |
| INI, PI, SQV/r, resistance possible, n=0, 3 | 0 | 0 |
| INI, PI, SQV/r, sensitive, n=0, 3 | 0 | 3 |
| INI, PI, TPV/r, resistant, n=0, 3 | 0 | 0 |
| INI, PI, TPV/r, resistance possible, n=0, 3 | 0 | 0 |
| INI, PI, TPV/r, sensitive, n=0, 3 | 0 | 3 |
| NNRTI, INI, DTG, resistant, n=2, 1 | 0 | 0 |
| NNRTI, INI, DTG, resistance possible, n=2, 1 | 0 | 0 |
| NNRTI, INI, DTG, sensitive, n=2, 1 | 2 | 1 |
| NNRTI, INI, EVG, resistant, n=2, 1 | 1 | 0 |
| NNRTI, INI, EVG, resistance possible, n=2, 1 | 0 | 0 |
| NNRTI, INI, EVG, sensitive, n=2, 1 | 1 | 1 |
| NNRTI, INI, RAL, resistant, n=2, 1 | 1 | 0 |
| NNRTI, INI, RAL, resistance possible, n=2, 1 | 0 | 0 |
| NNRTI, INI, RAL, sensitive, n=2, 1 | 1 | 1 |
| NNRTI, NNRTI, DLV, resistant, n=2, 1 | 0 | 0 |
| NNRTI, INI, DLV, resistance possible, n=2, 1 | 0 | 0 |
| NNRTI, NNRTI, DLV, sensitive, n=2, 1 | 2 | 1 |
| NNRTI, NNRTI, EFV, resistant, n=2, 1 | 1 | 1 |
| NNRTI, INI, EFV, resistance possible, n=2, 1 | 0 | 0 |
| NNRTI, NNRTI, EFV, sensitive, n=2, 1 | 1 | 0 |
| NNRTI, NNRTI, ETR, resistant, n=2, 1 | 0 | 0 |
| NNRTI, NNRTI, ETR, resistance possible,n=2, 1 | 2 | 0 |
| NNRTI, NNRTI, ETR, sensitive, n=2, 1 | 0 | 1 |
| NNRTI, NNRTI, NVP, resistant, n=2, 1 | 1 | 1 |
| NNRTI, NNRTI, NVP, resistance possible, n=2, 1 | 0 | 0 |
| NNRTI, NNRTI, NVP, sensitive, n=2, 1 | 1 | 0 |
| NNRTI, NNRTI, RPV, resistant, n=2, 1 | 2 | 0 |
| NNRTI, NNRTI, RPV, resistance possible, n=2, 1 | 0 | 0 |
| NNRTI, NNRTI, RPV, sensitive, n=2, 1 | 0 | 1 |
| NNRTI, NRTI, 3TC, resistant, n=2, 1 | 0 | 1 |
| NNRTI, NNRTI, 3TC, resistance possible, n=2, 1 | 0 | 0 |
| NNRTI, NRTI, 3TC, sensitive, n=2, 1 | 2 | 0 |
| NNRTI, NRTI, ABC, resistant, n=2, 1 | 0 | 0 |
| NNRTI, NRTI, ABC, resistance possible, n=2, 1 | 0 | 0 |
| NNRTI, NRTI, ABC, sensitive, n=2, 1 | 2 | 1 |
| NNRTI, NRTI, FTC, resistant, n=2, 1 | 0 | 1 |
| NNRTI, NRTI, FTC, resistance possible, n=2, 1 | 0 | 0 |
| NNRTI, NRTI, FTC, sensitive, n=2, 1 | 2 | 0 |
| NNRTI, NRTI, TDF, resistant, n=2, 1 | 0 | 0 |
| NNRTI, NRTI, TDF, resistance possible, n=2, 1 | 0 | 0 |
| NNRTI, NRTI, TDF, sensitive, n=2, 1 | 2 | 1 |
| NNRTI, NRTI, ZDV, resistant, n=2, 1 | 0 | 0 |
| NNRTI, NRTI, ZDV, resistance possible, n=2, 1 | 0 | 0 |
| NNRTI, NRTI, ZDV, sensitive, n=2, 1 | 2 | 1 |
| NNRTI, NRTI, d4T, resistant, n=2, 1 | 0 | 0 |
| NNRTI, NRTI, d4T, resistance possible, n=2, 1 | 0 | 0 |
| NNRTI, NRTI, d4T, sensitive, n=2, 1 | 2 | 1 |
| NNRTI, NRTI, ddI, resistant, n=2, 1 | 0 | 0 |
| NNRTI, NRTI, ddI, resistance possible, n=2, 1 | 0 | 1 |
| NNRTI, NRTI, ddI, sensitive, n=2, 1 | 2 | 0 |
| NNRTI, PI, ATV, resistant, n=2, 1 | 1 | 0 |
| NNRTI, PI, ATV, resistance possible, n=2, 1 | 0 | 0 |
| NNRTI, PI, ATV, sensitive, n=2, 1 | 1 | 1 |
| NNRTI, PI, ATV/r, resistant, n=2, 1 | 0 | 0 |
| NNRTI, PI, ATV/r, resistance possible, n=2, 1 | 1 | 0 |
| NNRTI, PI, ATV/r, sensitive, n=2, 1 | 1 | 1 |
| NNRTI, PI, DRV/r, resistant, n=2, 1 | 0 | 0 |
| NNRTI, PI, DRV/r, resistance possible, n=2, 1 | 0 | 0 |
| NNRTI, PI, DRV/r, sensitive, n=2, 1 | 2 | 1 |
| NNRTI, PI, FPV/r, resistant, n=2, 1 | 0 | 0 |
| NNRTI, PI, FPV/r, resistance possible, n=2, 1 | 0 | 0 |
| NNRTI, PI, FPV/r, sensitive, n=2, 1 | 2 | 1 |
| NNRTI, PI, IDV/r, resistant, n=2, 1 | 0 | 0 |
| NNRTI, PI, IDV/r, resistance possible, n=2, 1 | 0 | 0 |
| NNRTI, PI, IDV/r, sensitive, n=2, 1 | 2 | 1 |
| NNRTI, PI, LPV/r, resistant, n=2, 1 | 0 | 0 |
| NNRTI, PI, LPV/r, resistance possible, n=2, 1 | 0 | 0 |
| NNRTI, PI, LPV/r, sensitive, n=2, 1 | 2 | 1 |
| NNRTI, PI, NFV, resistant, n=2, 1 | 1 | 0 |
| NNRTI, PI, NFV, resistance possible, n=2, 1 | 0 | 0 |
| NNRTI, PI, NFV, sensitive, n=2, 1 | 1 | 1 |
| NNRTI, PI, RTV, resistant, n=2, 1 | 0 | 0 |
| NNRTI, PI, RTV, resistance possible, n=2, 1 | 0 | 0 |
| NNRTI, PI, RTV, sensitive, n=2, 1 | 2 | 1 |
| NNRTI, PI, SQV/r, resistant, n=2, 1 | 0 | 0 |
| NNRTI, PI, SQV/r, resistance possible, n=2, 1 | 0 | 0 |
| NNRTI, PI, SQV/r, sensitive, n=2, 1 | 2 | 1 |
| NNRTI, PI, TPV/r, resistant, n=2, 1 | 0 | 0 |
| NNRTI, PI, TPV/r, resistance possible, n=2, 1 | 0 | 0 |
| NNRTI, PI, TPV/r, sensitive, n=2, 1 | 2 | 1 |
Plasma samples were collected from participants who met confirmed virologic withdrawal criteria to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Phenotypic Resistance data for the following drugs: CAB, DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented. Phenotypic resistance, partially sensitive, and Sensitive were defined based on FC value from Monogram as: resistance (FC\>clinical higher cutoff/biologic cutoff), partially sensitive (FC \<=clinical higher cutoff and \> clinical lower cutoff), sensitive (FC \<= clinical lower cutoff/biologic cutoff).
| Participants | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| PI, INI, CAB, resistant , n=1, 0 | 0 | 0 |
| PI, INI, CAB, sensitive, n=1, 0 | 1 | 0 |
| PI, INI, DTG, resistant, n=1, 0 | 0 | 0 |
| PI, INI, DTG, partially sensitive, n=1, 0 | 0 | 0 |
| PI, INI, DTG, sensitive, n=1, 0 | 1 | 0 |
| PI, INI, EVG, resistant, n=1, 0 | 0 | 0 |
| PI, INI, EVG, sensitive, n=1, 0 | 1 | 0 |
| PI, INI, RAL, resistant, n=1, 0 | 0 | 0 |
| PI, INI, RAL, sensitive, n=1, 0 | 1 | 0 |
| PI, NNRTI, DLV, resistant, n=1, 0 | 0 | 0 |
| PI, NNRTI, DLV, sensitive, n=1, 0 | 1 | 0 |
| PI, NNRTI, EFV, resistant, n=1, 0 | 0 | 0 |
| PI, NNRTI, EFV, sensitive, n=1, 0 | 1 | 0 |
| PI, NNRTI, ETR, resistant, n=1, 0 | 0 | 0 |
| PI, NNRTI, ETR, partially sensitive, n=1, 0 | 0 | 0 |
| PI, NNRTI, ETR, sensitive, n=1, 0 | 1 | 0 |
| PI, NNRTI, NVP, resistant, n=1, 0 | 0 | 0 |
| PI, NNRTI, NVP, sensitive, n=1, 0 | 1 | 0 |
| PI, NNRTI, RPV, resistant, n=1, 0 | 1 | 0 |
| PI, NNRTI, RPV, sensitive, n=1, 0 | 0 | 0 |
| PI, NRTI, 3TC, resistant, n=1, 0 | 0 | 0 |
| PI, NRTI, 3TC, sensitive, n=1, 0 | 1 | 0 |
| PI, NRTI, ABC, resistant, n=1, 0 | 0 | 0 |
| PI, NRTI, ABC, partially sensitive, n=1, 0 | 0 | 0 |
| PI, NRTI, ABC, sensitive, n=1, 0 | 1 | 0 |
| PI, NRTI, FTC, resistant, n=1, 0 | 0 | 0 |
| PI, NRTI, FTC, sensitive, n=1, 0 | 1 | 0 |
| PI, NRTI, TDF, resistant, n=1, 0 | 0 | 0 |
| PI, NRTI, TDF, partially sensitive, n=1, 0 | 0 | 0 |
| PI, NRTI, TDF, sensitive, n=1, 0 | 1 | 0 |
| PI, NRTI, ZDV, resistant, n=1, 0 | 0 | 0 |
| PI, NRTI, ZDV, sensitive, n=1, 0 | 1 | 0 |
| PI, NRTI, d4T, resistant, n=1, 0 | 0 | 0 |
| PI, NRTI, d4T, sensitive, n=1, 0 | 1 | 0 |
| PI, NRTI, ddI, resistant, n=1, 0 | 0 | 0 |
| PI, NRTI, ddI, partially sensitive, n=1, 0 | 0 | 0 |
| PI, NRTI, ddI, sensitive, n=1, 0 | 1 | 0 |
| PI, PI, ATV, resistant, n=1, 0 | 0 | 0 |
| PI, PI, ATV, sensitive, n=1, 0 | 1 | 0 |
| PI, PI, DRV, resistant, n=1, 0 | 0 | 0 |
| PI, PI, DRV, partially sensitive, n=1, 0 | 0 | 0 |
| PI, PI, DRV, sensitive, n=1, 0 | 1 | 0 |
| PI, PI, FPV, resistant, n=1, 0 | 0 | 0 |
| PI, PI, FPV, partially sensitive, n=1, 0 | 0 | 0 |
| PI, PI, FPV, sensitive, n=1, 0 | 1 | 0 |
| PI, PI, IDV, resistant, n=1, 0 | 0 | 0 |
| PI, PI, IDV, sensitive, n=1, 0 | 1 | 0 |
| PI, PI, LPV, resistant, n=1, 0 | 0 | 0 |
| PI, PI, LPV, partially sensitive, n=1, 0 | 0 | 0 |
| PI, PI, LPV, sensitive, n=1, 0 | 1 | 0 |
| PI, PI, NFV, resistant, n=1, 0 | 0 | 0 |
| PI, PI, NFV, sensitive, n=1, 0 | 1 | 0 |
| PI, PI, RTV, resistant, n=1, 0 | 0 | 0 |
| PI, PI, RTV, sensitive, n=1, 0 | 1 | 0 |
| PI, PI, SQV, resistant, n=1, 0 | 0 | 0 |
| PI, PI, SQV, partially sensitive, n=1, 0 | 0 | 0 |
| PI, PI, SQV, sensitive, n=1, 0 | 1 | 0 |
| PI, PI, TPV, resistant, n=1, 0 | 0 | 0 |
| PI, PI, TPV, partially sensitive, n=1, 0 | 0 | 0 |
| PI, PI, TPV, sensitive, n=1, 0 | 1 | 0 |
| INI, INI, CAB, resistant , n=0, 3 | 0 | 0 |
| INI, INI, CAB, sensitive, n=0, 3 | 0 | 3 |
| INI, INI, DTG, resistant, n=0, 3 | 0 | 0 |
| INI, INI, DTG, partially sensitive, n=0, 3 | 0 | 0 |
| INI, INI, DTG, sensitive, n=0, 3 | 0 | 3 |
| INI, INI, EVG, resistant, n=0, 3 | 0 | 0 |
| INI, INI, EVG, sensitive, n=0, 3 | 0 | 3 |
| INI, INI, RAL, resistant, n=0, 3 | 0 | 0 |
| INI, INI, RAL, sensitive, n=0, 3 | 0 | 3 |
| INI, NNRTI, DLV, resistant, n=0, 3 | 0 | 0 |
| INI, NNRTI, DLV, sensitive, n=0, 3 | 0 | 3 |
| INI, NNRTI, EFV, resistant, n=0, 3 | 0 | 0 |
| INI, NNRTI, EFV, sensitive, n=0, 3 | 0 | 3 |
| INI, NNRTI, ETR, resistant, n=0, 3 | 0 | 0 |
| INI, NNRTI, ETR, partially sensitive, n=0, 3 | 0 | 0 |
| INI, NNRTI, ETR, sensitive, n=0, 3 | 0 | 3 |
| INI, NNRTI, NVP, resistant, n=0, 3 | 0 | 0 |
| INI, NNRTI, NVP, sensitive, n=0, 3 | 0 | 3 |
| INI, NNRTI, RPV, resistant, n=0, 3 | 0 | 0 |
| INI, NNRTI, RPV, sensitive, n=0, 3 | 0 | 3 |
| INI, NRTI, 3TC, resistant, n=0, 3 | 0 | 1 |
| INI, NRTI, 3TC, sensitive, n=0, 3 | 0 | 2 |
| INI, NRTI, ABC, resistant, n=0, 3 | 0 | 0 |
| INI, NRTI, ABC, partially sensitive, n=0, 3 | 0 | 0 |
| INI, NRTI, ABC, sensitive, n=0, 3 | 0 | 3 |
| INI, NRTI, FTC, resistant, n=0, 3 | 0 | 1 |
| INI, NRTI, FTC, sensitive, n=0, 3 | 0 | 2 |
| INI, NRTI, TDF, resistant, n=0, 3 | 0 | 0 |
| INI, NRTI, TDF, partially sensitive, n=0, 3 | 0 | 0 |
| INI, NRTI, TDF, sensitive, n=0, 3 | 0 | 3 |
| INI, NRTI, ZDV, resistant, n=0, 3 | 0 | 0 |
| INI, NRTI, ZDV, sensitive, n=0, 3 | 0 | 3 |
| INI, NRTI, d4T, resistant, n=0, 3 | 0 | 0 |
| INI, NRTI, d4T, sensitive, n=0, 3 | 0 | 3 |
| INI, NRTI, ddI, resistant, n=0, 3 | 0 | 0 |
| INI, NRTI, ddI, partially sensitive, n=0, 3 | 0 | 0 |
| INI, NRTI, ddI, sensitive, n=0, 3 | 0 | 3 |
| INI, PI, ATV, resistant, n=0, 3 | 0 | 0 |
| INI, PI, ATV, sensitive, n=0, 3 | 0 | 3 |
| INI, PI, DRV, resistant, n=0, 3 | 0 | 0 |
| INI, PI, DRV, partially sensitive, n=0, 3 | 0 | 0 |
| INI, PI, DRV, sensitive, n=0, 3 | 0 | 3 |
| INI, PI, FPV, resistant, n=0, 3 | 0 | 0 |
| INI, PI, FPV, partially sensitive, n=0, 3 | 0 | 0 |
| INI, PI, FPV, sensitive, n=0, 3 | 0 | 3 |
| INI, PI, IDV, resistant, n=0, 3 | 0 | 0 |
| INI, PI, IDV, sensitive, n=0, 3 | 0 | 3 |
| INI, PI, LPV, resistant, n=0, 3 | 0 | 0 |
| INI, PI, LPV, partially sensitive, n=0, 3 | 0 | 0 |
| INI, PI, LPV, sensitive, n=0, 3 | 0 | 3 |
| INI, PI, NFV, resistant, n=0, 3 | 0 | 0 |
| INI, PI, NFV, sensitive, n=0, 3 | 0 | 3 |
| INI, PI, RTV, resistant, n=0, 3 | 0 | 0 |
| INI, PI, RTV, sensitive, n=0, 3 | 0 | 3 |
| INI, PI, SQV, resistant, n=0, 3 | 0 | 0 |
| INI, PI, SQV, partially sensitive, n=0, 3 | 0 | 0 |
| INI, PI, SQV, sensitive, n=0, 3 | 0 | 3 |
| INI, PI, TPV, resistant, n=0, 3 | 0 | 0 |
| INI, PI, TPV, partially sensitive, n=0, 3 | 0 | 0 |
| INI, PI, TPV, sensitive, n=0, 3 | 0 | 3 |
| NNRTI, INI, CAB, resistant , n=2, 1 | 1 | 0 |
| NNRTI, INI, CAB, sensitive, n=2, 1 | 1 | 1 |
| NNRTI, INI, DTG, resistant, n=2, 1 | 0 | 0 |
| NNRTI, INI, DTG, partially sensitive, n=2, 1 | 0 | 0 |
| NNRTI, INI, DTG, sensitive, n=2, 1 | 2 | 1 |
| NNRTI, INI, EVG, resistant, n=2, 1 | 1 | 0 |
| NNRTI, INI, EVG, sensitive, n=2, 1 | 1 | 1 |
| NNRTI, INI, RAL, resistant, n=2, 1 | 1 | 0 |
| NNRTI, INI, RAL, sensitive, n=2, 1 | 1 | 1 |
| NNRTI, NNRTI, DLV, resistant, n=2, 0 | 2 | 0 |
| NNRTI, NNRTI, DLV, sensitive, n=2, 0 | 0 | 0 |
| NNRTI, NNRTI, EFV, resistant, n=2, 0 | 2 | 0 |
| NNRTI, NNRTI, EFV, sensitive, n=2, 0 | 0 | 0 |
| NNRTI, NNRTI, ETR, resistant, n=2, 0 | 0 | 0 |
| NNRTI, NNRTI, ETR, partially sensitive, n=2, 0 | 2 | 0 |
| NNRTI, NNRTI, ETR, sensitive, n=2, 0 | 0 | 0 |
| NNRTI, NNRTI, NVP, resistant, n=2, 0 | 2 | 0 |
| NNRTI, NNRTI, NVP, sensitive, n=2, 0 | 0 | 0 |
| NNRTI, NNRTI, RPV, resistant, n=2, 0 | 2 | 0 |
| NNRTI, NNRTI, RPV, sensitive, n=2, 0 | 0 | 0 |
| NNRTI, NRTI, 3TC, resistant, n=2, 0 | 0 | 0 |
| NNRTI, NRTI, 3TC, sensitive, n=2, 0 | 2 | 0 |
| NNRTI, NRTI, ABC, resistant, n=2, 0 | 0 | 0 |
| NNRTI, NRTI, ABC, partially sensitive, n=2, 0 | 0 | 0 |
| NNRTI, NRTI, ABC, sensitive, n=2, 0 | 2 | 0 |
| NNRTI, NRTI, FTC, resistant, n=2, 0 | 0 | 0 |
| NNRTI, NRTI, FTC, sensitive, n=2, 0 | 2 | 0 |
| NNRTI, NRTI, TDF, resistant, n=2, 0 | 0 | 0 |
| NNRTI, NRTI, TDF, partially sensitive, n=2, 0 | 0 | 0 |
| NNRTI, NRTI, TDF, sensitive, n=2, 0 | 2 | 0 |
| NNRTI, NRTI, ZDV, resistant, n=2, 0 | 1 | 0 |
| NNRTI, NRTI, ZDV, sensitive, n=2, 0 | 1 | 0 |
| NNRTI, NRTI, d4T, resistant, n=2, 0 | 0 | 0 |
| NNRTI, NRTI, d4T, sensitive, n=2, 0 | 2 | 0 |
| NNRTI, NRTI, ddI, resistant, n=2, 0 | 0 | 0 |
| NNRTI, NRTI, ddI, partially sensitive, n=2, 0 | 0 | 0 |
| NNRTI, NRTI, ddI, sensitive, n=2, 0 | 2 | 0 |
| NNRTI, PI, ATV, resistant, n=2, 0 | 0 | 0 |
| NNRTI, PI, ATV, sensitive, n=2, 0 | 2 | 0 |
| NNRTI, PI, DRV, resistant, n=2, 0 | 0 | 0 |
| NNRTI, PI, DRV, partially sensitive, n=2, 0 | 0 | 0 |
| NNRTI, PI, DRV, sensitive, n=2, 0 | 2 | 0 |
| NNRTI, PI, FPV, resistant, n=2, 0 | 0 | 0 |
| NNRTI, PI, FPV, partially sensitive, n=2, 0 | 0 | 0 |
| NNRTI, PI, FPV, sensitive, n=2, 0 | 2 | 0 |
| NNRTI, PI, IDV, resistant, n=2, 0 | 0 | 0 |
| NNRTI, PI, IDV, sensitive, n=2, 0 | 2 | 0 |
| NNRTI, PI, LPV, resistant, n=2, 0 | 0 | 0 |
| NNRTI, PI, LPV, partially sensitive, n=2, 0 | 0 | 0 |
| NNRTI, PI, LPV, sensitive, n=2, 0 | 2 | 0 |
| NNRTI, PI, NFV, resistant, n=2, 0 | 0 | 0 |
| NNRTI, PI, NFV, sensitive, n=2, 0 | 2 | 0 |
| NNRTI, PI, RTV, resistant, n=2, 0 | 0 | 0 |
| NNRTI, PI, RTV, sensitive, n=2, 0 | 2 | 0 |
| NNRTI, PI, SQV, resistant, n=2,0 | 0 | 0 |
| NNRTI, PI, SQV, partially sensitive, n=2, 0 | 0 | 0 |
| NNRTI, PI, SQV, sensitive, n=2, 0 | 2 | 0 |
| NNRTI, PI, TPV, resistant, n=2, 0 | 0 | 0 |
| NNRTI, PI, TPV, partially sensitive, n=2, 0 | 0 | 0 |
| NNRTI, PI, TPV, sensitive, n=2, 0 | 2 | 0 |
The PIN questionnaire explores the bother of pain at the injection site and injection site reactions (ISR), anxiety before and after injection, willingness to receive an HIV injectable treatment the following visit and satisfaction with the mode of treatment administration of individuals receiving injection and perceptions of individuals associated with receiving injections.This measure contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial.Scores range from 1 to 5, and questions are phrased in such a way as to ensure that 1 always equated with the most favourable perception of vaccination, and 5 the most unfavourable.Dimension scores include bother from ISR, leg movement, sleep and acceptability.The score of a domain is calculated as the mean of all items with the domain.Higher scores represent worse perception of injection. LOCFwas used as primary method of analysis
| Scores on the scale | CAB LA+RPV LA (Q4W) |
|---|---|
| Bother of ISRs, Week 41 | -0.21 ± 0.532 |
| Bother of ISRs, Week 48 | -0.21 ± 0.524 |
| Leg movement, Week 41 | -0.52 ± 0.903 |
| Leg movement, Week 48 | -0.59 ± 0.950 |
| Sleep, Week 41 | -0.56 ± 0.877 |
| Sleep, Week 48 | -0.56 ± 0.937 |
| Acceptance, Week 41 | -0.49 ± 1.094 |
| Acceptance, Week 48 | -0.54 ± 1.080 |
The PIN questionnaire explores the bother of pain at the injection site and injection site reactions(ISR), anxiety before and after injection, willingness to receive an HIV injectable treatment the following visit and satisfaction with the mode of treatment administration of individuals receiving injection and perceptions of individuals associated with receiving injections.This measure contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial.Scores range from 1 to 5, and questions are phrased in such a way as to ensure that 1 always equated with the most favourable perception of vaccination, and 5 the most unfavourable.Dimension scores include bother from ISR, leg movement, sleep and acceptability.The score of a domain is calculated as the mean of all items with the domain.Higher scores represent worse perception of injection. LOCF was used as primary method of analysis
| Percentage of participants | CAB LA+RPV LA (Q4W) |
|---|---|
| Local reaction, Week 5, total, n=296 | 141 |
| Local reaction,Week 5, very acceptable, n=296 | 77 |
| Local reaction, Week 5, moderate, n=296 | 54 |
| Local reaction, Week 5, little, n=296 | 15 |
| Local reaction, Week 5, not at all, n=296 | 9 |
| Pain, Week 5, total, n=296 | 86 |
| Pain, Week 5, very acceptable, n=296 | 103 |
| Pain, Week 5, moderate, n=296 | 59 |
| Pain, Week 5, little, n=296 | 29 |
| Pain, Week 5, not at all, n=296 | 19 |
| Local reaction, Week 41, total, n=300 | 188 |
| Local reaction, Week 41, very acceptable, n=300 | 77 |
| Local reaction, Week 41, moderate, n=300 | 24 |
| Local reaction, Week 41, little, n=300 | 6 |
| Local reaction, Week 41, not at all, n=300 | 5 |
| Pain, Week 41, total, n=300 | 166 |
| Pain, Week 41, very acceptable, n=300 | 85 |
| Pain, Week 41, moderate, n=300 | 31 |
| Pain, Week 41, little, n=300 | 12 |
| Pain, Week 41, not at all, n=300 | 6 |
| Local reaction, week 48, total, n=303 | 202 |
| Local reaction, Week 48, very acceptable, n=303 | 69 |
| Local reaction, Week 48, moderate, n=303 | 21 |
| Local reaction, Week 48, little, n=303 | 8 |
| Local reaction, Week 48, not at all, n=303 | 3 |
| Pain, Week 48, total, n=303 | 168 |
| Pain, Week 48, very acceptable, n=303 | 95 |
| Pain, Week 48, moderate, n=303 | 26 |
| Pain, Week 48, little, n=303 | 11 |
| Pain, Week 48, not at all, n=303 | 3 |
The HATQoL questionnaire was used to assess the health related QoL (HRQoL). It comprises of three dimensions: LISAT, medication worries (MEDWO) and disclosure worries (DISWO). The total imputed value score for LISAT is calculated on a 0-100 scale using the formula: LISAT 100=\[100 divided by (20 minus 4)\]\*(LISAT minus 4). A response of 5 in LISAT score shows satisfaction all of the time and 1 as none of the time. The higher the score, the greater satisfaction to life and the less worry. The transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% confidence interval (CI).Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Scores on a scale | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Week 24, n=292, 291 | 1.0 (-0.6 to 2.6) | 1.1 (-0.5 to 2.7) |
| Week 48, n=292, 297 | 1.1 (-0.6 to 2.8) | 0.1 (-1.6 to 1.7) |
The HATQoL questionnaire was used to assess the health related QoL (HRQoL). It comprises of three dimensions: LISAT, medication worries (MEDWO) and disclosure worries (DISWO). The total imputed value score for MEDWO is calculated on a 0-100 scale using the formula: MEDWO 100=\[100 divided by (20 minus 5)\]\*(MEDWO minus 5). A response of 1 in MEDWO score shows less medication worries all of the time and 5 as none of the time. The higher the score, the greater satisfaction to life and the less worry. The transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Scores on a scale | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Week 24, n=292, 290 | 4.2 (2.7 to 5.8) | -0.7 (-2.2 to 0.9) |
| Week 48, n=292, 296 | 4.0 (2.3 to 5.7) | -2.4 (-4.1 to -0.8) |
The HATQoL questionnaire was used to assess the health related QoL (HRQoL). It comprises of three dimensions: LISAT, medication worries (MEDWO) and disclosure worries (DISWO). The total imputed value score for DISWO is calculated on a 0-100 scale using the formula: DISWO 100=\[100 divided by (20 minus 5)\]\*(DISWO minus 5). A response of 1 in DISWO score shows less medication worries all of the time and 5 as none of the time. The higher the score, the greater satisfaction to life and the less worry. The transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Scores on a scale | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Week 24, n=291, 290 | 8.3 (5.6 to 11.0) | 3.0 (0.3 to 5.8) |
| Week 48, n=291, 296 | 4.6 (1.7 to 7.6) | 2.6 (-0.3 to 5.6) |
The SF-12 questionnaire consists of 7 questions which measures the degree of general health status and mental health distress. Each question is scored 0-5, except for question 2 scored 0-3. The HRQoL using SF-12 for the total score, physical component summary (PCS) and the mental component summary (MCS) were assessed for the two treatment groups. Missing Total or the component scores was imputed using LOCF. The PCS/MCS are calculated using computer software purchased from QualityMetric (http://www.qualitymetric.com). The higher the score, the better will be the health status. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Scores on a scale | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Total score, Week 24, n=291, 289 | 0.0 (-0.3 to 0.4) | -0.2 (-0.5 to 0.1) |
| Total score, Week 48, n=293, 296 | -0.0 (-0.4 to 0.3) | 0.0 (-0.3 to 0.4) |
| MCS, Week 24, n=289, 286 | 0.288 (-0.579 to 1.155) | -0.388 (-1.259 to 0.484) |
| MCS, Week 48, n=291, 293 | 0.260 (-0.638 to 1.158) | -0.375 (-1.270 to 0.520) |
| PCS, Week 24, n=286, 288 | 0.650 (0.087 to 1.213) | -0.047 (-0.608 to 0.514) |
| PCS, Week 48, n=288, 295 | 0.758 (0.184 to 1.332) | 0.062 (-0.505 to 0.629) |
The HIVTSQ for total treatment satisfaction score is computed with 1-11 items. These 1-11 items are summed to produce a score with a possible range of -33 to 33. The item 12 in the scale will be calculated as an individual score.The higher the score, the greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment.A score of 0 represents no change. A maximum of 5 items can be missing, the missing scores will be imputed with the mean of the completed item scores. If 6 or more items are missing, then the overall treatment satisfaction scale score should not be computed and will remain missing.LOCF was used as primary method of analysis. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. Data has been presented with respect to actual treatment received to the participants
| Scores on a scale | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Week 4b, n=295, 0 | 3.99 ± 8.982 | — |
| Week 24, n=300, 288 | 6.39 ± 10.328 | 1.08 ± 8.510 |
| Week 44, n=300, 294 | 6.02 ± 10.808 | 0.54 ± 9.877 |
The HIVTSQ for total treatment satisfaction score is computed with 1-11 items. These 1-11 items are summed to produce a score with a possible range of -33 to 33. The item 12 in the scale will be calculated as an individual score.The higher the score, the greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment.A score of 0 represents no change. A maximum of 5 items can be missing, the missing scores will be imputed with the mean of the completed item scores. If 6 or more items are missing, then the overall treatment satisfaction scale score should not be computed and will remain missing.LOCF was used as primary method of analysis. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. Data has been presented with respect to actual treatment received to the participants
| Scores on a scale | CAB LA+RPV LA (Q4W) |
|---|---|
| Change in Treatment Satisfaction Over Time Using HIVTSQ Change (HIVTSQc) at Week 48 in Q4W Arm | 29.05 ± 6.978 |
The ACCEPT questionnaire is a generic medication acceptance measure assessing how participants weigh advantages and disadvantages of long-term medication.The questionnaire consists of 25 items that capture six dimensions.3 questions that focus on general acceptance of study medication will be analyzed.Items on the scale are rated as 1-5 scores:1:totally disagree,2:somewhat disagree,3:somewhat agree, 4:totally agree and 5:I don't know.Total score of the dimension is calculated as the mean of the recoded items of the dimension and then linearly transformed to be on a scale from 0 to 100:score:Total Score=(mean of the recoded items in the dimension minus1)divided by2\*100.LOCF was used as primary method of analysis.Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI.Baseline value is defined as the latest pre-treatment assessment with a non-missing value.Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value
| Scores on a scale | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Week 8, n=302, 287 | 8.9 (6.3 to 11.6) | 1.0 (-1.7 to 3.8) |
| Week 24, 303, 295 | 12.3 (9.9 to 14.8) | 5.5 (3.0 to 8.0) |
| Week 48, n=302, 298 | 13.7 (11.2 to 16.3) | 3.0 (0.4 to 5.6) |
The NRS questionnaire is used to assess the tolerability of injections in CAB LA+RPV LA arm only. The questionnaire consists of one single question and will assess maximum level of pain experienced with the most recent injections ranking from no pain (0) to extreme pain (10). Missing scores was imputed using LOCF.
| Scores on a scale | CAB LA+RPV LA (Q4W) |
|---|---|
| Week 5 | 2.0 ± 2.94 |
| Week 40 | 0.5 ± 2.79 |
| Week 41 | 0.4 ± 2.83 |
HIVTSQc is a 12 item questionnaire. The individual treatment change item scores on HIVTSQc scale are rated as +3 ('much more satisfied', 'much more convenient', 'much more flexible',etc.) to -3 ('much less satisfied', 'much less convenient', 'much less flexible', etc.). The higher the score, the greater the improvement in satisfaction with each aspect of treatment and the lower the score, the greater the deterioration in satisfaction with each aspect of treatment. LOCF was used as primary method of analysis. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
| Scores on a scale | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Item 1; Week 4b; n=294, 0 | 0.3 ± 1.42 | — |
| Item 1; Week 24; n=300, 287 | 0.4 ± 1.46 | -0.1 ± 1.04 |
| Item 1; Week 44; n=300, 293 | 0.5 ± 1.42 | -0.1 ± 1.21 |
| Item 2; Week 4b; n=295, 0 | 0.0 ± 0.60 | — |
| Item 2; Week 24; n=300, 287 | 0.1 ± 0.70 | 0.0 ± 0.68 |
| Item 2; Week 44; n=300, 293 | 0.1 ± 0.84 | -0.1 ± 0.82 |
| Item 3; Week 4b; n=295, 0 | 0.4 ± 1.35 | — |
| Item 3; Week 24; n=300, 288 | 0.3 ± 1.47 | 0.1 ± 1.12 |
| Item 3; Week 44; n=300, 294 | 0.3 ± 1.45 | 0.0 ± 1.26 |
| Item 4; Week 4b; n=295, 0 | 0.3 ± 1.21 | — |
| Item 4; Week 24; n=300, 288 | 0.5 ± 1.29 | -0.0 ± 1.16 |
| Item 4; Week 44; n=300, 294 | 0.4 ± 1.30 | -0.1 ± 1.22 |
| Item 5; Week 4b; n=295, 0 | 0.5 ± 1.24 | — |
| Item 5; Week 24; n=300, 288 | 0.8 ± 1.32 | 0.1 ± 1.31 |
| Item 5; Week 44; n=300, 294 | 0.8 ± 1.42 | 0.0 ± 1.37 |
| Item 6; Week 4b; n=294, 0 | 0.5 ± 1.63 | — |
| Item 6; Week 24; n=299, 288 | 0.8 ± 1.77 | 0.2 ± 1.79 |
| Item 6; Week 44; n=299, 293 | 0.9 ± 1.72 | 0.2 ± 1.78 |
| Item 7; Week 4b; n=295, 0 | 0.2 ± 0.90 | — |
| Item 7; Week 24; n=300, 288 | 0.2 ± 0.94 | 0.1 ± 1.00 |
| Item 7; Week 44; n=300, 294 | 0.2 ± 0.99 | 0.2 ± 1.08 |
| Item 8; Week 4b; n=294, 0 | 0.3 ± 1.21 | — |
| Item 8; Week 24; n=299, 288 | 0.7 ± 1.27 | 0.1 ± 1.20 |
| Item 8; Week 44; n=299, 294 | 0.6 ± 1.31 | 0.0 ± 1.27 |
| Item 9; Week 4b; n=294, 0 | 0.4 ± 1.22 | — |
| Item 9; Week 24; n=299, 288 | 0.6 ± 1.27 | 0.1 ± 1.20 |
| Item 9; Week 44; n=299, 294 | 0.5 ± 1.32 | 0.0 ± 1.25 |
| Item 10; Week 4b; n=293, 0 | 0.8 ± 1.44 | — |
| Item 10; Week 24; n=298, 287 | 1.2 ± 1.56 | 0.3 ± 1.38 |
| Item 10; Week 44; n=298, 293 | 1.1 ± 1.64 | 0.2 ± 1.60 |
| Item 11; Week 4b; n=292, 0 | 0.4 ± 1.23 | — |
| Item 11; Week 24; n=297, 287 | 0.7 ± 1.31 | 0.1 ± 1.28 |
| Item 11; Week 44; n=297, 293 | 0.6 ± 1.45 | 0.1 ± 1.38 |
| Item 12; Week 4b; n=293, 0 | 0.3 ± 1.41 | — |
| Item 12; Week 24; n=298, 287 | 0.0 ± 1.52 | 0.1 ± 1.14 |
| Item 12; Week 44; n=298, 293 | 0.0 ± 1.58 | 0.2 ± 1.17 |
Blood samples were planned to be collected at indicated time points for PK analysis of CAB LA and RPV LA. Demographic parameters including, but not limited to, age, sex, race, body weight, body mass index, and relevant laboratory parameters were planned to be evaluated as potential predictors of inter subject variability for pharmacokinetic parameters.
No measurements were reported for this outcome.
Collected over Up to Week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | 0/308 (0%) | 13/308 (4.2%) | 263/308 (85.4%) |
| Current ART | 1/308 (0.3%) | 14/308 (4.5%) | 117/308 (38%) |
| Event | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| ColitisGastrointestinal disorders | 0/308 | 2/308 |
| Hepatitis AInfections and infestations | 1/308 | 1/308 |
| Acute hepatitis BInfections and infestations | 1/308 | 0/308 |
| Anal abscessInfections and infestations | 0/308 | 1/308 |
| AppendicitisInfections and infestations | 0/308 | 1/308 |
| Gastroenteritis Escherichia coliInfections and infestations | 1/308 | 0/308 |
| Liver abscessInfections and infestations | 1/308 | 0/308 |
| PneumoniaInfections and infestations | 0/308 | 1/308 |
| Pyelonephritis acuteInfections and infestations | 1/308 | 0/308 |
| Viral infectionInfections and infestations | 1/308 | 0/308 |
| Event | CAB LA+RPV LA (Q4W) | Current ART |
|---|---|---|
| Injection site painGeneral disorders | 231/308 | 0/308 |
| NasopharyngitisInfections and infestations | 52/308 | 42/308 |
| Injection site noduleGeneral disorders | 37/308 | 0/308 |
| HeadacheNervous system disorders | 34/308 | 17/308 |
| Upper respiratory tract infectionInfections and infestations | 32/308 | 25/308 |
| Injection site indurationGeneral disorders | 30/308 | 0/308 |
| Injection site swellingGeneral disorders | 23/308 | 0/308 |
| FatigueGeneral disorders | 22/308 | 6/308 |
| DiarrhoeaGastrointestinal disorders | 22/308 | 15/308 |
| PyrexiaGeneral disorders | 21/308 | 9/308 |
| Age, Continuous(Years) | CAB LA+RPV LA (Q4W) | Current ART | Total |
|---|---|---|---|
| Mean | 41.6 ± 9.99 | 43.2 ± 11.43 | 42.4 ± 10.76 |
| Sex: Female, Male(Participants) | CAB LA+RPV LA (Q4W) | Current ART | Total |
|---|---|---|---|
| Female | 99 | 104 | 203 |
| Male | 209 | 204 | 413 |
| Race/Ethnicity, Customized(Participants) | CAB LA+RPV LA (Q4W) | Current ART | Total |
|---|---|---|---|
| American Indian (AI) or Alaska Native (AN) | 8 | 8 | 16 |
| Asian-Central South Asian Heritage | 1 | 0 | 1 |
| Asian-Japanese/East/South-East Asian Heritage | 21 | 13 | 34 |
| Black or African American | 62 | 77 | 139 |
| Native Hawaiian or other Pacific Islander | 0 | 1 | 1 |
| White | 214 | 207 | 421 |
| AI or AN & Black/African American | 0 | 1 | 1 |
| AI or AN & Black/African American & White | 1 | 1 | 2 |
| Black/African American or White | 1 | 0 | 1 |
Showing the first 100 of 113 sites across 13 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study is available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below).
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Oct 2016 to primary completion in May 2018, 19 months.
Results were first posted in Jun 2019, 1 year after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 19 months is below that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabotegravir